ysioscapital.com
Last updated: 9/22/2026valid
Independent Directory - Important Information
This llms.txt file was publicly accessible and retrieved from ysioscapital.com. LLMS Central does not claim ownership of this content and hosts it for informational purposes only to help AI systems discover and respect website policies.
This listing is not an endorsement by ysioscapital.com and they have not sponsored this page. We are an independent directory service with no affiliation to the listed domain.
Copyright & Terms: Users should respect the original terms of service of ysioscapital.com. If you believe there is a copyright or terms of service violation, please contact us at support@llmscentral.com for prompt removal. Domain owners can also claim their listing.
Current llms.txt Content
Generated by All in One SEO Pro v5.0.1.1, this is an llms.txt file, used by LLMs to index the site.
# Ysios Capital
Backing the breakthroughs of tomorrow
## Sitemaps
- [XML Sitemap](https://ysioscapital.com/sitemap.xml): Contains all public & indexable URLs for this website.
## Posts
- [Ysios Capital 2025 / H1 2026 Review](https://ysioscapital.com/2026/07/28/ysios-capital-2025-h1-2026-review/) - Publication of Ysios Capital first annual review - Ysios Capital 2025 / H1 2026 Review
- [Xeltis raises an additional €20.5m of funding to advance aXess™ toward FDA approval and US commercial launch](https://ysioscapital.com/2026/07/28/xeltis-raises-an-additional-e20-5m-of-funding-to-advance-axess-toward-fda-approval-and-us-commercial-launch/) - Xeltis raises an additional €20.5m of funding to advance aXess™ toward FDA approval and US commercial launch
- [NEZGLYAL® (leriglitazone) receives a positive CHMP opinion for the treatment of cerebral Adrenoleukodystrophy (cALD), a rare neurodegenerative disease](https://ysioscapital.com/2026/07/24/nezglyal-leriglitazone-receives-a-positive-chmp-opinion-for-the-treatment-of-cerebral-adrenoleukodystrophy-cald-a-rare-neurodegenerative-disease/) - Recommendation based on NEXUS data; Minoryx and Neuraxpharm expect European Commission approval by the end of this quarter Barcelona, Spain and Düsseldorf, Germany – 24 July, 2026 – Minoryx Therapeutics and Neuraxpharm Group, announce that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation approval under exceptional
- [San Sebastián office](https://ysioscapital.com/2020/12/25/san-sebastian-office/)
- [Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen’s Rare Disease pipeline](https://ysioscapital.com/2026/07/22/ipsen-completes-acquisition-of-memo-therapeutics-ag-adding-first-in-class-asset-to-ipsens-rare-disease-pipeline/) - PARIS, FRANCE, 22 JULY 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK polyomavirus monoclonal antibody. About potravitug Potravitug is a first-in-class monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients. It has shown promising results
- [Barcelona office](https://ysioscapital.com/2020/12/25/barcelona-office/)
- [Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors](https://ysioscapital.com/2026/07/08/aura-biosciences-announces-appointment-of-jeremy-bender-ph-d-m-b-a-to-board-of-directors/) - Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
- [Xeltis makes first commercial implant of aXess™, its vascular access device for hemodialysis](https://ysioscapital.com/2026/07/07/xeltis-makes-first-commercial-implant-of-axess-its-vascular-access-device-for-hemodialysis/) - Xeltis makes first commercial implant of aXess™, its vascular access device for hemodialysis
- [Xeltis exceeds 50% enrollment in US Pivotal trial for aXess™, its vascular access device for hemodialysis](https://ysioscapital.com/2026/07/02/xeltis-exceeds-50-enrollment-in-us-pivotal-trial-for-axess-its-vascular-access-device-for-hemodialysis/) - Xeltis exceeds 50% enrollment in US Pivotal trial for aXess™, its vascular access device for hemodialysis
- [Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio](https://ysioscapital.com/2026/07/01/ipsen-to-acquire-memo-therapeutics-ag-adding-first-in-class-bk-polyomavirus-antibody-expanding-rare-disease-portfolio/) - Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio.
- [Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development](https://ysioscapital.com/2026/06/04/ona-therapeutics-raises-86-6-million-series-b-to-advance-first-in-class-adcs-into-clinical-development/) - Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development
- [Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma](https://ysioscapital.com/2026/06/01/aura-biosciences-announces-enrollment-completion-in-phase-3-compass-trial-of-bel-sar-in-early-choroidal-melanoma/) - Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
- [Adcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA® (Pembrolizumab) in a Phase Ib Study in Patients with Advanced Solid Tumors](https://ysioscapital.com/2026/05/26/adcendo-aps-announces-clinical-collaboration-and-supply-agreement-with-msd-to-evaluate-adce-t02-in-combination-with-keytruda-pembrolizumab-in-a-phase-ib-study-in-patients-with-advanced-solid-t/) - Adcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA® (Pembrolizumab) in a Phase Ib Study in Patients with Advanced Solid Tumors
- [Inbiomotion and HJ HyupJin enter a partnership for MAF Test® in South Korea](https://ysioscapital.com/2026/05/21/inbiomotion-and-hj-hyupjin-enter-a-partnership-for-maf-test-in-south-korea/) - Inbiomotion and HJ HyupJin enter a partnership for MAF Test® in South Korea
- [Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder](https://ysioscapital.com/2026/05/20/synendos-therapeutics-starts-phase-2-trial-in-generalized-anxiety-disorder/) - First time a Selective Endocannabinoid Reuptake Inhibitor (SERI) molecule is dosed in a patient population
- [Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares](https://ysioscapital.com/2026/05/05/aura-biosciences-announces-closing-of-299-million-public-offering-including-full-exercise-of-underwriters-option-to-purchase-additional-shares/) - Aura Biosciences Announces Closing of $299 Million Public Offering
- [Ysios Capital launches InceptionBio, a €100M fund to drive biotech company creation](https://ysioscapital.com/2026/03/27/ysios-capital-launches-inceptionbio-a-e100m-fund-to-drive-biotech-company-creation/) - InceptionBio is a new €100 million target-size fund focused on biotech company creation and early-stage projects, with a strong focus on Spain.
- [Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights](https://ysioscapital.com/2025/05/15/aura-biosciences-reports-first-quarter-2025-financial-results-and-business-highlights/) - Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights
- [Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors](https://ysioscapital.com/2025/04/02/aura-biosciences-announces-appointment-of-teresa-bitetti-to-board-of-directors/) - Appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company’s Board of Directors
- [BIOSPAIN](https://ysioscapital.com/2001/01/01/lsx-world-congress-europe-2026/)
- [CFO Forum](https://ysioscapital.com/2001/01/01/jefferies-global-healthcare-conference/)
- [Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences](https://ysioscapital.com/2001/01/01/19th-annual-european-life-sciences-ceo-forum/)
- [Swiss Biotech Day 2026](https://ysioscapital.com/2001/01/01/biocapital-europe-2026/)
- [Xeltis receives CE mark for aXess™, its aXess hemodialysis conduit ™, as it moves to commercialization](https://ysioscapital.com/2026/04/21/xeltis-receives-ce-mark-for-axess-its-axess-hemodialysis-conduit-as-it-moves-to-commercialization/) - Xeltis receives CE mark for aXess™, its aXess hemodialysis conduit ™, as it moves to commercialization
- [Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates](https://ysioscapital.com/2026/04/20/adcendo-aps-provides-updates-on-pipeline-progress-and-recent-achievements-for-its-first-and-best-in-class-antibody-drug-conjugates/) - Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates
- [UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science](https://ysioscapital.com/2026/04/17/ucb-to-acquire-neurona-therapeutics-advancing-its-innovative-leadership-in-epilepsy-through-regenerative-science/) - Neurona Therapeutics to be Acquired by UCB for up to $1.15 billion
- [Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline](https://ysioscapital.com/2026/04/15/adcendo-aps-completes-75-million-series-c-financing-to-continue-advancing-first-and-best-in-class-clinical-adc-pipeline/) - Adcendo Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline
- [NorthSea Therapeutics Announces Achievement of Key Regulatory Milestones for Orziloben](https://ysioscapital.com/2026/03/03/northsea-therapeutics-announces-achievement-of-key-regulatory-milestones-for-orziloben/) - NorthSea Therapeutics Announces Achievement of Key Regulatory Milestones for Orziloben
- [Ysios Capital appoints Joan Perelló as Managing Partner and Arturo Urrios as Partner to drive a new early-stage vertical](https://ysioscapital.com/2026/03/18/ysios-capital-appoints-joan-perello-as-managing-partner-and-arturo-urrios-as-partner-to-drive-a-new-early-stage-vertical/) - Joan Perelló and Arturo Urrios will lead a new vertical focused on company creation and early-stage biotech projects, with a strong focus on Spain.
- [Memo Therapeutics AG Enters into a Collaboration and Option Agreement with CSL for Development of Recombinant Polyclonal IgG Technology](https://ysioscapital.com/2026/02/09/memo-therapeutics-ag-enters-into-a-collaboration-and-option-agreement-with-csl-for-development-of-recombinant-polyclonal-igg-technology/) - Memo Therapeutics AG Enters into a Collaboration and Option Agreement with CSL for Development of Recombinant Polyclonal IgG Technology
- [SparingVision Successfully Completes PRODYGY Trial Patient Dosing with SPVN06, its Novel Neuroprotective Gene Therapy](https://ysioscapital.com/2026/02/09/sparingvision-successfully-completes-prodygy-trial-patient-dosing-with-spvn06-its-novel-neuroprotective-gene-therapy/) - SparingVision Successfully Completes PRODYGY Trial Patient Dosing with SPVN06, its Novel Neuroprotective Gene Therapy
- [Telescope Biotech Fund cierra 2025 como el Fondo de Inversión Libre más rentable del año en España](https://ysioscapital.com/2026/01/20/telescope-biotech-fund-cierra-2025-como-el-fondo-de-inversion-libre-mas-rentable-del-ano-en-espana/) - Telescope Biotech Fund, asesorado por Ysios y gestionado por Andbank, el FIL más rentable de España en 2025 (+52,5%)
- [Ysios Capital y Andbank se alían para lanzar el fondo Telescope Biotech Fund](https://ysioscapital.com/2024/12/17/ysios-capital-y-andbank-se-alian-para-lanzar-el-fondo-telescope-biotech-fund/) - El fondo invierte en compañías cotizadas del sector biotecnológico, con foco en EE.UU. La filosofía de inversión se centra en la innovación, la especialización, y el potencial de nuevas tecnologías para transformar la práctica médica. Ysios Capital será la entidad asesora del fondo y Andbank Wealth Management la entidad gestora. Madrid, 17 de diciembre de
- [Inbiomotion’s MAF Test® included in 2025 SEOM-GEICAM-SOLTI Clinical Practice Guidelines for Early-Stage Breast Cancer, further supporting its clinical utility](https://ysioscapital.com/2026/01/15/inbiomotions-maf-test-included-in-2025-seom-geicam-solti-clinical-practice-guidelines-for-early-stage-breast-cancer-further-supporting-its-clinical-utility/) - MAF Test® has been included in the 2025 SEOM-GEICAM-SOLTI Clinical Practice Guidelines for Early-Stage Breast Cancer
- [VarmX and Rentschler Biopharma partner to advance novel coagulation therapy toward Phase 3 and commercialization](https://ysioscapital.com/2026/01/08/varmx-and-rentschler-biopharma-partner-to-advance-novel-coagulation-therapy-toward-phase-3-and-commercialization/) - VarmX and Rentschler Biopharma expand collaboration from early development to late‑stage and commercial manufacturing of VMX-C001
- [SpliceBio Appoints Don Munoz as Chief Financial Officer](https://ysioscapital.com/2026/01/06/splicebio-appoints-don-munoz-as-chief-financial-officer/) - Don Munoz is a seasoned biotechnology finance leader with deep experience in financial strategy, operations and corporate development, complemented by a strong background in healthcare investment banking.
- [SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007, a Dual-AAV Gene Therapy for Stargardt Disease](https://ysioscapital.com/2026/01/08/splicebio-initiates-dose-expansion-portion-of-phase-1-2-astra-clinical-trial-for-sb-007-a-dual-aav-gene-therapy-for-stargardt-disease/) - SpliceBio Initiates Dose-Expansion Portion of Phase 1/2 ASTRA Clinical Trial for SB-007, a Dual-AAV Gene Therapy for Stargardt Disease
- [Xeltis secures nearly €50m from the European Investment Bank (EIB) and existing shareholders to advance aXess, its vascular access conduit to the market](https://ysioscapital.com/2025/12/02/xeltis-secures-nearly-e50m-from-the-european-investment-bank-eib-and-existing-shareholders-to-advance-axess-its-vascular-access-conduit-to-the-market/) - Xeltis secures nearly €50m from the European Investment Bank (EIB) and existing shareholders to advance aXess, its vascular access conduit to the market
- [Memo Therapeutics AG Presents Long Term Follow-Up Data from its Phase II SAFE KIDNEY Trial of Potravitug and Real World Data on the Challenges and Resource Utilization of Managing Kidney Transplant Recipients at ASN Kidney Week Meeting](https://ysioscapital.com/2025/11/07/memo-therapeutics-ag-presents-long-term-follow-up-data-from-its-phase-ii-safe-kidney-trial-of-potravitug-and-real-world-data-on-the-challenges-and-resource-utilization-of-managing-kidney-transplant-re/) - Memo Therapeutics AG Presents Long Term Follow-Up Data from its Phase II SAFE KIDNEY Trial of Potravitug and Real World Data on the Challenges and Resource Utilization of Managing Kidney Transplant Recipients at ASN Kidney Week Meeting
- [Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025](https://ysioscapital.com/2025/11/07/data-for-lorundrostat-in-chronic-kidney-disease-and-hypertension-presented-at-american-society-of-nephrology-asn-kidney-week-2025/) - The presentations at ASN Kidney Week demonstrated the breadth and strength of lorundrostat’s clinical program.
- [Neurona Therapeutics Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to NRTX-1001 in the Treatment of Drug-Resistant Focal Epilepsy](https://ysioscapital.com/2025/11/05/neurona-therapeutics-announces-priority-medicines-prime-designation-granted-by-the-european-medicines-agency-ema-to-nrtx-1001-in-the-treatment-of-drug-resistant-focal-epilepsy/) - Neurona Therapeutics Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to NRTX-1001 in the Treatment of Drug-Resistant Focal Epilepsy
- [SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA Trial](https://ysioscapital.com/2025/10/28/sparingvision-doses-first-patient-with-spvn20-for-advanced-retinitis-pigmentosa-in-nyrvana-trial/) - SparingVision Doses First Patient with SPVN20 for Advanced Retinitis Pigmentosa in NYRVANA Trial
- [Neurona Expands Investigation of NRTX-1001 Cell Therapy into Mesial Temporal Lobe Epilepsy (MTLE) without Mesial Temporal Sclerosis (MTS)](https://ysioscapital.com/2025/10/07/neurona-expands-investigation-of-nrtx-1001-cell-therapy-into-mesial-temporal-lobe-epilepsy-mtle-without-mesial-temporal-sclerosis-mts/) - Neurona Expands Investigation of NRTX-1001 Cell Therapy into Mesial Temporal Lobe Epilepsy (MTLE) without Mesial Temporal Sclerosis (MTS) First subject received unilateral administration of NRTX-1001 in a new non-MTS cohort; no significant surgical complications or adverse events reported to date – Data from this non-MTS cohort, together with results from Neurona’s ongoing Phase 1/2 trials in unilateral and bilateral MTLE and planned Phase 3 EPIC study, are intended to support a future BLA
- [Neurona Announces Publication in Neuron Reporting Durable Preclinical Engraftment of Human Interneuron Cell Therapy](https://ysioscapital.com/2025/07/11/neurona-announces-publication-in-neuron-reporting-durable-preclinical-engraftment-of-human-interneuron-cell-therapy/) - Neurona Announces Publication in Neuron Reporting Durable Preclinical Engraftment of Human Interneuron Cell Therapy
- [Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors](https://ysioscapital.com/2025/10/16/tagworks-pharmaceuticals-announces-cta-authorization-and-initiation-of-phase-0-1-clinical-trial-for-tgw211-a-radiopharmaceutical-for-the-treatment-of-her2-tumors/) - Tagworks Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors
- [Ona Therapeutics Appoints Oncology Drug Development Veteran Dr. Antoine Yver as Chair to Accelerate ADC Programs to Clinical Inflection Points](https://ysioscapital.com/2025/10/14/ona-therapeutics-appoints-oncology-drug-development-veteran-dr-antoine-yver-as-chair-to-accelerate-adc-programs-to-clinical-inflection-points/) - Ona Therapeutics Appoints Oncology Drug Development Veteran Dr. Antoine Yver as Chair to Accelerate ADC Programs to Clinical Inflection Points
- [Adcendo ApS Announces FDA Fast Track Designation Granted to ADCE-D01 for the Treatment of Soft Tissue Sarcoma](https://ysioscapital.com/2025/10/09/adcendo-aps-announces-fda-fast-track-designation-granted-to-adce-d01-for-the-treatment-of-soft-tissue-sarcoma/) - Adcendo ApS Announces FDA Fast Track Designation Granted to ADCE-D01 for the Treatment of Soft Tissue Sarcoma
- [Kynexis Announces First Patient Dosed in Phase 2 Clinical Trial of KYN-5356 for Cognitive Impairment Associated With Schizophrenia](https://ysioscapital.com/2025/09/30/kynexis-announces-first-patient-dosed-in-phase-2-clinical-trial-of-kyn-5356-for-cognitive-impairment-associated-with-schizophrenia/) - Kynexis Announces First Patient Dosed in Phase 2 Clinical Trial of KYN-5356 for Cognitive Impairment Associated With Schizophrenia
- [ReproNovo announces clinical trial approval notice for RPN-001 in China](https://ysioscapital.com/2025/09/30/repronovo-announces-clinical-trial-approval-notice-for-rpn-001-in-china/) - Repronovo announces clinical trial approval notice for RPN-001 in China
- [AM-Pharma Completes Enrollment in Phase 2 Study of Ilofotase Alfa for Prevention of Cardiac Surgery-Associated Renal Damage](https://ysioscapital.com/2025/10/02/am-pharma-completes-enrollment-in-phase-2-study-of-ilofotase-alfa-for-prevention-of-cardiac-surgery-associated-renal-damage/) - AM-Pharma Completes Enrollment in Phase 2 Study of Ilofotase Alfa for Prevention of Cardiac Surgery-Associated Renal Damage
- [VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001](https://ysioscapital.com/2025/09/25/varmx-receives-phase-1-waiver-from-japanese-regulator-pmda-for-lead-asset-vmx-c001/) - VarmX receives Phase 1 waiver from Japanese regulator PMDA for lead asset VMX-C001
- [Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors](https://ysioscapital.com/2025/09/09/tagworks-pharmaceuticals-announces-initiation-of-third-dose-level-in-ongoing-phase-1-clinical-trial-of-tgw101-for-the-treatment-of-solid-tumors/) - Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors
- [Xeltis poised for commercialization following excellent clinical data from aXess EU pivotal multicentre trial](https://ysioscapital.com/2025/09/24/xeltis-poised-for-commercialization-following-excellent-clinical-data-from-axess-eu-pivotal-multicentre-trial/) - Xeltis announces successful clinical data from the aXess EU pivotal trial, demonstrating the transformative potential of aXess in hemodialysis treatment.
- [Synendos Therapeutics Reports Positive and Highly Promising Topline Results from Phase 1 Trials, Paving the Way for Phase 2 in Mental Health](https://ysioscapital.com/2025/09/24/synendos-therapeutics-reports-positive-and-highly-promising-topline-results-from-phase-1-trials-paving-the-way-for-phase-2-in-mental-health/) - S ynendos Therapeutics Reports Positive and Highly Promising Topline Results from Phase 1Trials, Paving the Way for Phase 2 in Mental Health
- [Journal of Medical Economics study shows significant cost savings via MAF Test® - guided adjuvant bisphosphonate therapy for early-stage breast cancer](https://ysioscapital.com/2025/09/18/journal-of-medical-economics-study-shows-significant-cost-savings-via-maf-test-guided-adjuvant-bisphosphonate-therapy-for-early-stage-breast-cancer/) - Journal of Medical Economics study shows significant cost savings via MAF Test® - guided adjuvant bisphosphonate therapy for early-stage breast cancer
- [VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment](https://ysioscapital.com/2025/09/16/varmx-partners-with-csl-in-a-strategic-collaboration-and-option-agreement-to-develop-novel-investigational-coagulation-treatment/) - VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational coagulation treatment
- [VarmX receives FDA Fast Track Designation for lead asset VMX-C001](https://ysioscapital.com/2025/09/03/varmx-receives-fda-fast-track-designation-for-lead-asset-vmx-c001/) - Fast Track Designation is granted by the FDA for products that are intended for the treatment of serious or life-threatening diseases or conditions.
- [Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares](https://ysioscapital.com/2025/09/04/mineralys-therapeutics-announces-closing-of-upsized-287-5-million-underwritten-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares/) - Mineralys Therapeutics (Nasdaq: MLYS) closes $287.5M upsized stock offering to fund lorundrostat development for hypertension, CKD, OSA and related diseases.
- [Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock](https://ysioscapital.com/2025/09/02/mineralys-therapeutics-announces-pricing-of-upsized-250-0-million-underwritten-public-offering-of-common-stock/) - Mineralys Therapeutics prices upsized $250M public offering to fund lorundrostat clinical development, manufacturing, and pre-commercialization efforts
- [Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need](https://ysioscapital.com/2025/09/05/mineralys-therapeutics-presents-subgroup-analyses-of-phase-3-launch-htn-trial-demonstrating-efficacy-and-safety-of-lorundrostat-in-hypertension-participants-with-high-unmet-medical-need/) - Mineralys announced new subgroup analyses from the Phase 3 Launch-HTN trial
- [Leriglitazone Marketing Authorization Application submitted for treatment of cerebral adrenoleukodystrophy has been validated by European Medicines Agency](https://ysioscapital.com/2025/07/23/leriglitazone-marketing-authorization-application-submitted-for-treatment-of-cerebral-adrenoleukodystrophy-has-been-validated-by-european-medicines-agency/) - Minoryx’s MAA for leriglitazone (NEZGLYAL®) to treat cALD has been validated by EMA and is now under review by the CHMP.
- [World First: CorWave's Undulating Membrane Heart Pump Implanted in First Patient](https://ysioscapital.com/2025/07/09/world-first-corwaves-undulating-membrane-heart-pump-implanted-in-first-patient/) - CorWave announces the world’s first implantation in a patient of its Left Ventricular Assist System (LVAS), the first heart pump based on breakthrough wave membrane technology.
- [Memo Therapeutics AG Publishes Study on its Potent Antibody for Treatment of BKPyV Infection in Kidney Transplantation](https://ysioscapital.com/2025/07/23/memo-therapeutics-ag-publishes-study-on-its-potent-antibody-for-treatment-of-bkpyv-infection-in-kidney-transplantation/) - Memo Therapeutics AG Publishes Study on its Potent Antibody for Treatment of BKPyV Infection in Kidney Transplantation
- [Xeltis announces positive data for Xabg, its coronary artery bypass conduit, in EU clinical trial](https://ysioscapital.com/2025/07/17/xeltis-announces-positive-data-for-xabg-its-coronary-artery-bypass-conduit-in-eu-clinical-trial/) - Xeltis announces positive data for Xabg, its coronary artery bypass conduit, in EU clinical trial
- [Xeltis successfully passes evaluation phase for €10million investment from European Innovation Council](https://ysioscapital.com/2025/04/08/xeltis-successfully-passes-evaluation-phase-for-e10million-investment-from-european-innovation-council/) - Xeltis is one of only seven companies to successfully pass evaluation phase of EIC Strategic Technologies for Europe Platform (STEP) Scale Up call Funding to support commercialization of its groundbreaking bioresorbable vascular conduits EINDHOVEN, The Netherlands, 8 April 2025 - Xeltis, a leading developer of transformative implants that enable the natural creation of living and
- [Minoryx receives a EUR 26.9m grant within the framework of the European IPCEI Med4Cure project for the continued development of leriglitazone in lethal orphan CNS diseases](https://ysioscapital.com/2025/07/17/minoryx-receives-a-eur-26-9m-grant-within-the-framework-of-the-european-ipcei-med4cure-project-for-the-continued-development-of-leriglitazone-in-lethal-orphan-cns-diseases/) - Minoryx receives €26.9m grant within the framework of the European IPCEI Med4Cure project for the continued development of leriglitazone in lethal orphan CNS diseases
- [Topflight Pharma Development Veteran Joins Synendos](https://ysioscapital.com/2025/07/15/topflight-pharma-development-veteran-joins-synendos/) - Dr. George Garibaldi is named Chief Medical Officer (CMO) as Synendos transitions from Phase 1 into Phase 2 of its clinical development strategy
- [Cytoki Pharma Highlights Data Reinforcing Therapeutic Potential of Lipidated IL22 for IBD in Digestive Diseases and Sciences Publication](https://ysioscapital.com/2025/05/08/findings-support-lipidated-il-22-as-a-differentiated-treatment-option-to-address-the-significant-unmet-need-in-ibd/) - Results strongly support continued development of Cytoki’s oral IL-22 program for UC which is part of its growing preclinical pipeline of IL-22-based assets SØBORG, DENMARK – May 8, 2025 – Cytoki Pharma ApS (Cytoki), a clinical-stage biotechnology company pioneering a new class of medicines that harness interleukin-22 (IL-22) biology to drive improved metabolic and other
- [VarmX receives IND approval for Phase 3 trial of VMX-C001 in Urgent Surgery](https://ysioscapital.com/2025/07/08/varmx-receives-ind-approval-for-phase-3-trial-of-vmx-c001-in-urgent-surgery/) - VarmX receives IND approval for Phase 3 trial of VMX-C001 in Urgent Surgery
- [Top Spanish hospitals adopt the MAF Test to improve breast cancer treatment](https://ysioscapital.com/2025/07/17/top-spanish-hospitals-adopt-the-maf-test-to-improve-breast-cancer-treatment/) - Top Spanish hospitals adopt the Inbiomotion MAF Test to improve breast cancer treatment
- [Repronovo announces first participant included in U.S. Phase 2 trial of RPN-001 for male infertility](https://ysioscapital.com/2025/07/01/repronovo-announces-first-participant-included-in-u-s-phase-2-trial-of-rpn-001-for-male-infertility/) - First participant included in u.s. phase 2 trial of RPN-001 for male infertility
- [Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat](https://ysioscapital.com/2025/06/30/mineralys-therapeutics-announces-journal-of-the-american-medical-association-jama-publication-of-pivotal-phase-3-launch-htn-trial-for-lorundrostat/) - The Launch-HTN trial is the largest trial of an aldosterone synthase inhibitor completed in participants with uncontrolled or treatment resistant hypertension Lorundrostat 50 mg once daily demonstrated clinically meaningful reductions in systolic blood pressure, with a 16.9 mmHg reduction at Week 6 and a 19.0 mmHg reduction at Week 12 Lorundrostat was generally well-tolerated; and
- [Cytoki Pharma Announces First Patient Dosed in Phase 2 Study of CK-0045 in Obesity and Type 2 Diabetes](https://ysioscapital.com/2024/11/04/cytoki-pharma-announces-first-patient-dosed-in-phase-2-study-of-ck-0045-in-obesity-and-type-2-diabetes/) - Cytoki Pharma Announces First Patient Dosed in Phase 2 Study of CK-0045 in Obesity and Type 2 Diabetes
- [Memo Therapeutics AG Publishes Study in Frontiers in Pharmacology Demonstrating Therapeutic Antibody Transcytosis Across the Kidney Barrier After Intravenous Administration](https://ysioscapital.com/2025/06/11/memo-therapeutics-ag-publishes-study-in-frontiers-in-pharmacology-demonstrating-therapeutic-antibody-transcytosis-across-the-kidney-barrier-after-intravenous-administration/) - Study in Frontiers in Pharmacology detailing the transport of therapeutic IgG1 antibodies across the kidney endothelial barrier.
- [SparingVision appoints Dr. Kali Stasi as Chief Medical Officer](https://ysioscapital.com/2025/06/09/sparingvision-appoints-dr-kali-stasi-as-chief-medical-officer/) - Experienced global leader in ophthalmology and gene therapy to advance SparingVision’s clinical programs towards registration and commercialization
- [Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria](https://ysioscapital.com/2025/06/17/mineralys-therapeutics-announces-positive-topline-results-from-phase-2-explore-ckd-trial-of-lorundrostat-for-the-treatment-of-hypertension-in-subjects-with-ckd-and-albuminuria/) - Positive topline data from its Phase 2 trial evaluating the safety and efficacy of 25 mg of lorundrostat in subjects with hypertension and comorbid CKD
- [Neurona Doses First Patient in Phase 1/2 Trial of NRTX-1001 Cell Therapy in Adults with Drug-Resistant, Bilateral Mesial Temporal Lobe Epilepsy (MTLE)](https://ysioscapital.com/2025/06/18/neurona-doses-first-patient-in-phase-1-2-trial-of-nrtx-1001-cell-therapy-in-adults-with-drug-resistant-bilateral-mesial-temporal-lobe-epilepsy-mtle/) - First patient received bilateral administration of NRTX-1001; no significant surgical complications or adverse events reported to date Trial funded by a $14 million grant from California Institute for Regenerative Medicine Data from this bilateral trial, together with results from the previously announced Phase 3 EPIC study in unilateral MTLE, are intended to support a future
- [ANACONDA Biomed Receives CE Mark for Its ANA5 Funnel Catheter to Treat Ischemic Stroke](https://ysioscapital.com/2025/06/18/anaconda-biomed-receives-ce-mark-for-its-ana5-funnel-catheter-to-treat-ischemic-stroke/) - ANACONDA Biomed Receives CE Mark for Its ANA5 Funnel Catheter to Treat Ischemic Stroke
- [Anaconda Biomed Appoints Dr. Charles Carignan as New Chairman of the Board of Directors](https://ysioscapital.com/2025/06/11/anaconda-biomed-appoints-dr-charles-carignan-as-new-chairman-of-the-board-of-directors/) - Anaconda Biomed Appoints Dr. Charles Carignan as New Chairman of the Board of Directors
- [SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines](https://ysioscapital.com/2025/06/11/splicebio-secures-135-million-series-b-financing-to-advance-lead-program-sb-007-in-stargardt-disease-and-expand-pipeline-of-genetic-medicines/) - SpliceBio Secures $135 Million Series B Financing to Advance Lead Program SB-007 in Stargardt Disease and Expand Pipeline of Genetic Medicines
- [Adcendo ApS Announces First Patient Dosed in Phase I/II ADCElerate1 Trial of ADCE-D01](https://ysioscapital.com/2025/06/10/adcendo-aps-announces-first-patient-dosed-in-phase-i-ii-adcelerate1-trial-of-adce-d01/) - First patient has been dosed in Phase I/II ADCElerate1 clinical trial evaluating ADCE-D01 in patients with metastatic and/or unresectable soft tissue sarcoma
- [Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)](https://ysioscapital.com/2025/05/26/mineralys-therapeutics-announces-late-breaking-presentation-of-data-from-the-launch-htn-pivotal-trial-of-lorundrostat-in-uncontrolled-or-resistant-hypertension-at-34th-european-meeting-on-hypertension/) - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world setting Lorundrostat 50 mg dosed once daily demonstrated clinically meaningful and sustained reductions in systolic blood pressure, with a 16.9 mmHg reduction at Week 6 (-9.1 mmHg placebo
- [ReproNovo raises $65 million Series A financing to advance phase 2 clinical trials of novel therapies in reproductive medicine and women’s health](https://ysioscapital.com/2025/05/21/repronovo-raises-65-million-series-a-financing-to-advance-phase-2-clinical-trials-of-novel-therapies-in-reproductive-medicine-and-womens-health/) - ReproNovo raises $65 million Series A financing to advance phase 2 clinical trials of novel therapies in reproductive medicine and women’s health.
- [CorWave Announces Successful Completion of 6-Month Chronic In Vivo Study, Paving the Way for Clinical Trial Initiation](https://ysioscapital.com/2025/04/24/corwave-announces-successful-completion-of-6-month-chronic-in-vivo-study-paving-the-way-for-clinical-trial-initiation/) - CorWave Announces Successful Completion of 6-Month Chronic In Vivo Study, Paving the Way for Clinical Trial Initiation
- [Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101 and Appoints Keith Orford, MD, PhD, as Chief Medical Officer](https://ysioscapital.com/2025/04/22/tagworks-pharmaceuticals-announces-fda-clearance-of-ind-application-and-initiation-of-phase-1-clinical-trial-for-tgw101-and-appoints-keith-orford-md-phd-as-chief-medical-officer/) - Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101 and Appoints Keith Orford, MD, PhD, as Chief Medical Officer
- [SparingVision Receives FDA Support to Initiate Phase II trial of SPVN06 in Geographic Atrophy Secondary to Dry-AMD](https://ysioscapital.com/2025/04/22/sparingvision-receives-fda-support-to-initiate-phase-ii-trial-of-spvn06-in-geographic-atrophy-secondary-to-dry-amd/) - SparingVision Receives FDA Support to Initiate Phase II trial of SPVN06 in Geographic Atrophy Secondary to Dry-AMD
- [Anaconda Biomed Announces Publication of ANAIS Study Results in the American Journal of Neuroradiology](https://ysioscapital.com/2025/04/16/anaconda-biomed-announces-publication-of-anais-study-results-in-the-american-journal-of-neuroradiology/) - Data support use of its ANA funnel catheter as an adjunct to stent retriever thrombectomy in the treatment of acute ischemic stroke
- [Anaconda Biomed Enrolls First U.S. Patient in the ATHENA Clinical Trial Evaluating ANA Funnel Catheter for Ischemic Stroke Treatment](https://ysioscapital.com/2025/04/04/anaconda-biomed-enrolls-first-u-s-patient-in-the-athena-clinical-trial-evaluating-ana-funnel-catheter-for-ischemic-stroke-treatment/) - Anaconda Biomed Enrolls First U.S. Patient in the ATHENA Clinical Trial Evaluating ANA Funnel Catheter for Ischemic Stroke Treatment
- [Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline](https://ysioscapital.com/2025/04/04/neurona-therapeutics-raises-102-million-to-fuel-nrtx-1001-phase-3-epic-epilepsy-trial-and-advance-regenerative-cell-therapy-pipeline/) - Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline
- [CorWave Announces the Appointment of Dawn Sadlowski-Buisserez as Vice President of Operations to Support the Ramp-Up of Production](https://ysioscapital.com/2025/04/02/corwave-announces-the-appointment-of-dawn-sadlowski-buisserez-as-vice-president-of-operations-to-support-the-ramp-up-of-production/) - Clichy, France, April 2nd, 2025 – CorWave, a French company developing and manufacturing innovative cardiac assist devices, announces the appointment of Dawn Sadlowski-Buisserez as Vice President of Operations. Dawn Sadlowski Buisserez brings extensive experience in implantable medical devices to support CorWave's production scale-up. Her expertise is a major asset for CorWave’s industrial development and its
- [Adcendo ApS Announces Changes in Board of Directors and Strengthens Executive Leadership Team](https://ysioscapital.com/2025/04/01/adcendo-aps-announces-changes-in-board-of-directors-and-strengthens-executive-leadership-team/) - Adcendo ApS Announces Changes in Board of Directors and Strengthens Executive Leadership Team
- [Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)](https://ysioscapital.com/2025/03/29/mineralys-therapeutics-announces-late-breaking-data-from-advance-htn-pivotal-trial-of-lorundrostat-in-uncontrolled-and-resistant-hypertension-presented-at-the-american-college-of-cardiologys/) - Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile Lorundrostat is a highly selective aldosterone synthase inhibitor that disrupts aldosterone biosynthesis rather than blocking the mineralocorticoid receptor Data from Advance-HTN support the potential of lorundrostat
- [LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update](https://ysioscapital.com/2025/03/28/lava-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-a-business-update/) - Focused on the evaluation of strategic alternatives Adopted a restructuring plan to extend capital resources, incurring a reduction in workforce of 30% to support the evaluation of strategic options and the Phase 1 study for LAVA-1266 Phase 1 enrollment in LAVA-1266 clinical trial underway Johnson and Johnson development milestone of $5.0 million achieved and received
- [LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers](https://ysioscapital.com/2025/01/10/lava-doses-first-patient-in-phase-1-lava-1266-study-in-hematological-cancers/) - LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody® First-in-human study enrolling adult patients with CD123-expressing AML or MDS Initial Phase 1 data read-out expected by year-end 2025 UTRECHT, The Netherlands and PHILADELPHIA, Jan. 10, 2025 (GLOBE NEWSWIRE) - LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific
- [LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027](https://ysioscapital.com/2024/12/10/lava-reports-third-quarter-2024-financial-results-and-announces-pipeline-reprioritization-and-cash-runway-extension-into-2027/) - Reprioritized pipeline to focus on LAVA-1266, with continued support for partnered programs with Pfizer and Johnson and Johnson
- [LAVA Reports Second Quarter 2024 Financial Results and Business Update](https://ysioscapital.com/2024/08/20/lava-reports-second-quarter-2024-financial-results-and-business-update/) - Continued progress in Phase 1/2a dose escalation for LAVA-1207, including the monotherapy arm, now enrolling in dose level 12, and the pembrolizumab combination Favorable safety profile for LAVA-1207 Next data update for LAVA-1207 program expected in Q4 2024 Strong balance sheet with cash of $86.8 million supports runway into mid-2026 UTRECHT, The Netherlands and PHILADELPHIA,
- [Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET](https://ysioscapital.com/2025/03/25/mineralys-therapeutics-to-host-kol-call-to-discuss-clinical-data-from-launch-htn-and-advance-htn-pivotal-trials-tuesday-april-1-2025-at-800-am-et/) - Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET
- [Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress](https://ysioscapital.com/2025/03/24/positive-data-from-phase-1-trial-of-bel-sar-in-patients-with-non-muscle-invasive-bladder-cancer-nmibc-presented-at-the-40th-annual-european-association-of-urology-congress/) - Clinical Complete Responses Observed with Single Low-Dose of Bel-sar in Patients with Intermediate and High-Risk NMIBC with Robust Cell-Mediated Immunity and Urothelial Field Effect Favorable Safety Profile; Only Grade 1 Drug-Related Adverse Events Reported in Less Than 10% of Patients Data Supports Potential for a Paradigm Shifting Approach in the Front-Line Treatment of patients with NMIBC
- [Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights](https://ysioscapital.com/2025/03/25/aura-biosciences-reports-fourth-quarter-and-full-year-2024-financial-results-and-business-highlights/) - Positive Phase 1 Trial Data in Non-Muscle Invasive Bladder Cancer (NMIBC)
- [Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock](https://ysioscapital.com/2025/03/18/mineralys-therapeutics-announces-closing-of-underwriters-option-to-purchase-additional-shares-in-connection-with-public-offering-of-common-stock/) - Announced today the closing of the sale of an additional 1,944,444 shares of its common stock at a public offering price of $13.50 per share
- [SpliceBio Announces First Patient Dosed in Phase 1/2 ASTRA Study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease](https://ysioscapital.com/2025/03/13/splicebio-announces-first-patient-dosed-in-phase-1-2-astra-study-of-sb-007-a-dual-aav-gene-therapy-for-stargardt-disease/) - SB-007 addresses the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations SB-007 is the first dual AAV gene therapy in clinical development for Stargardt disease BARCELONA, SPAIN, 13 March 2025 – SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations in
- [Xeltis expands Medical Advisory Board with World Leading Experts in Clinical Nephrology](https://ysioscapital.com/2025/03/11/xeltis-expands-medical-advisory-board-with-world-leading-experts-in-clinical-nephrology/) - Leading nephrologists Dr. An De Vriese and Dr. Monnie Wasse join as Company continues clinical advancement
- [Mineralys Therapeutics Announces Proposed Public Offering of Common Stock](https://ysioscapital.com/2025/03/11/mineralys-therapeutics-announces-proposed-public-offering-of-common-stock/) - RADNOR, Pa., March 10, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that it has commenced an underwritten public offering of $250.0 million of shares of
- [Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension](https://ysioscapital.com/2025/03/10/mineralys-therapeutics-announces-positive-topline-results-from-launch-htn-and-advance-htn-pivotal-trials-of-lorundrostat-for-the-treatment-of-uncontrolled-or-resistant-hypertension/) - Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension
- [MedLumics® Announces the Publication of FIM Results for the AblaView® (PF) Ablation System in (AF) Patients, Including Clinical Safety and Our Ability to Predict Durable Lesions at 3 Months With 100% Specificity](https://ysioscapital.com/2025/03/05/medlumics-announces-the-publication-of-fim-results-for-the-ablaview-pf-ablation-system-in-af-patients-including-clinical-safety-and-our-ability-to-predict-durable-lesions-at-3-months/) - MADRID--(BUSINESS WIRE)- March, 5 2025 -“We would like to thank the investigation site team and particularly the investigators and proctors in this groundbreaking first-in human trial and for enabling the publication of these important validating results.” Peter Hinchliffe, CEO MedLumics “Join us as we raise our Series B funding of €15m to reach our regulatory clinical trial
- [NorthSea Therapeutics Announces Publication of Positive Results from Phase 2b ICONA Clinical Trial of Icosabutate in Biopsy-Confirmed F1-F3 MASH in Journal of Hepatology](https://ysioscapital.com/2025/03/06/northsea-therapeutics-announces-publication-of-positive-results-from-phase-2b-icona-clinical-trial-of-icosabutate-in-biopsy-confirmed-f1-f3-mash-in-journal-of-hepatology/) - NorthSea Therapeutics Announces Publication of Positive Results from Phase 2b ICONA Clinical Trial of Icosabutate in Biopsy-Confirmed F1-F3 MASH in Journal of Hepatology
- [Minoryx announces dosing of the first patient with leriglitazone in the phase 2a study in Rett’s Syndrome (TREE study)](https://ysioscapital.com/2025/03/05/minoryx-announces-dosing-of-the-first-patient-with-leriglitazone-in-the-phase-2a-study-in-retts-syndrome-tree-study/) - TREE is a phase 2a clinical study assessing the safety and efficacy of lead candidate leriglitazone.
- [SparingVision appoints Anjeza Gjino as Chief Financial Officer](https://ysioscapital.com/2025/03/03/sparingvision-appoints-anjeza-gjino-as-chief-financial-officer/) - SparingVision appoints Anjeza Gjino as Chief Financial Officer
- [Adcendo ApS Announces U.S. FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02](https://ysioscapital.com/2025/02/26/adcendo-aps-announces-u-s-fda-clearance-of-ind-application-for-phase-i-tiffany-01-trial-of-adce-t02/) - Adcendo ApS Announces U.S. FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02
- [NorthSea Therapeutics Announces Expansion of Leadership Team with Key Industry Veteran Hires](https://ysioscapital.com/2025/02/20/northsea-therapeutics-announces-expansion-of-leadership-team-with-key-industry-veteran-hires/) - NorthSea Therapeutics Announces Expansion of Leadership Team with Key Industry Veteran Hires
- [Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy](https://ysioscapital.com/2025/02/20/neurona-unveils-phase-3-epic-study-for-nrtx-1001-cell-therapy-in-epilepsy/) - Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy
- [Ona Therapeutics Strengthens Leadership Team to Accelerate First-in-Class ADCs into Clinical Development Across Cancer Types](https://ysioscapital.com/2025/02/19/ona-therapeutics-strengthens-leadership-team/) - Dr. Aleix Prat, an internationally recognized leader in drug and biomarker development appointed Chair of the Advisory Board Dr. Jutta Amersdorffer appointed as Chief Medical Officer and Stéphane Durant des Aulnois appointed as Chief Financial Officer Accelerating development of first-in-class ADCs in multiple large solid tumor types designed against novel targets with a focus on
- [Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria](https://ysioscapital.com/2025/02/04/mineralys-therapeutics-completes-enrollment-in-explore-ckd-phase-2-trial-of-lorundrostat-for-the-treatment-of-hypertension-in-subjects-with-stage-2-to-3b-ckd-and-albuminuria/) - Continues to anticipate announcing topline data from Explore-CKD trial in Q2 2025 RADNOR, Pa., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that it
- [SparingVision advances PRODYGY trial into Phase II following positive DSMB recommendation](https://ysioscapital.com/2025/01/21/sparingvision-advances-prodygy-trial-into-phase-ii-following-positive-dsmb-recommendation/) - DSMB confirms favorable safety profile of SPVN06 across all three doses in patients with severe advanced rod-cone dystrophy (RCD)(n=9) Trial to progress to phase II to evaluate the two highest doses of SPVN06 in patients with intermediate advanced RCD Paris, 21 January 2025 – SparingVision (“the Company”), a clinical-stage genomic medicine company transforming the treatment
- [Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension](https://ysioscapital.com/2025/01/08/mineralys-therapeutics-announces-phase-2-clinical-trial-of-lorundrostat-for-obstructive-sleep-apnea-in-patients-with-hypertension/) - Obstructive sleep apnea Mineralys’ third precision, targeted indication for lorundrostat, further expanding its market potential in aldosterone-driven diseases
- [Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval](https://ysioscapital.com/2025/01/07/xeltis-announces-completion-of-enrolment-in-eu-pivotal-trial-for-axess-and-prepares-for-market-approval/) - Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval.
- [Anaconda Biomed Appoints Trent Reutiman New CEO](https://ysioscapital.com/2025/01/07/anaconda-biomed-appoints-trent-reutiman-new-ceo/) - Seasoned Medtech Executive to Expand Company Presence Into U.S. BARCELONA, Spain & MARIN, Calif.--(BUSINESS WIRE)-- Anaconda Biomed S.L., a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, has announced that it has named long-time medtech executive Trent Reutiman as its new CEO. Based in California’s San Francisco Bay Area, Reutiman
- [Kynexis Announces Positive Topline Results from Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia](https://ysioscapital.com/2024/12/17/kynexis-announces-positive-topline-results-from-phase-1-study-of-kyn-5356-a-potential-treatment-for-cognitive-impairment-associated-with-schizophrenia/) - KYN-5356, an innovative, first-in-class small molecule inhibitor of KAT-II, a key enzyme in the kynurenine pathway implicated in schizophrenia, was shown to be safe and well-tolerated in the phase 1 study in healthy volunteers Initial data show clear evidence of target engagement and suggestive evidence of cognitive improvement, adding to body of evidence that supports
- [SpliceBio Announces U.S. FDA IND Clearance of SB-007 to Commence Phase 1/2 Clinical Study in Patients with Stargardt Disease](https://ysioscapital.com/2024/12/12/splicebio-announces-u-s-fda-ind-clearance-of-sb-007-to-commence-phase-1-2-clinical-study-in-patients-with-stargardt-disease/) - SB-007 is the only IND-cleared, clinical-stage therapeutic addressing the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations Phase 1/2 ASTRA study set to begin in the first half of 2025, supported by POLARIS, a pioneering company-sponsored natural history study in Stargardt disease First ever IND clearance for
- [Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy](https://ysioscapital.com/2024/12/11/leriglitazone-has-met-the-primary-endpoint-in-nexus-the-pivotal-trial-for-pediatric-patients-with-cerebral-adrenoleukodystrophy/) - Statistically significant difference in arrested disease in leriglitazone treated patients when compared to the natural history of the disease Submission of European marketing authorization application (MAA) for leriglitazone expected mid-2025 Barcelona, Spain and Düsseldorf, Germany – 11 December 2024 – Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central
- [QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing](https://ysioscapital.com/2024/11/28/qiagen-strengthens-qiastat-dx-with-new-barcelona-site-to-drive-growth-in-infectious-diseases-and-precision-medicine-testing/) - New Barcelona site to help drive global expansion of QIAstat-Dx as QIAGEN expands local presence with multi-year investment Site in Esplugues de Llobregat to serve as an innovation hub for QIAstat-Dx, supporting the development of infectious disease tests and precision medicine applications BARCELONA, Spain & VENLO, the Netherlands--(BUSINESS WIRE)-- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA)
- [Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy Announced at 2024 Annual Meeting of the American Epilepsy Society](https://ysioscapital.com/2024/12/06/neurona-therapeutics-presents-positive-clinical-update-new-data-from-nrtx-1001-cell-therapy-trial-in-drug-resistant-epilepsy-announced-at-2024-annual-meeting-of-the-american-epilepsy-society/) - Neurona Therapeutics Presents Positive Clinical Update: New Data from NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy Announced at 2024 Annual Meeting of the American Epilepsy Society
- [Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First- in-class ADC Pipeline](https://ysioscapital.com/2024/11/25/adcendo-aps-completes-oversubscribed-135-million-series-b-financing-to-advance-first-in-class-adc-pipeline/) - Financing led by TCGX, including new investment from TPG, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, with participation from all existing investors Proceeds will be used to support the advancement of multiple first-in-class ADC programs into the clinic and through clinical proof of concept Copenhagen, Denmark – November
- [AELIX’s HTI HIV Vaccine Investigational Assets Acquired by Gilead Sciences](https://ysioscapital.com/2024/11/25/aelixs-hti-hiv-vaccine-investigational-assets-acquired-by-gilead-sciences/) - AELIX’s HTI HIV Vaccine Investigational Assets Acquired by Gilead Sciences
- [Ysios Capital ESG Report](https://ysioscapital.com/2024/11/20/esg_report_2024/) - Ysios Capital’s mission to improve patients’ lives and create a positive societal impact by funding the development of transformative therapies.
- [Xeltis announces FDA Breakthrough Device Designation for aXessTM and first patient treated in US pivotal trial](https://ysioscapital.com/2024/11/14/xeltis-announces-fda-breakthrough-device-designation-for-axesstm-and-first-patient-treated-in-us-pivotal-trial/) - Designation recognizes aXess has the potential of providing a more effective vascular access option for dialysis patients, bringing significant advantages over current therapies First patient treated in US pivotal trial, marking significant clinical milestone EINDHOVEN, The Netherlands, 14 November 2024 – Xeltis, a leading developer of transformative implants that enable the natural creation of living
- [KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update](https://ysioscapital.com/2024/08/06/kala-bio-reports-second-quarter-2024-financial-results-and-provides-corporate-update/) - KALA BIO Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- [KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update](https://ysioscapital.com/2024/05/14/kala-bio-reports-first-quarter-2024-financial-results-and-provides-corporate-update/) - KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update
- [KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update](https://ysioscapital.com/2024/03/29/kala-bio-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-corporate-update/) - Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 -- -- Exploring opportunities to expand KPI-012 into additional corneal indications -- -- Cash resources as of December 31, 2023, together with proceeds from the March 2024 private placement and anticipated funding remaining from CIRM award, expected to fund
- [Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights](https://ysioscapital.com/2024/11/12/aura-biosciences-reports-third-quarter-2024-financial-results-and-business-highlights/) - Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights
- [Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update](https://ysioscapital.com/2024/11/11/mineralys-therapeutics-reports-third-quarter-2024-financial-results-and-provides-corporate-update/) - Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering topline data in mid first half of 2025 Ongoing enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025 – Conference call today at
- [VarmX announces appointment of John Glasspool as CEO](https://ysioscapital.com/2024/11/12/varmx-announces-appointment-of-john-glasspool-as-ceo/) - John has over 30 years’ experience within the global biopharma industry, linking science and business.
- [Xeltis expands leadership team with appointment of Luc Verhees as Vice President of Clinical Business Development](https://ysioscapital.com/2024/11/05/xeltis-expands-leadership-team-with-appointment-of-luc-verhees-as-vice-president-of-clinical-business-development/) - Xeltis expands leadership team with appointment of Luc Verhees as Vice President of Clinical Business Development
- [Memo Therapeutics AG Appoints Frits van Alphen, MD as Chief Development Officer](https://ysioscapital.com/2024/11/04/memo-therapeutics-ag-appoints-frits-van-alphen-md-as-chief-development-officer/) - Frits is an industry veteran with a proven track record in nephrology drug development, including the successful development of Velphoro® and Ferinject® at Vifor Pharma Schlieren / Zurich, Switzerland, 4 November, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer,
- [Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant Patients](https://ysioscapital.com/2024/11/01/memo-therapeutics-ag-announces-last-patient-enrolled-in-phase-ii-clinical-trial-of-potravitug-for-treatment-of-bk-viremia-in-kidney-transplant-patients/) - Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial
- [Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension](https://ysioscapital.com/2024/10/30/mineralys-therapeutics-completes-enrollment-ahead-of-schedule-in-launch-htn-the-second-pivotal-trial-of-lorundrostat-for-the-treatment-of-hypertension/) - Topline data now anticipated in mid first half of 2025 Management to host virtual KOL event today to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program for lorundrostat in hypertension RADNOR, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical
- [MedLumics new CEO and Board Member announces 10 patients treated in First in Man (FIM) clinical trial with the real-time visually guided AblaView PFA System.](https://ysioscapital.com/2024/10/29/medlumics-new-ceo-and-board-member-announces-10-patients-treated-in-first-in-man-fim-clinical-trial-with-the-real-time-visually-guided-ablaview-pfa-system/) - MADRID – 29 October 2024 – MedLumics , a medical device company developing fiber optically guided platform technologies for the treatment, initially, of Atrial fibrillation (AF), announced today 10 patients treated in the company’s First in Man clinical trial. The AblaView Unipolar Pulsed Field (PF) Ablation System, used in this trial, features MedLumics unique, real-time, fiber optic, visually guided AF
- [SparingVision Presents Updates on PRODYGY Trial and PHENOROD2 Study at ESGCT 2024](https://ysioscapital.com/2024/10/24/sparingvision-presents-updates-on-prodygy-trial-and-phenorod2-study-at-esgct-2024/) - First oral presentation on PRODYGY at a major cell and gene therapy-focused conference Completion of PRODYGY Step 1 (9 patients treated across three doses through dose escalation) Paris, 24 October 2024 – SparingVision (“the Company”), a clinical-stage genomic medicine company transforming the treatment of retinal disease, today announces the presentation of a progress update from
- [Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy](https://ysioscapital.com/2024/08/27/alex-bastian-joins-memo-therapeutics-ag-as-vp-commercial-strategy/) - Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy
- [Vivet Therapeutics Presents Three Posters on Cerebrotendinous Xanthomatosis Program and Novel AAV Gene Delivery Platform at European Society of Gene and Cell Therapy Annual Congress 2024](https://ysioscapital.com/2024/10/22/vivet-therapeutics-presents-three-posters-on-cerebrotendinous-xanthomatosis-program-and-novel-aav-gene-delivery-platform-at-european-society-of-gene-and-cell-therapy-annual-congress-2024/) - Vivet Therapeutics Presents Three Posters on Cerebrotendinous Xanthomatosis Program and Novel AAV Gene Delivery Platform at European Society of Gene and Cell Therapy Annual Congress 2024
- [Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma](https://ysioscapital.com/2024/10/17/aura-biosciences-reports-positive-phase-2-end-of-study-results-evaluating-bel-sar-as-a-first-line-treatment-for-early-stage-choroidal-melanoma-2/) - Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial
- [Inbiomotion and SPA - Società Prodotti Antibiotici (SPA Farma) sign an exclusive agreement for MAF Test® in Italy](https://ysioscapital.com/2024/10/09/inbiomotion-and-spa-societa-prodotti-antibiotici-spa-farma-sign-an-exclusive-agreement-for-maf-test-in-italy/) - Inbiomotion and SPA - Società Prodotti Antibiotici (SPA Farma) sign an exclusive agreement for MAF Test® in Italy
- [Adcendo Announces US FDA Clearance of IND Application for Phase I/II First-in-Human ADCElerate-01 Trial of ADCE-D01 (uPARAP Receptor Targeting ADC) Trial in Patients with Metastatic and/or Unresectable Soft Tissue Sarcoma (STS)](https://ysioscapital.com/2024/10/08/adcendo-announces-us-fda-clearance-of-ind-application-for-phase-i-ii-first-in-human-adcelerate-01-trial-of-adce-d01-uparap-receptor-targeting-adc-trial-in-patients-with-metastatic-and-or-unresectabl/) - ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor which is highly overexpressed in mesenchymal cancers including multiple STS subtypes The Phase I/II ADCElerate-01 trial is designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of ADCE-D01 as a monotherapy in patients with metastatic and/or unresectable STS Copenhagen, Denmark, October 8th, 2024 –
- [Tagworks Pharmaceuticals Appoints Ken Mills as Chief Executive Officer](https://ysioscapital.com/2024/10/01/tagworks-pharmaceuticals-appoints-ken-mills-as-chief-executive-officer/) - Biotech industry veteran to lead Tagworks as the company prepares to bring its novel platform and lead antibody-drug conjugate (ADC) program for solid tumors into the clinic in 2025
- [Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension](https://ysioscapital.com/2024/09/25/mineralys-therapeutics-completes-target-enrollment-in-pivotal-advance-htn-trial-of-lorundrostat-for-the-treatment-of-hypertension/) - On track to announce topline data in Q1 2025 Virtual KOL event scheduled on October 30th to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program for lorundrostat in hypertension RADNOR, Pa., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company
- [SparingVision Reports Progress on SPVN06 at Major Ophthalmology Conferences](https://ysioscapital.com/2024/09/23/sparingvision-reports-progress-on-spvn06-at-major-ophthalmology-conferences/) - SPVN06 demonstrates continued favorable safety profile at 12 months for low dose and 6 months for medium dose in PRODYGY Phase I/II trial Data presented at the Retina Society Annual Scientific Meeting (Lisbon, September 11) and Euretina Congress (Barcelona, September 21) Paris, 23 September 2024 – SparingVision (“the Company”), a clinical-stage genomic medicine company transforming the
- [Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate](https://ysioscapital.com/2024/09/10/neurona-therapeutics-receives-3-8-million-cirm-grant-for-the-development-of-next-generation-neural-cell-therapy-candidate/) - San Francisco, CA, September 10, 2024 – Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded a $3.8M grant to support the development of a next generation neural cell therapy candidate. “We’re grateful for the ongoing partnership
- [Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update](https://ysioscapital.com/2024/08/13/mineralys-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate-update/) - Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- [Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights](https://ysioscapital.com/2024/08/08/aura-biosciences-reports-first-quarter-2024-financial-results-and-business-highlights-2/) - Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights
- [Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on First-in-class ADC Drug Candidate Targeting Tissue Factor](https://ysioscapital.com/2024/08/20/adcendo-aps-and-multitude-therapeutics-inc-announce-global-development-and-commercialization-agreement-on-first-in-class-adc-drug-candidate-targeting-tissue-factor/) - Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on First-in-class ADC Drug Candidate Targeting Tissue Factor
- [Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia](https://ysioscapital.com/2024/09/18/engrail-therapeutics-initiates-enx-104-clinical-program-for-the-treatment-of-major-depressive-disorder-characterized-by-anhedonia/) - Engrail Therapeutics Initiates ENX-104 Clinical Program for the Treatment of Major Depressive Disorder Characterized by Anhedonia
- [Engrail Therapeutics Appoints Paul Cayer as Chief Financial Officer and Saira Ramasastry to Board of Directors](https://ysioscapital.com/2024/08/08/engrail-therapeutics-appoints-paul-cayer-as-chief-financial-officer-and-saira-ramasastry-to-board-of-directors/) - Engrail Therapeutics Appoints Paul Cayer as Chief Financial Officer and Saira Ramasastry to Board of Directors
- [Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma](https://ysioscapital.com/2024/09/12/aura-biosciences-reports-positive-phase-2-end-of-study-results-evaluating-bel-sar-as-a-first-line-treatment-for-early-stage-choroidal-melanoma/) - Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
- [Cytoki Pharma Announces Positive Phase 1 Data Showing Potential of CK-0045 to Improve Cardiometabolic Risk Factors](https://ysioscapital.com/2024/07/23/cytoki-pharma-announces-positive-phase-1-data-showing-potential-of-ck-0045-to-improve-cardiometabolic-risk-factors/) - Cytoki announced positive data from a Phase 1 study evaluating the safety, tolerability, and pharmacokinetics of CK-0045, its lead lipidated IL-22 candidate
- [Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs](https://ysioscapital.com/2024/06/26/neurona-therapeutics-appoints-dr-nadia-agopyan-as-senior-vice-president-of-regulatory-affairs/) - There is a high unmet medical need in refractory focal epilepsy, and NRTX-1001 potentially represents a breakthrough, with the goal to provide persistent seizure control from a single administration.
- [Neurona Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for NRTX-1001 in Focal Epilepsy](https://ysioscapital.com/2024/06/18/neurona-therapeutics-receives-fdas-regenerative-medicine-advanced-therapy-rmat-designation-for-nrtx-1001-in-focal-epilepsy/) - Neurona Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for NRTX-1001 in Focal Epilepsy
- [Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer](https://ysioscapital.com/2024/06/11/neurona-therapeutics-appoints-dr-manher-joshi-as-chief-medical-officer/) - a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for disorders of the nervous system
- [Neurona Therapeutics Presents Positive Clinical Update from NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2024 Annual Meeting](https://ysioscapital.com/2024/04/15/neurona-therapeutics-presents-positive-clinical-update-from-nrtx-1001/) - a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for the potential treatment of neurological disorders
- [LAVA provides business updates and reports first quarter 2024 financial results](https://ysioscapital.com/2024/05/21/lava-provides-business-updates-and-reports-first-quarter-2024-financial-results/) - LAVA a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta (δ2) T cell engagers,
- [Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors](https://ysioscapital.com/2024/06/14/mineralys-therapeutics-appoints-biopharmaceutical-executive-alexander-m-gold-m-d-to-its-board-of-directors/) - Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors
- [Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update](https://ysioscapital.com/2024/05/09/mineralys-therapeutics-reports-first-quarter-2024-financial-results-and-provides-corporate-update/) - Clinical-stage biopharmaceutical focused on developing medicines to target hypertension, chronic kidney disease (CKD) & other diseases driven by dysregulated aldosterone
- [Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights](https://ysioscapital.com/2024/05/09/aura-biosciences-reports-first-quarter-2024-financial-results-and-business-highlights/) - Clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer
- [Memo Therapeutics ag appoints Paul Carter as Chairperson](https://ysioscapital.com/2024/07/08/memo-therapeutics-ag-appoints-paul-carter-as-chairperson/) - Paul has had an extensive executive career in the biopharma space, with commercial and M&A expertise spanning North America, Europe, and Asia.
- [Xeltis appoints Shawn Gage as Vice President of US Clinical Affairs](https://ysioscapital.com/2024/07/23/xeltis-appoints-shawn-gage-as-vice-president-of-us-clinical-affairs/) - Brings extensive experience in design, development, and implementation of US medtech clinical trial strategy for hemodialysis and vascular access Follows expansion of Xeltis’ clinical presence in the US after recent IDE approval for aXessTM US pivotal trial EINDHOVEN, Netherlands, July 23, 2024 /PRNewswire/ -- Xeltis, a leading developer of transformative implants that enable the natural creation of living and
- [Anaconda Biomed Receives IDE Approval to Initiate Enrollment in the ATHENA Study](https://ysioscapital.com/2024/07/17/anaconda-biomed-receives-ide-approval-to-initiate-enrollment-in-the-athena-study/) - Anaconda Biomed Receives IDE Approval to Initiate Enrollment in the ATHENA Study
- [Dr Gloria Gonzalez-Aseguinolaza, Chief Scientific Officer of Vivet Therapeutics Receives the Rosalind Franklin Society Special Award in Science](https://ysioscapital.com/2024/07/16/dr-gloria-gonzalez-aseguinolaza-chief-scientific-officer-of-vivet-therapeutics-receives-the-rosalind-franklin-society-special-award-in-science/) - Recognition of her pioneering gene therapy research Coordinated the first ever gene therapy clinical trial utilizing AAVs as a vector for the treatment of an inherited liver metabolic disease for acute intermittent porphyria Her work on AAVs has been instrumental in creating Vivet’s research platform and advancing development of Vivet’s lead gene therapy for Wilson’s
- [Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy in compassionate-use study published in Brain](https://ysioscapital.com/2024/06/11/leriglitazone-halts-disease-progression-in-adult-patients-with-early-cerebral-adrenoleukodystrophy-in-compassionate-use-study-published-in-brain/) - In a French early-access program study, 10 of 13 patients were clinically and radiologically stable Mataró, Barcelona, Spain, 11 June, 2024 - Minoryx Therapeutics (“Minoryx”), a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announce that results from a compassionate use study of leriglitazone for treatment of
- [Kynexis Appoints Esteemed Scientific Advisory Board Members to Advance Precision Therapeutics for Brain Diseases](https://ysioscapital.com/2024/05/24/kynexis-appoints-esteemed-scientific-advisory-board-members-to-advance-precision-therapeutics-for-brain-diseases/) - Esteemed Scientific Advisory Board Members to Advance Precision Therapeutics for Brain Diseases
- [Xeltis receives IDE approval from FDA for initiation of US pivotal trial for aXessTM, its restorative vascular access conduit](https://ysioscapital.com/2024/06/13/xeltis-receives-ide-approval-from-fda-for-initiation-of-us-pivotal-trial-for-axesstm-its-restorative-vascular-access-conduit/) - aXess is a restorative arteriovenous dialysis conduit which allows vascular access for hemodialysis through the creation of a new, permanent, living vessel EINDHOVEN, The Netherlands, 13 June 2024 - Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announces that it has gained approval from the US
- [Mineralys Therapeutics Announces $120 Million Private Placement Financing](https://ysioscapital.com/2024/02/08/mineralys-therapeutics-announces-120-million-private-placement-financing/) - Mineralys Therapeutics Announces $120 Million Private Placement Financing
- [Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders](https://ysioscapital.com/2024/02/09/neurona-therapeutics-raises-120m-to-advance-groundbreaking-pipeline-of-regenerative-cell-therapy-candidates-for-chronic-neurological-disorders/) - The financing, co-led by Viking Global Investors and Cormorant Asset Management with participation from The Column Group along with additional new and existing investors, follows promising early clinical data from NRTX-1001 epilepsy program San Francisco, CA, February 8, 2024 – Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders,
- [Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies](https://ysioscapital.com/2024/03/20/ysios-capital-joins-engrail-therapeutics-157m-series-b-financing/) - Proceeds to Support Advancement of Engrail’s Pipeline for Neuropsychiatric and Neurodevelopmental Disorder SAN DIEGO – March 19, 2024 – Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, today announced the close of an oversubscribed $157 million Series B financing round. The
- [Memo Therapeutics increases Series C financing to CHF 45 million](https://ysioscapital.com/2024/05/07/memo-therapeutics-increases-series-c-financing-to-chf-45-million/) - Additional CHF 20 million raised from new investors Ysios Capital and Kurma Partners as well as from existing investors.
- [Adcendo ApS Announces Extension of Series A Financing to EUR 98M to Further Bolster its First-in-Class ADC Pipeline](https://ysioscapital.com/2024/05/29/adcendo-aps-announces-extension-of-series-a-financing-to-eur-98m-to-further-bolster-its-first-in-class-adc-pipeline/) - Funds will be used to further strengthen growing pipeline of first in class ADC assets, including lead asset targeting uPARAP
- [AM-Pharma Announces Appointment of Russell Greig as Chairman.](https://ysioscapital.com/2012/01/12/am-pharma-announces-appointment-of-russell-greig-as-chairman/) - Bunnik, The Netherlands, 4 January 2012. AM-Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of recombinant human Alkaline Phosphatase (AP) for treatment of Acute Kidney Injury and Inflammatory bowel diseases, today announced the appointment of Dr Russell Greig as Chairman of the Supervisory Board. Dr Greig served nearly three decades with
- [Xeltis secures additional €12.5 million from European Innovation Council Fund in final close of D2 financing](https://ysioscapital.com/2023/08/14/xeltis-secures-additional-e12-5-million-from-european-innovation-council-fund-in-final-close-of-d2-financing/) - Xeltis announces closing of an additional €12.5 million in funding from the European Innovation Council (EIC) Fund, set up by the European Commission
- [VarmX Promotes CSO Dr. Jeffrey Lawson to New CEO and Moves to New State-of-the-Art Facility](https://ysioscapital.com/2023/10/12/varmx-promotes-cso-dr-jeffrey-lawson-to-new-ceo-and-moves-to-new-state-of-the-art-facility/) - VarmX Promotes CSO Dr. Jeffrey Lawson to New CEO and Moves to New State-of-the-Art Facility
- [Synendos Therapeutics Expands Series A to CHF 24 million with new investment](https://ysioscapital.com/2021/04/20/synendos-therapeutics-expands-series-a-to-chf-24-million-with-new-investment/) - Ysios Capital joins existing syndicate co-led by Kurma Partners and Sunstone Life Science Ventures.
- [Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights](https://ysioscapital.com/2024/03/27/aura-biosciences-reports-fourth-quarter-and-full-year-2023-financial-results-and-business-highlights/) - Enrolling Patients in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions; Granted SPA Agreement by FDA Data Expected Mid-2024 from Ongoing Phase 1 Trial in Bladder Cancer (Non-Muscle Invasive Bladder Cancer and Muscle Invasive Bladder Cancer) Strong Cash Position into Second Half of 2026 BOSTON--(BUSINESS WIRE)--Mar. 27, 2024-- Aura Biosciences, Inc. (NASDAQ: AURA),
- [Lava provides business updates and reports fourth quarter and year-end financial results](https://ysioscapital.com/2024/03/20/lava-provides-business-updates-and-reports-fourth-quarter-and-year-end-financial-results/) - LAVA-1207 progressing in Phase 1/2a study, with pembrolizumab combination expected to begin in Q2 2024
- [Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update](https://ysioscapital.com/2024/03/21/mineralys-therapeutics-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-corporate-update/) - Enrollment in the two pivotal trials of lorundrostat for the treatment of uHTN or rHTN is on track, with topline data expected for Advance-HTN trial in Q4 2024 and Launch-HTN trial in 2H 2025
- [Fusion Pharmaceuticals To Be Acquired By AstraZeneca, Accelerating Development Of Next-Generation Radioconjugates To Treat Cancer](https://ysioscapital.com/2024/03/19/fusion-pharmaceuticals-to-be-acquired-by-astrazeneca-accelerating-development-of-next-generation-radioconjugates-to-treat-cancer/) - Accelerating Development Of Next-Generation Radioconjugates To Treat Cancer
- [NorthSea Therapeutics Initiates Phase 2A Trial of Orziloben (NST-6179) in Intestinal Failure-Associated Liver Disease (IFALD)](https://ysioscapital.com/2024/02/21/northsea-therapeutics-initiates-phase-2a-trial-of-orziloben-nst-6179-in-intestinal-failure-associated-liver-disease-ifald/) - Phase 2a study evaluating the safety, tolerability, PK, and PD of Orziloben in Intestinal failure-associated liver disease (IFALD)
- [SparingVision Presents Initial SPVN06 Safety Data at the Macula Society 47th Annual Meeting](https://ysioscapital.com/2024/02/08/sparingvision-presents-initial-spvn06-safety-data-at-the-macula-society-47th-annual-meeting/) - Positive initial safety data from the Phase I/II PRODYGY clinical trial of its investigational gene therapy, SPVN06, for the treatment of retinitis pigmentosa
- [Inbiomotion and Source BioScience sign an exclusive agreement for MAF Test® in United Kingdom and Ireland](https://ysioscapital.com/2024/02/08/inbiomotion-and-source-bioscience-sign-an-exclusive-agreement-for-maf-test-in-united-kingdom-and-ireland/) - Inbiomotion and Source BioScience sign an exclusive agreement for MAF Test® in United Kingdom and Ireland to
- [Vivet Therapeutics receives EUR 4.9 million to advance development of a gene therapy](https://ysioscapital.com/2024/02/01/vivet-therapeutics-receives-eur-4-9-million-to-advance-development-of-a-gene-therapy/) - Vivet Therapeutics receives EUR 4.9 million to advance development of a gene therapy
- [Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510](https://ysioscapital.com/2024/01/18/synendos-therapeutics-ag-granted-ema-clinical-trial-authorisation-for-first-in-class-endocannabinoid-system-modulator-syt-510/) - Synendos Therapeutics transitions to a clinical-stage biotech company developing innovative Endocannabinoid System (ECS) treatments for neuropsychiatric, neuroinflammatory and other Central Nervous System (CNS) disorders Clinical Trial will investigate the safety, tolerability and pharmacokinetics of Synendos’ first-in-class ECS modulator BASEL, Switzerland – 18 January 2024 – Synendos Therapeutics AG (Synendos), a world leader in innovative Endocannabinoid System
- [Lava Therapeutics announces collaboration with Merck & co., inc., Rahway, NJ, USA to evaluate Lava-1207 in combination with Keytruda®](https://ysioscapital.com/2024/01/26/lava-therapeutics-announces-collaboration-with-merck-co-inc-rahway-nj-usa-to-evaluate-lava-1207-in-combination-with-keytruda/) - Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC Enrollment will continue in the monotherapy and IL-2 combination arms of the study UTRECHT, The Netherlands and PHILADELPHIA, Jan. 25, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), today announced that it has entered into a clinical
- [SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa](https://ysioscapital.com/2024/01/24/sparingvision-reaches-final-dose-escalation-step-in-prodygy-trial-with-spvn06-for-retinitis-pigmentosa/) - SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa
- [Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia](https://ysioscapital.com/2024/01/04/kynexis-announces-initiation-of-first-in-human-phase-1-study-of-kyn-5356-a-potential-treatment-for-cognitive-impairment-associated-with-schizophrenia/) - Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia.
- [Am-Pharma initiates Phase 2 trial of Ilofotase Alfa for Cardiac Surgery-Associated Renal Damage](https://ysioscapital.com/2024/01/16/am-pharma-initiates-phase-2-trial-of-ilofotase-alfa-for-cardiac-surgery-associated-renal-damage/) - Trial will evaluate ilofotase alfa as a treatment to prevent renal damage in at-risk patients following open heart surgery Ilofotase alfa’s clinical record of renal protective effects supports therapeutic potential in underserved and high-need indication Utrecht, The Netherlands, January 16, 2024 – AM-Pharma B.V. today announced that the first patients have been treated in a Phase 2 clinical
- [Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer](https://ysioscapital.com/2024/01/04/mineralys-therapeutics-appoints-minji-kim-ph-d-as-chief-business-officer/) - Minji Kim, Ph.D., as Chief Business Officer, brings more than two decades of experience in business development, strategic leadership, and scientific research.
- [SpliceBio Appoints Leading Ophthalmology Expert Aniz Girach as Chief Medical Officer Retinal Disease](https://ysioscapital.com/2024/01/03/splicebio-appoints-leading-ophthalmology-expert-aniz-girach-as-chief-medical-officer/) - Dr Girach is an ophthalmologist with over 25 years’ industry experience in the field of Medical Retina and Genetic Therapy for inherited retinal diseases.
- [Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension](https://ysioscapital.com/2023/12/21/mineralys-therapeutics-announces-first-subject-dosed-in-launch-htn-the-second-pivotal-trial-of-lorundrostat-for-the-treatment-of-hypertension/) - Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
- [Biocytogen Enters into Antibody Agreement with Ona Therapeutics to Develop Antibody-Drug Conjugates Targeting Solid Tumors](https://ysioscapital.com/2023/12/18/biocytogen-enters-into-antibody-agreement-with-ona-therapeutics-to-develop-antibody-drug-conjugates-targeting-solid-tumors/) - Beijing, China and Barcelona, Spain, December 18th, 2023 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotech company focusing on the discovery and development of novel antibody therapeutics, today announces an antibody evaluation, option and license agreement with Ona Therapeutics (“Ona”), a Spanish biotech company specialized in unravelling novel biology to design
- [CorWave announces the appointment of Fairuz Hasni as Vice President Human Resources](https://ysioscapital.com/2023/12/05/corwave-announces-the-appointment-of-fairuz-hasni-as-vice-president-human-resources/) - CorWave announces the appointment of Fairuz Hasni as Vice President Human Resources
- [Inbiomotion and The Scientific Group sign an exclusive distribution agreement of MAF Test® for the Sub-Saharan Africa](https://ysioscapital.com/2023/12/13/inbiomotion-and-the-scientific-group-sign-an-exclusive-distribution-agreement-of-maf-test-for-the-sub-saharan-africa/) - MAF Test® will benefit an estimated 10,200 new patients each year just in South Africa
- [Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023](https://ysioscapital.com/2023/11/17/outstanding-12-month-first-in-human-data-from-xeltis-axess-hemodialysis-vascular-conduit-trial-presented-at-veithsymposium-2023/) - aXess demonstrated exceptional patency rates and no infections to date EINDHOVEN, The Netherlands – 17 November 2023, Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announces outstanding 12-month data from its first-in-human (FIH) aXess vascular conduit trial (NCT04898153). The data was presented yesterday by Prof. Dr.
- [Minoryx announces enrollment of first patients with cerebral Adrenoleukodystrophy (cALD) in US Phase 3 clinical trial, CALYX](https://ysioscapital.com/2023/11/16/minoryx-announces-enrollment-of-first-patients-with-cerebral-adrenoleukodystrophy-cald-in-us-phase-3-clinical-trial-calyx/) - As part of CALYX, Minoryx is conducting an extensive pre-screening MRI-based campaign aimed at identifying eligible adult X-ALD patients with cerebral Adrenoleukodystrophy (cALD) Mataró, Barcelona, Spain, November 16, 2023 - Minoryx Therapeutics, a registration stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announces the first patients
- [KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update](https://ysioscapital.com/2023/08/04/kala-bio-reports-second-quarter-2023-financial-results-and-provides-corporate-update/) - Actively enrolling patients in CHASE Phase 2b clinical trial of KPI-012 for the treatment of PCED; topline data targeted for 2Q 2024
- [KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update](https://ysioscapital.com/2023/11/13/kala-bio-reports-third-quarter-2023-financial-results-and-provides-corporate-update/) - Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024
- [Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023](https://ysioscapital.com/2023/11/11/mineralys-therapeutics-further-defines-endotype-specific-targeted-approach-to-treatment-of-uncontrolled-or-resistant-hypertension-with-lorundrostat-data-at-aha-scientific-sessions-2023/) - Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023
- [NorthSea Therapeutics to Present ICONA Phase 2b Data as an Oral Late-breaker Session at the 2023 AASLD Liver Meeting](https://ysioscapital.com/2023/11/10/northsea-therapeutics-to-present-icona-phase-2b-data-as-an-oral-late-breaker-session-at-the-2023-aasld-liver-meeting/) - Study results identify NASH patients with Type 2 Diabetes as the key target population for Icosabutate therapy
- [Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights](https://ysioscapital.com/2023/11/09/aura-biosciences-reports-third-quarter-2023-financial-results-and-provides-clinical-development-and-operational-highlights/) - Received FDA Agreement Under Special Protocol Assessment (SPA) for the CoMpass Phase 3 Clinical Trial
- [Publication in Nature Cell Biology deciphers the mechanism by which the MAF protein promotes breast cancer metastasis](https://ysioscapital.com/2023/11/10/publication-in-nature-cell-biology-deciphers-the-mechanism-by-which-the-maf-protein-promotes-breast-cancer-metastasis/) - Publication in Nature Cell Biology deciphers the mechanism by which the MAF protein promotes breast cancer metastasis
- [Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update](https://ysioscapital.com/2023/11/07/mineralys-therapeutics-reports-third-quarter-2023-financial-results-and-provides-corporate-update/) - On track to initiate planned Phase 3 pivotal Launch-HTN trial of lorundrostat to treat patients with uncontrolled or resistant hypertension in 2H 2023 Expect to initiate planned Phase 2 Explore-CKD trial of lorundrostat alone and in combination with SGLT2 inhibitor to treat hypertensive patients with chronic kidney disease (CKD) in 2H 2023 – Conference call
- [Aura Biosciences Announces Proposed Public Offering of Common Stock](https://ysioscapital.com/2023/11/06/aura-biosciences-announces-proposed-public-offering-of-common-stock/) - BOSTON--(BUSINESS WIRE)--Nov. 6, 2023-- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the launch of an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by Aura.
- [Aura Biosciences Announces Pricing of Public Offering of Common Stock](https://ysioscapital.com/2023/11/06/aura-biosciences-announces-pricing-of-public-offering-of-common-stock-2/) - BOSTON--(BUSINESS WIRE)--Nov. 6, 2023-- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $9.00 per share. The gross proceeds from the offering
- [Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma](https://ysioscapital.com/2023/11/06/aura-biosciences-receives-fda-agreement-under-special-protocol-assessment-spa-for-compass-phase-3-clinical-trial-of-belzupacap-sarotalocan-bel-sar-in-early-stage-choroidal-melanoma/) - FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma
- [Kynexis Launched to Advance Precision Therapeutics for Brain Diseases](https://ysioscapital.com/2023/11/07/ysios-invest-in-57me-series-a-of-kynexis/) - Lead Candidate KYN-5356, a First-In-Class Small Molecule KAT-II Inhibitor Advancing Toward the Clinic for Cognitive Impairment Associated With Schizophrenia
- [Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting](https://ysioscapital.com/2023/11/02/mineralys-therapeutics-presents-new-post-hoc-analysis-from-target-htn-phase-2-trial-of-lorundrostat-in-late-breaking-poster-session-at-asn-kidney-week-2023-meeting/) - Analysis further supports obesity-associated dysregulated aldosterone as an endotype predictive of enhanced response to lorundrostat treatment in patients with uncontrolled or treatment-resistant hypertension Endotype identification from Target-HTN may represent a shift towards targeted, precision-directed therapy for hypertension management in future treatment paradigm Ongoing Advance-HTN trial, first of two pivotal studies, will further characterize hypertensive endotype
- [Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023](https://ysioscapital.com/2023/10/31/aura-biosciences-to-present-updated-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-bel-sar-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melano/) - Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023
- [Anaconda Biomed Announces Additional Granted Patents for its Innovative Thrombectomy Device for Ischemic Stroke Treatment](https://ysioscapital.com/2023/10/12/anaconda-biomed-announces-additional-granted-patents-for-its-innovative-thrombectomy-device-for-ischemic-stroke-treatment/) - Anaconda Biomed Announces Additional Granted Patents for its Innovative Thrombectomy Device for Ischemic Stroke Treatment
- [Cytoki Pharma Presents Preclinical Data Demonstrating Weight Reduction and Improved Glucose Control with Lipidated IL-22 at ObesityWeek 2023](https://ysioscapital.com/2023/10/16/cytoki-pharma-presents-preclinical-data-demonstrating-weight-reduction-and-improved-glucose-control-with-lipidated-il-22-at-obesityweek-2023/) - Cytoki Pharma Presents Preclinical Data Demonstrating Weight Reduction and Improved Glucose Control with Lipidated IL-22 at ObesityWeek 2023
- [NorthSea Therapeutics Receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the Treatment of Intestinal Failure-Associated Liver Disease](https://ysioscapital.com/2023/10/17/northsea-therapeutics-receives-fda-rare-pediatric-disease-designation-for-sefa-6179-for-the-treatment-of-intestinal-failure-associated-liver-disease/) - NorthSea Therapeutics Receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the Treatment of Intestinal Failure-Associated Liver Disease
- [SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Disease](https://ysioscapital.com/2023/10/17/splicebio-enters-collaboration-with-spark-therapeutics-to-develop-a-gene-therapy-targeting-an-inherited-retinal-disease/) - SpliceBio is eligible to receive upfront, opt-in and milestone payments up to $216 million plus royalties.
- [AM-Pharma announces positive clinical data from phase 1b study evaluating ilofotase alfa in hypophosphatasia](https://ysioscapital.com/2023/10/11/am-pharma-announces-positive-clinical-data-from-phase-1b-study-evaluating-ilofotase-alfa-in-hypophosphatasia/) - Ilofotase alfa demonstrates pharmacologically relevant effect on disease specific biomarkers and a positive safety profile in adult patients with hypophosphatasia; Data to be presented by Lothar Seefried, MD, at the American Society for Bone and Mineral Research’s Symposium on Rare Bone Diseases on Thursday, October 12, 2023 Utrecht, The Netherlands, October 11, 2023 – AM-Pharma
- [CorWave announces the grand opening of its manufacturing facility on the banks of the Seine, next to Paris](https://ysioscapital.com/2023/10/09/ccorwave-announces-the-grand-opening-of-its-manufacturing-facility-on-the-banks-of-the-seine-next-to-paris/) - The company occupies over 2,400m² of production, laboratory, and office space, bringing together its headquarters, R&D center and its first manufacturing facility of almost 1,000m².
- [Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments](https://ysioscapital.com/2023/10/03/aura-biosciences-strengthens-and-expands-leadership-team-with-key-appointments/) - J. Jill Hopkins, M.D., Appointed as Chief Medical Officer and President of Research & Development Mark Plavsic, Ph.D., Appointed as Chief Technology Officer
- [Palex and Inbiomotion introduce pioneering test to aid oncologists in predicting recurrence and survival rates in breast cancer patients](https://ysioscapital.com/2023/09/28/palex-and-inbiomotion-introduce-pioneering-test-to-aid-oncologists-in-predicting-recurrence-and-survival-rates-in-breast-cancer-patients/) - Palex and Inbiomotion introduce pioneering test, MAFTEst, to aid oncologists in predicting recurrence and survival rates in breast cancer patients
- [CorWave announces the appointment of Magalie Durrèche as Chief Financial Officer](https://ysioscapital.com/2023/09/26/corwave-announces-the-appointment-of-magalie-durreche-as-chief-financial-officer/) - Magalie Durrèche has over twenty years of experience in corporate finance, mainly in the industrial sector
- [SparingVision Selects Second Target in Strategic Collaboration with Intellia Therapeutics](https://ysioscapital.com/2023/09/26/sparingvision-selects-second-target-in-strategic-collaboration-with-intellia-therapeutics/) - Milestone broadens partnership to develop novel ocular therapies using CRISPR-based technologies
- [Am-Pharma announces updated clinical development strategy](https://ysioscapital.com/2023/09/26/am-pharma-announces-updated-clinical-development-strategy/) - Phase 1b study of ilofotase alfa as enzyme replacement therapy in hypophosphatasia patients being finalized, results to be announced before end of 2023
- [Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas](https://ysioscapital.com/2023/09/14/mineralys-therapeutics-expands-its-board-of-directors-with-appointments-of-glenn-sblendorio-and-daphne-karydas/) - Ms. Karydas and Mr. Sblendorio bring executive, financial and operational leadership experience in biotechnology and biopharmaceuticals markets.
- [Mineralys Therapeutics Announces JAMA Publication of Full Target-HTN Phase 2 Trial Results for Lorundrostat in Uncontrolled and Treatment-Resistant Hypertension](https://ysioscapital.com/2023/09/10/mineralys-therapeutics-announces-jama-publication-of-full-target-htn-phase-2-trial-results-for-lorundrostat-in-uncontrolled-and-treatment-resistant-hypertension/) - Robust trial design and results led to lorundrostat being first of new class, aldosterone synthase inhibitors, to start pivotal clinical program in hypertension
- [Mineralys Therapeutics Presents Target-HTN Phase 2 Trial Results in Late-Breaking Science Session at 2023 AHA Hypertension Scientific Sessions](https://ysioscapital.com/2023/09/10/mineralys-therapeutics-presents-target-htn-phase-2-trial-results-in-late-breaking-science-session-at-2023-aha-hypertension-scientific-sessions/) - Pivotal clinical program for lorundrostat as a treatment of patients with uncontrolled and resistant hypertension ongoing, with topline data from Advance-HTN and Launch-HTN trials expected in first half of 2024 and mid-2025, respectively
- [Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update](https://ysioscapital.com/2023/08/07/mineralys-therapeutics-reports-second-quarter-2023-financial-results-and-provides-corporate-update/) - On track to initiate planned Phase 3 pivotal Launch-HTN trial of lorundrostat for the treatment of uncontrolled or resistant hypertension in 2H 2023
- [SparingVision Named a ‘Fierce 15’ Company by Fierce Biotech](https://ysioscapital.com/2023/08/28/sparingvision-named-a-fierce-15-company-by-fierce-biotech/) - Sparingvision has been named by Fierce Biotech as one of 2023’s ‘Fierce 15’ biotechnology companies, designating it as one of the most innovative and promising biotechnology companies in the industry.
- [SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial](https://ysioscapital.com/2023/08/30/sparingvision-reports-positive-initial-safety-data-from-the-first-cohort-treated-in-its-prodygy-phase-i-ii-gene-therapy-trial/) - Lead gene therapy asset, SPVN06, reported to be well-tolerated in first dosed cohort at low dose with a favorable safety profile
- [Lava Therapeutics provides business update and reports second quarter 2023 financial results](https://ysioscapital.com/2023/08/22/ava-therapeutics-provides-business-update-and-reports-second-quarter-2023-financial-results/) - Clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta T cell engagers
- [Xeltis appoints Luciën van Os as Chief Operating Officer](https://ysioscapital.com/2023/09/12/xxeltis-appoints-lucien-van-os-as-chief-operating-officer/) - Luciën joins Xeltis with more than 20 years of experience in the life sciences sector, including a number of senior leadership roles at medical device companies.
- [Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights](https://ysioscapital.com/2023/08/09/aura-biosciences-reports-second-quarter-2023-financial-results-and-provides-clinical-development-and-operational-highlights/) - Start-up Activities for the Global Ph3 Trial Ongoing with Release of Drug Product Manufactured with Commercial Process and First Patient Expected to be Dosed in 2H 2023
- [Synendos Therapeutics AG Co-Founder and SAB Member, Professor Jürg Gertsch, Presents Groundbreaking New Findings on an Endocannabinoid Transporter at Cannabinoid Research Conference](https://ysioscapital.com/2023/07/18/synendos-therapeutics-ag-co-founder-and-sab-member-professor-jurg-gertsch-presents-groundbreaking-new-findings-on-an-endocannabinoid-transporter-at-cannabinoid-research-conference/) - Synendos Therapeutics Co-Founder, Professor Jürg Gertsch, Presents Groundbreaking New Findings on an Endocannabinoid Transporter at Cannabinoid Research Conference
- [Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)](https://ysioscapital.com/2023/07/18/mineralys-therapeutics-announces-expansion-of-planned-phase-2-trial-of-lorundrostat-alone-and-in-combination-with-sglt2-inhibitor-to-treat-patients-with-chronic-kidney-disease-ckd/) - Mineralys Therapeutics expands Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease
- [SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics](https://ysioscapital.com/2023/07/13/sparingvision-sells-ex-vivo-girk-technology-to-tenpoint-therapeutics/) - SparingVision remains focused on in vivo genomic medicines, with SPVN20, a GIRK-based gene therapy candidate, expected to reach clinical stage in 2024
- [Adcendo Appoints Experienced Drug Developer Dr. Lone H. Ottesen as Chief Medical Officer](https://ysioscapital.com/2023/06/20/adcendo-appoints-experienced-drug-developer-dr-lone-h-ottesen-as-chief-medical-officer/) - Adcendo further builds its world class team to accelerate development of lead ADC asset uPARAP and to expand its first-in-class ADC pipeline
- [Tagworks Pharmaceuticals Announces $65 Million in Series A Financing to Advance Click-to-Release Therapeutics](https://ysioscapital.com/2023/06/22/tagworks-pharmaceuticals-announces-65-million-in-series-a-financing-to-advance-click-to-release-therapeutics/) - Click-to-Release platform enables on-target activation of antibody-drug conjugates (ADCs) & immunomodulators &off-target deactivation of radiopharmaceuticals.
- [SpliceBio Appoints David Favre, D.V.M., Ph.D., as Chief Development Officer to Accelerate Development of its Lead AAV Gene Therapy Program](https://ysioscapital.com/2023/06/20/splicebio-appoints-david-favre-d-v-m-ph-d-as-chief-development-officer-to-accelerate-development-of-its-lead-aav-gene-therapy-program/) - SpliceBio Appoints David Favre, D.V.M., Ph.D., as Chief Development Officer to Accelerate Development of its Lead AAV Gene Therapy Program
- [CorWave Announces Second Closing of Its Series C Funding at €61M To Finance Its First Industrial Deployment](https://ysioscapital.com/2023/06/20/1-corwave-announces-second-closing-of-its-series-c-funding-at-e61m-to-finance-its-first-industrial-deployment/) - CorWave Announces Second Closing of Its Series C Funding at €61M To Finance Its First Industrial Deployment
- [LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash Runway](https://ysioscapital.com/2023/06/14/lava-therapeutics-provides-updates-on-clinical-programs-and-extends-the-cash-runway/) - LAVA will continue to advance LAVA-1207, its Gammabody program designed to target the prostate-specific membrane antigen as well as earlier stage programs.
- [LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results](https://ysioscapital.com/2023/06/09/lava-therapeutics-provides-business-update-and-reports-first-quarter-2023-financial-results/) - Lead development candidate selected by Janssen Biotech under research collaboration provides a milestone payment to LAVA
- [LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development](https://ysioscapital.com/2023/06/01/lava-therapeutics-announces-selection-by-janssen-of-lead-gamma-delta-t-cell-engager-bispecific-antibody-to-move-toward-clinical-development/) - LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical Development
- [Mineralys Therapeutics to Participate in the Jefferies Healthcare Conference](https://ysioscapital.com/2023/05/31/mineralys-therapeutics-to-participate-in-the-jefferies-healthcare-conference/) - Mineralys Therapeutics a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone.
- [Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy](https://ysioscapital.com/2023/05/31/minoryx-gains-fda-approval-to-initiate-a-phase-3-clinical-trial-in-patients-with-cerebral-adrenoleukodystrophy/) - Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy
- [Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-Class ADC Pipeline](https://ysioscapital.com/2023/05/30/adcendo-aps-announces-option-license-agreement-with-duality-biologics-to-enhance-optionality-to-further-expand-first-in-class-adc-pipeline/) - Strengthening of strategic option license agreement to cover additional novel ADC targets
- [VarmX raises €30 million Series B2 financing for IND approval and preparations for pivotal trial](https://ysioscapital.com/2023/05/25/varmx-raises-e30-million-series-b2-financing-for-ind-approval-and-preparations-for-pivotal-trial/) - VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation
- [Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis](https://ysioscapital.com/2023/05/23/galecto-completes-dosing-in-52-week-phase-2b-galactic-1-trial-of-gb0139-in-idiopathic-pulmonary-fibrosis/) - GALACTIC-1 is a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial being conducted across approximately 100 centers globally.
- [SparingVision Presents New Data on SPVN20 Program at ASGCT 2023](https://ysioscapital.com/2023/05/22/sparingvision-presents-new-data-on-spvn20-program-at-asgct-2023/) - SPVN20 gene therapy product uniquely positioned to restore visual acuity and color vision in patients with late-stage retinitis pigmentosa and other inherited retinal diseases
- [ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors](https://ysioscapital.com/2023/05/23/ona-therapeutics-announces-the-appointment-of-dr-pamela-klein-to-its-board-of-directors/) - ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors
- [Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update](https://ysioscapital.com/2023/05/16/mineralys-therapeutics-reports-first-quarter-2023-financial-results-and-provides-corporate-update/) - Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
- [Aura Biosciences to Participate in the JMP Securities Life Sciences Conference](https://ysioscapital.com/2023/05/15/aura-biosciences-to-participate-in-the-jmp-securities-life-sciences-conference/) - Aura Biosciences to Participate in the JMP Securities Life Sciences Conference
- [Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights](https://ysioscapital.com/2023/05/12/aura-biosciences-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-clinical-development-and-operational-highlights/) - Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
- [Babyscripts and MemorialCare Mark Three-year Partnership with Significant Results in Blood Pressure Risk Identification and Patient Engagement in Maternal Populations](https://ysioscapital.com/2023/05/11/babyscripts-and-memorialcare-mark-three-year/) - Babyscripts & MemorialCare Mark 3 Partnership with Significant Results in Blood Pressure Risk Identification and Patient Engagement in Maternal Populations
- [Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update](https://ysioscapital.com/2023/05/10/kala-pharmaceuticals-reports-first-quarter-2023-financial-results/) - Announced positive data from initial safety portion of CHASE Phase 2b clinical trial of KPI-012; now enrolling primary safety and efficacy portion of trial,
- [Babyscripts Welcomes New Executive VP of Revenue Andrew Reeve](https://ysioscapital.com/2023/05/03/babyscripts-welcomes-new-executive-vp-of-revenue-andrew-reeve/) - Role will drive growth, focus Babyscripts’ strategic expansion in payer and provider markets
- [Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension](https://ysioscapital.com/2023/05/02/mineralys-therapeutics-announces-first-patient-dosed-in-the-advance-htn-pivotal-trial-of-lorundrostat-for-the-treatment-of-uncontrolled-and-resistant-hypertension/) - first patient dosed in the ADVANCE-HTN pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled hypertension (uHTN) and resistant hypertension
- [Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress](https://ysioscapital.com/2023/04/28/xeltis-presents-excellent-six-month-first-in-human-data-from-axess-hemodialysis-vascular-graft-trial-at-vascular-access-society-congress/) - Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress
- [SparingVision Presents Progress of its Lead Gene Therapy Program SPVN06 at ARVO 2023](https://ysioscapital.com/2023/04/27/sparingvision-presents-progress-of-its-lead-gene-therapy-program-spvn06-at-arvo-2023/) - Data demonstrated the absorption and shedding of SPVN06, which was transiently observed in blood and tears, and high tropism for the retina.
- [Minoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD)](https://ysioscapital.com/2023/04/25/minoryx-presents-positive-interim-results-from-nexus-registration-study/) - Minoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD
- [Anaconda Biomed Names New Chairperson, Appoints Chief Medical Officer](https://ysioscapital.com/2023/04/20/anaconda-biomed-names-new-chairperson-appoints-chief-medical-officer/) - Company Appoints De Novo Ventures Co-Founder Richard Ferrari as Chairperson, and Names Hendrik Lambert, PhD., as Chief Medical Officer
- [Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect](https://ysioscapital.com/2023/04/12/kala-pharmaceuticals-receives-fda-fast-track-designation-for-kpi-012-a-human-msc-s-therapy-for-persistent-corneal-epithelial-defect/) - FDAhas granted Fast Track designation for Kala’s human mesenchymal stem cell secretome (MSC-S) therapy or the treatment of persistent corneal epithelial defect
- [LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results](https://ysioscapital.com/2023/04/11/lava-therapeutics-provides-business-update-and-reports-fourth-quarter-and-year-end-2022-financial-results/) - Initial clinical data for LAVA-051 suggest a favorable safety profile and initial anti-tumor activity in the ongoing dose escalation Phase 1/2a clinical trial
- [Adcendo ApS to Present Data on the Expression of the Novel ADC target uPARAP in Soft Tissue and Bone Sarcoma at the 2023 American Association for Cancer Research (AACR) Annual Meeting](https://ysioscapital.com/2023/04/13/adcendo-aps-to-present-data-on-the-expression-of-the-novel-adc-target-uparap-in-soft-tissue-and-bone-sarcoma-at-the-2023-american-association-for-cancer-research-aacr-annual-meeting/) - Data demonstrate that uPARAP is widely expressed at high levels across multiple sarcoma subtypes
- [SparingVision appoints Joseph C. Papa as Chairman](https://ysioscapital.com/2023/04/05/sparingvision-appoints-joseph-c-papa-as-chairman/) - Former Bausch and Lomb Chairman and CEO joins as non-executive independent Chairman of SparingVision
- [Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering](https://ysioscapital.com/2023/02/14/mineralys-therapeutics-announces-pricing-of-upsized-initial-public-offering/) - Pricing of its upsized initial public offering of 12,000,000 shares of common stock at an initial public offering price of $16.00 per share
- [Adcendo raises EUR 51 Million in Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers](https://ysioscapital.com/2021/04/29/ysios-capital-co-leads-eur-51-million-series-a-financing-in-adcendo/) - Innovative antibody-drug conjugates directed at novel cancer targets to treat cancer in several indications with high unmet needs.
- [Adcendo ApS Announces Extension of Series A Financing to 82M EUR to Ensure Broad Development of its First-in-class ADC Pipeline](https://ysioscapital.com/2023/04/04/adcendo-aps-announces-extension-of-series-a/) - Series A Financing extension led by Pontifax Venture Capital and existing investors Novo Holdings and Ysios Capital, raising an additional 31M EUR
- [Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED](https://ysioscapital.com/2023/03/27/kala-pharmaceuticals-announces-positive-safety-update-from-cohort-1/) - Now proceeding to Cohort 2 to evaluate the safety and efficacy of two doses of KPI-012 in a multicenter, randomized, double-masked, vehicle-controlled trial
- [Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights](https://ysioscapital.com/2023/03/15/aura-biosciences-reports-fourth-quarter-and-full-year-2022-financial-results/) - U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Belzupacap Sarotalocan (bel-sar) for the Treatment of Choroidal Metastasis
- [Mineralys Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update](https://ysioscapital.com/2023/03/16/mineralys-therapeutics-reports-financial-results/) - IPO and Nasdaq listing completed in February 2023 with total net proceeds of approximately $202.0 million
- [Lava Therapeutics announces appointment of Christy J. Oliger to its board of directors](https://ysioscapital.com/2023/03/10/lava-therapeutics-announces-appointment-of-christy-j-oliger/) - Ms. Oliger brings extensive commercial, portfolio management, and senior leadership experience to the role.
- [Am-Pharma to present data from phase 3 revival study at upcoming scientific conferences](https://ysioscapital.com/2023/03/09/am-pharma-to-present-data-from-phase-3/) - The global Phase 3 REVIVAL study assessed the efficacy and safety of ilofotase alfa, AM-Pharma’s human recombinant alkaline phosphatase, in patients with SA-AKI
- [VarmX Appoints Dr. Jeffrey Lawson, MD, PhD as Chief Scientific Officer](https://ysioscapital.com/2023/03/09/varmx-appoints-dr-jeffrey-lawson/) - Dr. Lawson will take over the role from Prof. Dr. Pieter Reitsma, CSO and founder of VarmX, who will continue to serve as a special advisor to the Company.
- [VarmX appoints Paul Roos as Chief Financial Officer](https://ysioscapital.com/2023/01/31/varmx-appoints-paul-roos-as-chief-financial-officer/) - Paul has a wealth of experience in the international life sciences industry and investment banking.
- [Lava Therapeutics announces the appointment of Dr. Charles Morris as Chief Medical Officer](https://ysioscapital.com/2023/02/06/lava-therapeutics-announces-the-appointment-of-dr-charles-morris-as-chief-medical-officer/) - Dr. Morris is a medical oncologist with over 25 years of oncology drug development experience
- [Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update](https://ysioscapital.com/2023/03/03/kala-pharmaceuticals-reports-fourth-quarter-and-full-year-2022-financial-results-and-provides-corporate-update/) - Enrolled first patient in CHASE Phase 2b clinical trial evaluating KPI-012 for PCED; Top-line data targeted for 1Q 2024
- [Mineralys Therapeutics Presents Positive Lorundrostat Results from the Phase 2 Target-HTN Trial at ACC.23/WCC](https://ysioscapital.com/2023/03/04/mineralys-therapeutics-presents-positive-lorundrostat-results/) - Lorundrostat demonstrated clinically meaningful blood pressure reduction in individuals with uncontrolled hypertension
- [AELIX Therapeutics presents positive results from randomized placebocontrolled phase IIa therapeutic HIV vaccine and immune modulator combination clinical trial](https://ysioscapital.com/2023/02/22/elix-therapeutics-presents-positive-results-from-randomized-placebocontrolled-phase-iia-therapeutic-hiv/) - Investigational AELIX HTI vaccine in combination with Gilead’s investigational Toll-Like Receptor 7 (TLR7) agonist, vesatolimod, enabled an extended period without antiretroviral treatment (ART) in people with HIV on antiretroviral therapy
- [Xeltis raises €32 million to drive clinical development of world’s most advanced restorative cardiovascular devices](https://ysioscapital.com/2023/02/21/xeltis-raises-e32-million/) - Use of proceeds to advance Xeltis’ aXess vascular access graft into pivotal clinical trials
- [Lava Therapeutics announces initial data from the ongoing phase 1/2a clinical trial of LAVA-1207 in therapy refractory MCRPC at the 2023 ASCO GU symposium](https://ysioscapital.com/2023/02/16/lava-therapeutics-announces-initial-data-from-the-ongoing-phase-1-2a-clinical-trial-of-lava-1207-in-therapy-refractory-mcrpc-at-the-2023-asco-gu-symposium/) - Favorable safety profile to date, with no occurrence of high-grade (>2) cytokine release syndrome or dose-limiting toxicities
- [Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administrationat the Macula Society 46th Annual Meeting](https://ysioscapital.com/2023/02/16/aura-biosciences-announces-positive-interim-phase-2/) - Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administrationat
- [Mineralys Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares](https://ysioscapital.com/2023/02/15/mineralys-therapeutics-announces-closing-of-initial-public-offering/) - The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $220.8 million.
- [The Lancet Neurology publishes results from Minoryx Therapeutics Phase 2/3 ADVANCE clinical trial of leriglitazone in X-linked Adrenoleukodystrophy](https://ysioscapital.com/2023/01/19/the-lancet-neurology-publishes-results-from-minoryx-therapeutics-phase-2-3-advance-clinical-trial-of-leriglitazone-in-x-linked-adrenoleukodystrophy/) - Leriglitazone was well tolerated,& significant benefit was shown through clinically meaningful myelopathy endpoints and reduced progression of cerebral lesions.
- [Ysios Capital strengthens its team with internal promotions and a new Venture Partner](https://ysioscapital.com/2023/01/19/ysios-capital-strengthens-its-team-with-internal-promotions-and-a-new-venture-partner/) - These appointments add operational capacities supporting Ysios’ mission to build leading life sciences companies.
- [LAVA Therapeutics Announces Appointment of New Directors to the Board](https://ysioscapital.com/2023/01/06/lava-therapeutics-announces-appointment-of-new-directors-to-the-board/) - Peter A. Kiener, DPhil and Mary E. Wadlinger to Join LAVA Board
- [NorthSea Therapeutics provides clinical update reflecting progress across NASH and metabolic disorders programmes](https://ysioscapital.com/2023/01/05/northsea-therapeutics-provides-clinical-update/) - NorthSea Therapeutics now has three phase II clinical stage assets in development based on its SEFA platform
- [NorthSea Therapeutics appoints Morris J. Birnbaum to the Board](https://ysioscapital.com/2022/12/21/northsea-therapeutics-appoints-morris-j-birnbaum-to-the-board/) - Former Pfizer Internal Medicine CSO joins the Board as an independent board member.
- [Inbiomotion appoints Ralf van den Berg as Chief Operating Officer](https://ysioscapital.com/2022/12/20/inbiomotion-appoints-ralf-van-den-berg-as-chief-operating-officer/) - Ralf van den Berg will drive Inbiomotion in his aim to position MAFTEST® for routine characterization of breast cancer tumors.
- [SparingVision’s lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa](https://ysioscapital.com/2022/12/01/sparingvisions-lead-asset-spvn06-clears-ind-application/) - SparingVision set to advance into the clinic with breakthrough gene-independent approach targeting retinitis pigmentosa (RP), one of the leading causes of blindness globally 33-patient Phase I/II clinical trial PRODYGY includes safety/tolerability, efficacy and quality of life endpoints First safety data expected in 2023 with full read-out expected in 2025 Paris, December 1, 2022 – SparingVision
- [SparingVision Presents Validating Data of its Lead Gene Therapy Programs, SPVN06 and SPVN20, at ESGCT 2022](https://ysioscapital.com/2022/10/13/sparingvision-presents-validating-data-of-its-lead-gene-therapy-programs-spvn06-and-spvn20-at-esgct-2022/) - Data supports progression into first-in-human clinical trial with SPVN06 Paris, October 13, 2022 – SparingVision (“the Company”), a genomic medicine company developing vision-saving treatments for ocular diseases, has presented data on its two lead gene-independent assets, SPVN06 and SPVN20, at the European Society of Gene and Cell Therapies (ESGCT) 29th Congress held in Edinburgh, UK, this week (11-14
- [Aura Biosciences Announces Pricing of Public Offering of Common Stock](https://ysioscapital.com/2022/12/01/aura-biosciences-announces-pricing-of-public-offering-of-common-stock/) - Aura Biosciences Announces Pricing of Public Offering of Common Stock
- [Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension](https://ysioscapital.com/2022/11/16/mineralys-therapeutics-announces-positive-topline-phase-2-data/) - Key clinical data from Target-HTN demonstrated clinically meaningful efficacy in the treatment of patients with uncontrolled and resistant hypertension
- [Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage](https://ysioscapital.com/2022/11/11/aura-announces-global-phase-3-trial-design/) - Evaluate the efficacy and safety of belzupacap sarotalocan with suprachoroidal administration, for the first-line treatment of early-stage choroidal melanoma (CM).
- [Xeltis starts pivotal clinical trial with first ever restorative synthetic hemodialysis access graft](https://ysioscapital.com/2022/11/11/xeltis-starts-pivotal-clinical-trial/) - The aXess graft turns into a living blood vessel, promising an unprecedented, immediate and durable solution for hemodialysis patients
- [Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe](https://ysioscapital.com/2022/11/10/minoryx-and-neuraxpharm-announce-a-strategic-alliance/) - Licensing agreement for the European rights to leriglitazone, currently under EMA review for the orphan indication X-linked Adrenoleukodystrophy (X-ALD).
- [Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update](https://ysioscapital.com/2022/11/09/kala-pharmaceuticals-reports-third-quarter-2022-financial-results-and-provides-corporate-update/) - Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
- [Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients](https://ysioscapital.com/2022/11/08/galecto-presents-positive-clinical-data-at-aasld-showing-statistically-significant-improvements-in-important-liver-parameters-in-decompensated-cirrhosis-patients/) - Statistically significant reductions observed in ALT, AST and GGT, supporting further development of GB1211 in severe liver diseases
- [Positive results from AELIX’ HIV therapeutic vaccine clinical study published in Nature Medicine](https://ysioscapital.com/2022/11/02/positive-results-from-aelix-hiv-therapeutic-vaccine-clinical-study-published-in-nature-medicine/) - Positive results of AELIX’ therapeutic HIV vaccine, leading to prolonged period without AntiRetroviral Treatment (ART), and supporting the use of HTI vaccine for combination cure strategies for HIV
- [AM-Pharma provides business update and outcome of pre-planned interim futility analysis of phase 3 REVIVAL study](https://ysioscapital.com/2022/10/20/am-pharma-provides-business-update/) - REVIVAL study evaluated AM-Pharma’s proprietary recombinant alkaline phosphatase, ilofotase alfa, for the treatment of patients with sepsis-associated acute kidney injury (SA-AKI).
- [Xeltis presented promising FIH data on restorative hemodialysis access graft at PVC congress](https://ysioscapital.com/2022/10/17/xeltis-presented-promising-fih-data-on-restorative-hemodialysis-access-graft-at-pvc-congress/) - Xeltis announced very promising preliminary efficacy and safety results from one of the centers participating in the AXESS first-in-human (FIH) clinical trial.
- [Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022](https://ysioscapital.com/2022/10/03/aura-biosciences-announces-interim-phase-2-data/) - Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan
- [Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer](https://ysioscapital.com/2022/09/29/aura-biosciences-announces-first-patient-dosed/) - Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
- [GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target](https://ysioscapital.com/2022/09/29/gb2064-shows-reduction-in-fibrosis/) - Galecto's GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target
- [Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors](https://ysioscapital.com/2022/09/27/seagen-and-lava-therapeutics-announce-exclusive-worldwide-license-agreement/) - Seagen to Develop and Commercialize LAVA-1223, a Bispecific T Cell Engager Designed to Target and Activate Gamma Delta T Cells in EGFR-Expressing Solid Tumors.
- [Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD)](https://ysioscapital.com/2022/09/14/minoryxs-marketing-authorization-application-for-its-lead-candidate-leriglitazone-validated-by-ema/) - Minoryx‘s Marketing Authorization Application for its lead candidate leriglitazone validated by EMA for orphan indication X-linked Adrenoleukodystrophy (X-ALD)
- [SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases](https://ysioscapital.com/2022/09/14/sparingvision-raises-e75-million-series-b/) - First-in-human trials of breakthrough gene therapy products and advance CRISPR-based genome editing portfolio in collaboration with Intellia Therapeutics.
- [Xeltis receives commitment from Grand Pharma to invest €15M as cornerstone of ongoing Series D2 financing round](https://ysioscapital.com/2022/08/09/xeltis-receives-commitment-from-grand-pharma-to-invest-e15m/) - Equity and licensing investment for aXess device marks first commercial deal EINDHOVEN, The Netherlands – August 09, 2022 – Xeltis, a medtech company developing the most advanced polymer-based restorative cardiovascular devices, today announced that the Chinese company, Grand Pharmaceutical Group Ltd (0512.HK), has committed to invest €15 million in equity and license fees, as a
- [Study shows that selection of breast cancer patients for adjuvant bisphosphonate therapy based on Inbiomotion’s MAFTEST® reduces the risk of death in comparison with current clinical guidance](https://ysioscapital.com/2022/07/14/study-shows-that-selection-of-breast-cancer-patients-for-adjuvant-bisphosphonate-therapy-based-on-inbiomotions-maftest/) - Study shows that selection of breast cancer patients for adjuvant bisphosphonate therapy based on Inbiomotion’s MAFTEST® reduces the risk of death in comparison with current clinical guidance
- [Declaration of conformity drawn up for MAFTEST®](https://ysioscapital.com/2022/07/13/declaration-of-conformity-drawn-up-for-maftest/) - Conformity assessment for the unique in vitro diagnostic medical device MAFTEST® developed by Inbiomotion was completed and the declaration of conformity was drawn up.
- [LAVA Therapeutics highlights encouraging clinical updates on lead program, LAVA-051, in chronic lymphocytic leukemia and multiple myeloma patients](https://ysioscapital.com/2022/06/16/lava-therapeutics-highlights-encouraging-clinical-updates-on-lead-program-lava-051-in-chronic-lymphocytic-leukemia-and-multiple-myeloma-patients-2/) - Clinical update call featuring LAVA-051 investigator Dr. Arnon Kater and Company management summarized initial Phase 1/2a clinical trial data presented at 2022 ASCO and EHA meetings UTRECHT, The Netherlands and PHILADELPHIA, June 16, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma
- [Am-Pharma announces publication of in vivo acute kidney injury study demonstrating ilofotase alfa’s dual protective mechanism](https://ysioscapital.com/2022/07/05/am-pharma-announces-publication-of-in-vivo-acute-kidney-injury-study-demonstrating-ilofotase-alfas-dual-protective-mechanism/) - Study shows that ilofotase alfa protects the kidney through the activation of adenosine receptors in rats and mice following ischemia reperfusion induced AKI.
- [Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer](https://ysioscapital.com/2022/06/30/aura-biosciences-receives-fda-fast-track-designation-for-belzupacap/) - Fast Track designation for belzupacap sarotalocan (AU-011), Aura’s first VDC product candidate, for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).
- [Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma](https://ysioscapital.com/2022/06/22/aura-biosciences-reports-topline-data-from-a-retrospective-study-of-belzupacap-sarotalocan-au-011-versus-plaque-radiotherapy-supporting-the-value-of-a-vision-preserving-therapy-for-the-treatment-of/) - In this Retrospective Matched Case Control Study, Belzupacap Sarotalocan Achieved Statistically Significant Vision Preservation
- [Galecto Announces First Patient Enrolled in Phase 2 Trial of GB1211 in Combination with Atezolizumab for First-Line Treatment of NSCLC](https://ysioscapital.com/2022/06/16/galecto-announces-first-patient-enrolled/) - The initiation of GALLANT-1 continues Galecto’s strategy to treat cancer and fibrotic diseases through developing targeted therapeutics.
- [Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting](https://ysioscapital.com/2022/06/17/aura-biosciences-to-present-updated-belzupacap-sarotalocan-au-011-data/) - Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting
- [LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients](https://ysioscapital.com/2022/06/16/lava-therapeutics-highlights-encouraging-clinical-updates-on-lead-program-lava-051-in-chronic-lymphocytic-leukemia-and-multiple-myeloma-patients/) - Clinical update call featuring LAVA-051 investigator Dr. Arnon Kater and Company management summarized initial Phase 1/2a clinical trial data presented at 2022 ASCO and EHA meetings
- [LAVA Therapeutics Announces Two Appointments to its Board of Directors](https://ysioscapital.com/2022/06/15/lava-therapeutics-announces-two-appointments-to-its-board-of-directors/) - James Noble and Jay Backstrom, M.D, M.P.H, bring vast global leadership experiences at public biopharmaceutical companies
- [Ysios Capital appoints Wen Wen Cheng as Head of Legal](https://ysioscapital.com/2022/06/16/ysios-capital-appoints-wen-wen-cheng-as-head-of-legalcipal/) - Wen Wen Cheng joins Ysios Capital as Head of Legal after 10 years at Cuatrecasas, Barcelona. This addition will strengthen the Ysios Capital team by incorporating an expert in legal matters. SAN SEBASTIÁN/BARCELONA, June 16, 2022– Ysios Capital, a European life sciences venture capital firm, today announced that it has appointed Wen Wen Cheng as
- [Ysios Capital strengthens its team with the appointment of Thomas Harth as Principal](https://ysioscapital.com/2022/03/04/ysioscapitalappointsthomasharth/) - Thomas will be responsible for sourcing and evaluating investment opportunities representing Ysios as member of the portfolio companies`board of directors.
- [Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension](https://ysioscapital.com/2022/06/09/ysios-joins-mineralys-therapeutics-closes-118-million-oversubscribed-series-b-financing/) - Highly Selective Aldosterone Synthase Inhibitor to Address Abnormally Elevated Aldosterone, an Underlying Cause of Hypertension Prevalent.
- [Minoryx raises €51 million to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy](https://ysioscapital.com/2022/05/31/minoryx-raises-e51-million/) - Funds will support the marketing authorization review process for male patients with AMN and launch preparations in Europe
- [Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF](https://ysioscapital.com/2022/04/26/galecto-completes-enrollment-in-global-phase-2b-galactic/) - IPF is a life-threatening, rapidly progressing and irreversible disease causing scarring of the lungs and significantly impairing lung function.
- [Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting](https://ysioscapital.com/2022/05/26/galecto-to-present-new-data-on-oral-galectin-3-inhibitor-gb1211-at-the-2022-asco-annual-meeting/) - Galecto’s oral galectin-3 inhibitor candidate, GB1211, reverses galectin-3 induced blockade of checkpoint inhibitors binding to PD-1/PD-L1 in pre-clinical models
- [Galecto to Participate at Jefferies Healthcare Conference](https://ysioscapital.com/2022/05/31/galecto-to-participate-at-jefferies-healthcare-conference/) - A live webcast of the presentation will be available on the “News & Events” section of Galecto’s Investor website
- [LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting](https://ysioscapital.com/2022/06/01/lava-therapeutics-to-present-initial-phase-1-2a-clinical-trial-dose-escalation-data-of-lava-051-in-chronic-lymphocytic-leukemia-and-multiple-myeloma-patients-at-the-2022-american-society-of-clinical-o/) - presentation of initial dose-escalation data from the Phase 1/2a clinical trial of LAVA-051
- [Minoryx presents topline results from Phase 2/3 “ADVANCE” study demonstrating significant clinical benefit of leriglitazone in adrenomyeloneuropathy (AMN)](https://ysioscapital.com/2021/01/26/minoryx-presents-topline-results-from-phase-2-3-advance-study-demonstrating-significant-clinical-benefit-of-leriglitazone-in-adrenomyeloneuropathy-amn/) - Largest prospective efficacy study conducted in the orphan disease AMN Leriglitazone significantly reduces progression of cerebral lesions and myelopathy symptoms Minoryx preparing for discussions with regulators for approval of leriglitazone for AMN patients Mataró, Barcelona, Spain, January 26, 2021 – Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating
- [Minoryx Therapeutics raises €21.3M in Series B funding round](https://ysioscapital.com/2018/09/26/minoryx-therapeutics-raises-e21-3m-in-series-b/) - New investment will allow indication expansion of Minoryx’s lead compound, MIN-102 Mataró, Barcelona, Spain, September 26, 2018- Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces the completion of a Series B funding round of €21.3M. The proceeds will enable the company to expand the list of indications
- [Minoryx Therapeutics completes Series A funding of €19.4M ($21.7M)](https://ysioscapital.com/2015/10/14/minoryx-therapeutics-completes-series-a-funding-of-e19-4/) - Funds will help company reach clinical validation for lead candidate in X-ALD, a rare neurodegenerative and life-threatening disease Mataró, Barcelona, Spain, October 14, 2015 - Minoryx Therapeutics, a drug development company specialized in the discovery of new drugs for orphan diseases, today announces it has completed a Series A funding round of €19.4M ($21.7M). Ysios
- [Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting](https://ysioscapital.com/2022/05/27/aura-biosciences-announces-publication-of-preclinical-data/) - These data show that AU-011, a first in class VDC, in combination with immune checkpoint inhibition is effective against both primary tumors and distant metastases in a preclinical model
- [LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results](https://ysioscapital.com/2022/05/17/lava-therapeutics-provides-business-update/) - LAVA-1207 Phase 1/2a trial in metastatic castration-resistant prostate cancer dosed the first patients and is on track to report initial data in H2 2022
- [Aura Biosciences to Participate in Upcoming Investor Conferences](https://ysioscapital.com/2022/05/25/aura-biosciences-to-participate-in-upcoming-investor-conferences/) - Clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications
- [SparingVision Presents Additional Data on its Breakthrough Gene Therapy Approach SPVN06 at ASGCT 2022](https://ysioscapital.com/2022/05/19/sparingvision-presents-additional-data/) - Findings provide additional preclinical validation ahead of IND/CTA submission planned in Q3 2022
- [Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.](https://ysioscapital.com/2022/05/23/kala-announces-entry-into-definitive-agreement-to-sell/) - Kala Will Receive $60 Million in Upfront Payment; Eligible to Receive Additional Sales-Based Milestone Payments
- [Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights](https://ysioscapital.com/2022/05/12/aura-biosciences-reports-first-quarter-2022-financial-results-and-provides-clinical-development-and-operational-highlights/) - Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
- [LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematologic Malignancies](https://ysioscapital.com/2022/05/12/lava-therapeutics-announces-fda-ind-clearance/) - LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematologic Malignancies
- [CVRx® Receives MR-Conditional Labeling Approval for its Barostim™ Heart Failure System](https://ysioscapital.com/2022/05/10/cvrx-receives-mr-conditional-labeling-approval/) - CVRx has received U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR) conditional labeling for its Barostim System.
- [Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference idal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting](https://ysioscapital.com/2022/05/03/aura-biosciences-to-present-at-the-2022-bank-of-america-healthcare-conference-idal-metastasis-an-additional-ocular-oncology-indication-at-the-2022-arvo-annual-meeting/) - Elisabet de los Pinos, PhD, Chief Executive Officer of Aura will present at the 2022 Bank of America Healthcare Conference.
- [LAVA Therapeutics to Participate at the UBS Global Healthcare Conference](https://ysioscapital.com/2022/05/05/lava-therapeutics-to-participate-at-the-ubs-global-healthcare-conference/) - Immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta Tcell engagers to transform the treatment of cancer.
- [SparingVision Presents Progress of its Lead Gene Therapy Program, SPVN06, at ARVO 2022](https://ysioscapital.com/2022/05/05/presents-progress-of-its-lead-gene-therapy-program-spvn06-at-arvo-2022/) - SparingVision is a genomic medicines company with a mission to translate pioneering science into vision saving treatments.
- [Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for EYSUVIS®](https://ysioscapital.com/2022/05/03/kala-pharmaceuticals-announces-new-commercial-and-medicare-coverage-for-eysuvis/) - Now Covered by the largest Pharmacy Benefit Manager in the United States and Humana Medicare Expands Commercial coverage to 92% of total commercial lives
- [SparingVision announces Oral Presentation of SPVN06 Data at ASGCT 2022](https://ysioscapital.com/2022/05/03/sparingvision-announces-oral-presentation-of-spvn06-data/) - SparingVision announces Oral Presentation of SPVN06 Data at ASGCT 2022
- [Aura Biosciences Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting](https://ysioscapital.com/2022/05/03/aura-biosciences-presents-preclinical-data-highlighting-au-011s-anti-tumor-activity-in-choroidal-metastasis-an-additional-ocular-oncology-indication-at-the-2022-arvo-annual-meeting/) - Aura Biosciences Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication
- [Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer](https://ysioscapital.com/2022/05/03/adcendo-appoints-dominik-mumberg-phd-as-chief-scientific-officer/) - Adcendo building a world class team of experienced biotech & pharma executives and renowned leaders in the ADC field
- [Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis](https://ysioscapital.com/2022/03/29/galecto-completes-enrollment-in-phase-1b-2a-gulliver/) - Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis
- [Galecto Reports Financial Results for the Year Ended December 31, 2021](https://ysioscapital.com/2022/02/17/galecto-reports-financial-results-for-the-year-ended-december-31-2021/) - Continued pipeline progress with three potentially first-in-class product candidates Strong cash position with cash runway into 2H 2024
- [LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting](https://ysioscapital.com/2022/04/27/lava-therapeutics-to-present-updated-lava-051-clinical-data/) - Updated interim data from the dose escalation phase of the ongoing Phase 1/2a clinical trial of LAVA-051
- [Xeltis’ clinical study with restorative hemodialysis access graft, aXess, shows promising early puncturing, patency and safety data](https://ysioscapital.com/2022/04/27/xeltis-clinical-study-with-restorative-hemodialysis-access-graft/) - Xeltis` preliminary results from its restorative hemodialysis access graft, aXess clinical trial, showed very promising early puncturing, patency and safety data.
- [Cvrx reports first quarter 2022 financial and operating results](https://ysioscapital.com/2022/04/25/cvrx-reports-first-quarter-2022-financial-and-operating-results/) - Cvrx reports first quarter 2022 financial and operating results.
- [Multi-center Clinical Study Data on Anaconda Biomed’s Mechanical Thrombectomy System Published in Stroke](https://ysioscapital.com/2022/04/05/multi-center-clinical-study-data-on-anaconda-biomeds-mechanical-thrombectomy-system-published-in-stroke/) - Multi-center clinical study data supporting Anaconda Biomed’s ANA Advanced Neurovascular Access™ (ANA) Catheter System for treating ischemic stroke has been published in the journal Stroke.
- [400 patients have been enrolled in am-pharma’s pivotal phase 3 study of ilofotase alfa for the treatment of sepsis-associated acute kidney injury](https://ysioscapital.com/2022/04/25/400-patients-have-been-enrolled-in-am-pharmas-pivotal-phase-3-study-of-ilofotase-alfa-for-the-treatment-of-sepsis-associated-acute-kidney-injury/) - REVIVAL study evaluates AM-Pharma’s proprietary recombinant alkaline phosphatase, ilofotase alfa, for the treatment of patients with sepsis-associated acute kidney injury (SA-AKI).
- [Data Presentation on uPARAP targeting ADCs in Osteosarcoma PDX Models at the 2022 AACR Annual Meeting](https://ysioscapital.com/2022/04/11/data-presentation-on-uparap-targeting-adcs-in-osteosarcoma/) - The poster presentation highlights the preclinical evaluation of several of Adcendo´s ADC candidates for the treatment of osteosarcoma
- [SparingVision to Highlight Progress of its Lead Gene Therapy Program SPVN06 and Research on Retinitis Pigmentosa at ARVO 2022](https://ysioscapital.com/2022/03/31/sparingvision-to-highlight-progress-of-its-lead-gene-therapy-program-spvn06-and-research-on-retinitis-pigmentosa-at-arvo-2022/) - Sparingvisionill be presenting data on its lead product candidate SPVN06 and the natural history of retinitis pigmentosa, its core focus indication.
- [Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights](https://ysioscapital.com/2022/03/23/aura-biosciences-reports-fourth-quarter-and-full-year-2021-financial-results-and-provides-clinical-development-and-operational-highlights/) - On Track to Initiate Pivotal Trial in Choroidal Melanoma and Phase 1 Trial in Non-Muscle Invasive Bladder Cancer with AU-011 in 2H 2022
- [Aura Biosciences Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma)](https://ysioscapital.com/2022/03/21/aura-biosciences-announces-orphan-drug-designation-granted-to-au-011-by-european-commission-for-the-treatment-of-uveal-melanoma-includes-choroidal-melanoma/) - AU-011 was previously granted Orphan Drug Designation for the treatment of uveal melanoma by the U.S. Food and Drug Administration.
- [CorWave to set up its manufacturing facility and expand to a new site next to Paris](https://ysioscapital.com/2022/03/17/corwave-to-set-up-its-manufacturing-facility-and-expand-to-a-new-site-next-to-paris/) - The industrial start-up is preparing to move to larger premises capable of hosting its R&D center and the manufacturing facility needed to enter the clinical and commercial phases.
- [Aura Biosciences to Host Virtual Investor Day Focused on Ocular Oncology with Key Thought Leaders on March 22](https://ysioscapital.com/2022/03/15/aura-biosciences-to-host-virtual-investor-day/) - The program will include an overview of choroidal melanoma (CM), AU-011’s novel mechanism of action, and a summary of the clinical data on AU-011 in CM to date.
- [LAVA Therapeutics To Present at the Oppenheimer 32nd Annual Healthcare Conference 2022](https://ysioscapital.com/2022/03/10/lava-therapeutics-to-present-at-the-oppenheimer-32nd-annual-healthcare-conference-2022/) - LAVA Therapeutics a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer.
- [Am-Pharma announces two presentations at the 27th international conference on advances in critical care nephrology](https://ysioscapital.com/2022/03/07/am-pharma-announces-two-presentations-at-the-27th-international-conference-on-advances-in-critical-care-nephrology/) - New data underscoring the correlation between acute kidney injury severity and patient outcomes following cardiac surgery.
- [Aura Biosciences to Present Preclinical Data Highlighting AU 011’s Potential to Target a Broad Number of Tumor Types at the 2022 AACR Annual Meeting](https://ysioscapital.com/2022/03/08/aura-biosciences-to-present-preclinical-data/) - Results demonstrate the potential wide applicability of AU-011 in targeting a number of solid tumor types and will be presented as part of the 2022 AACR.
- [Kala Pharmaceuticals Announces EYSUVIS® Now Covered on UnitedHealthcare Commercial and Cigna Medicare](https://ysioscapital.com/2022/03/08/kala-pharmaceuticals-announces-eysuvis-now-covered-on-unitedhealthcare-commercial-and-cigna-medicare/) - Expands Commercial Coverage to 118 million lives and Medicare Coverage to 7.1 million lives
- [Lava Therapeutics presents initial LAVA-051 clinical data at the ESMO Targeted Anticancer Therapies Congress 2022](https://ysioscapital.com/2022/03/08/lava-therapeutics-presents-initial-lava-051-clinical-data/) - LAVA-051 preliminary data shows encouraging initial clinical safety; no dose-limiting toxicity or cytokine release syndrome.
- [SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline](https://ysioscapital.com/2022/02/16/splicebio-raises-eur-50m-in-oversubscribed-series-a/) - Financing co-led by UCB Ventures and Ysios Capital with participation by New Enterprise Associates, Gilde Healthcare, Novartis Venture Fund and Asabys Partners.
- [Splice Bio appoints Jean-Philippe Combal as Chairman of the Board of Directors](https://ysioscapital.com/2021/01/21/splice-bio-appoints-jean-philippe-combal-as-chairman-of-the-board-of-directors/) - Dr. Combal is a proven senior executive & biotechnology entrepreneur with 30 years of experience in the pharma & biotech industry in the field of gene therapy.
- [ProteoDesign announces new Investment led by Ysios Capital and rebrands as Splice Bio](https://ysioscapital.com/2020/09/15/proteodesign-announces-new-investment-led-by-ysios-capital-and-rebrands-as-splice-bio-2/) - ProteoDesign announces new Investment led by Ysios Capital and rebrands as Splice Bio.
- [NorthSea Therapeutics Initiates Phase 1 Trial of SEFA-6179, Targeting the Orphan Indication Intestinal Failure-Associated Liver Disease](https://ysioscapital.com/2022/02/02/northsea-therapeutics-initiates-phase-1-trial-of-sefa-6179/) - Beneficial effects of SEFA-6179 in preventing the development of parenteral nutrition-induced cholestasis and liver injury associated with IFALD
- [LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-1207 for Metastatic Castration-Resistant Prostate Cancer](https://ysioscapital.com/2022/02/01/lava-therapeutics-announces-treatment-of-first-patient-in-phase-1-2a-clinical-trial-of-lava-1207-for-metastatic-castration-resistant-prostate-cancer/) - LAVA’s Lead Solid Tumor Program and Second Gammabody™ T cell Engager Enters the Clinic
- [Lava Therapeutics annouces participation in the SVB Leerink 11th Annual Global Healthcare Conference 2022](https://ysioscapital.com/2022/01/28/lava-therapeutics-annouces-participation-in-the-svb-leerink-11th-annual-global-healthcare-conference-2022/) - Access to the recording will be available following the conference under the "Events" tab on the investor relations section of the LAVA Therapeutics website.
- [Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care](https://ysioscapital.com/2022/01/27/galecto-publishes-results-showing-safety-and-efficacy-of-the-gb0139-inhaled-galectin-3-inhibitor-in-hospitalized-covid-19-patients-on-standard-of-care/) - Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease
- [Galecto Adds Experienced Biotech Executive Stephanie Oestreich as Chief Business Officer](https://ysioscapital.com/2022/01/05/galecto-adds-experienced-biotech-executive-stephanie-oestreich-as-chief-business-officer/) - Galecto Adds Experienced Biotech Executive Stephanie Oestreich as Chief Business Officer, he brings extensive experience in business and drug development.
- [Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial](https://ysioscapital.com/2021/12/13/galecto-announces-positive-preliminary-results-for-oral-galectin-3-inhibitor-gb1211-in-part-1-of-its-phase-1b-2a-liver-cirrhosis-trial/) - GB1211 observed to be safe and well tolerated in initial twelve randomized subjects, including six hepatically impaired liver cirrhosis patients
- [Galecto Provides Enrollment Update on Phase 2a MYLOX-1 Trial and Reiterates Expected Timing of Multiple Data Readouts in 2022](https://ysioscapital.com/2021/12/20/galecto-provides-enrollment-update-on-phase-2a-mylox-1-trial-and-reiterates-expected-timing-of-multiple-data-readouts-in-2022/) - Company has enrolled 10 of the targeted 16 patients in the trial. Anticipates interim data in mid-2022 and topline data from full trial in 2H 2022.
- [AM-Pharma Announces Enrollment and Financing of COVID-19 Cohort in Phase III REVIVAL Trial](https://ysioscapital.com/2021/01/07/am-pharma-announces-enrollment-and-financing-of-covid-19-cohort-in-phase-iii-revival-trial/) - COVID-19 patients with sepsis-associated acute kidney injury will be included in an exploratory cohort in the pivotal trial enrolling up to 1,600SA-AKI patients
- [AM-Pharma and Leading Experts Publish Report on State-of-the-Art Clinical Trials in Acute Kidney Injury](https://ysioscapital.com/2022/01/26/am-pharma-and-leading-experts-publish-report-on-state-of-the-art-clinical-trials-in-acute-kidney-injury/) - The article provides insights on important advances in the understanding of AKI as a disease spectrum with an urgent need for new treatments.
- [LAVA Therapeutics Presents Preclinical Data on its GammabodyTM T Cell Engager Platform at the 21st Annual PepTalk Conference](https://ysioscapital.com/2022/01/18/lava-therapeutics-presents-preclinical-data-on-its-gammabodytm-t-cell-engager-platform-at-the-21st-annual-peptalk-conference/) - Recruit gamma delta T cells with its bispecific antibody platform results in potent anti-tumor activity while avoiding off-tumor toxicity and cytokine release syndrome
- [Lava Therapeutics to present corporate overview at 40TH annual J.P. Morgan healthcare conference](https://ysioscapital.com/2021/12/20/lava-therapeutics-to-present-corporate-overview/) - Stephen Hurly, chief executive officer, will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 12
- [NorthSea Therapeutics Completes US$80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders](https://ysioscapital.com/2021/12/17/northsea-therapeutics-completes-us80-million-series-c/) - Financing co-led by Ysios Capital and Forbion Growth to Advance Clinical Programs in Metabolic Disorders
- [First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Reversal Agent, VMX-C001](https://ysioscapital.com/2021/12/15/first-subjects-dosed-in-first-in-human-trial-for-varmxs/) - Treatment of the first subjects in its first-in-human study for lead compound VMX-C001, and the transition of VarmX from a preclinical into a clinical company.
- [SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer](https://ysioscapital.com/2021/12/10/sparingvision-strengthens-leadership-team/) - Sparingvision appoints Dr Mehdi Gasmi as Chief Operating Officer (COO), as well as other senior appointments, further strengthening the SparingVision team.
- [ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors](https://ysioscapital.com/2021/12/02/ona-therapeutics-appoints-dr-michel-detheux/) - Seasoned biotech executive with a wealth of experience and a track-record of strategic alliances in the immuno-oncology space
- [Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders](https://ysioscapital.com/2021/12/01/adcendo-further-strengthens-management-team-and-scientific-advisory-board-with-appointment-of-international-adc-leaders/) - Building the team with experienced biotech experts and renowned leaders in the ADC field. Underscores company’s commitment to progressing lead program on novel ADC target uPARAP
- [Dutch med-tech innovator Xeltis lands €15 million European financing from EIB](https://ysioscapital.com/2021/11/22/dutch-med-tech-innovator-xeltis-lands-e15-million-european-financing-from-eib/) - EIB has signed a €15 million quasi-equity agreement with Dutch-based medical technology company Xeltis, supported under the pan-European Guarantee Fund (EGF).
- [Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology](https://ysioscapital.com/2021/11/22/vifor-pharma-to-acquire-sanifit-to-further-strengthen-late-stage-pipeline-in-nephrology/) - Vifor Pharma to acquire Sanifit, a clinical-stage cardio-renal biopharmaceutical company focused on treatments for progressive vascular calcification disorders.
- [Sanifit Announces Initiation of First Clinical Trial of SNF472 in Patients with Calciphylaxis](https://ysioscapital.com/2016/10/20/sanifit-announces-initiation-of-first-clinical-trial-of-snf472-in-patients-with-calciphylaxis/) - Sanifit Announces Initiation of First Clinical Trial of SNF472 in Patients with Calciphylaxis.
- [Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Diseases](https://ysioscapital.com/2021/11/17/kala-pharmaceuticals-acquires-combangio-expanding-its-pipeline-with-a-clinical-stage-novel-biologic-for-the-treatment-of-persistent-corneal-epithelial-defect-pced-and-other-rare-ocular-surface-dise/) - Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect and other Rare Ocular Surface Diseases
- [Sanifit announces €72.2M ($80.9M) financing in Spain’s largest private biotech fundraise](https://ysioscapital.com/2019/06/26/sanifit-announces-e72-2m-80-9m-financing-in-spains-largest-private-biotech-fundraise/) - Proceeds to enable progression of orphan designated lead candidate SNF472 into pivotal phase 3 trial for treatment of calciphylaxis. Round led by Spanish investor Caixa Capital Risc. Deal supported by new investors Columbus Venture Partners and Alta Life Sciences in addition to international consortium of existing shareholders. Palma, Spain and San Diego, USA, 26 June
- [Sanifit appoints Preston S. Klassen MD, MHS as Chief Medical Officer and announces new US subsidiary](https://ysioscapital.com/2016/06/07/sanifit-appoints-preston-s-klassen-announces-new-us-subsidiary/) - Former Head of R&D at Orexigen Therapeutics and Therapeutic Area Head for Nephrology at Amgen appointed as CMO CMO appointment and launch of US subsidiary are significant steps in establishing a US presence Palma de Mallorca, Spain, 07 June 2016 - Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today
- [Sanifit Expands Board with Senior Hire](https://ysioscapital.com/2016/05/11/sanifit-expands-board-with-senior-hire/) - Keith R. Leonard, Former President & CEO of Kythera Biopharmaceuticals Appointed to Sanifit’s Board of Directors.
- [Sanifit announces the creation of a Steering Committee for its Phase 2b ESRD Clinical Program with SNF472](https://ysioscapital.com/2015/12/21/sanifit-and-mitelos-make-available-to-doctors-and-patients-a-new-alternative-in-osteoporosis-1/) - The newly created Steering Committee includes 4 well known scientists and clinicians who will provide the overall supervision of the phase 2b study with SNF472.
- [Sanifit and Mitelos make available to Doctors and patients a new alternative in osteoporosis](https://ysioscapital.com/2015/11/25/sanifit-and-mitelos-make-available-to-doctors-and-patients-a-new-alternative-in-osteoporosis/) - Sanifit and Mitelos have successfully concluded the development, registration and industrial scaled up of SNF671
- [Aura Biosciences Presents Final Phase 1b/2 Data for its first Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology 2021 Annual Meeting](https://ysioscapital.com/2021/11/16/aura-biosciences-presents-final-phase-1b-2-data-for-its-first-virus-like-drug-conjugate-au-011-in-patients-with-choroidal-melanoma-at-the-american-academy-of-ophthalmology-2021-annual-meeting/) - Presentations Include Final Safety and Efficacy Data from the Phase 1b/2 Trial using Intravitreal Administration and Updated Safety Data from the Phase 2 Trial
- [Sanifit raises €36.6M ($41.3M) in Series C financing round](https://ysioscapital.com/2015/09/08/sanifit-raises-e36-6m-in-a-series-c-oversubscribed-financing/) - The investment was led by Ysios Capital and supported by a substantial syndicate of new investors including Lundbeckfond, Forbion, Gilde, Baxter, Edrip, Caixa.
- [Ysios Capital’s portfolio company Aura Biosciences prices IPO on NASDAQ](https://ysioscapital.com/2021/11/03/ysios-capitals-portfolio-company-aura-biosciences-prices-ipo-on-nasdaq/) - Clinical-stage oncology company developing novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively.
- [AM-Pharma Appoints Alexander Bastian as Vice President Value & Market Access](https://ysioscapital.com/2021/11/04/am-pharma-appoints-alexander-bastian-as-vice-president-value-market-access/) - AM-Pharma developing therapeutics for severe medical conditions, today announced the appointment of Alexander Bastian as Vice President Value & Market Access.
- [Galecto Announces Clinical Collaboration with Roche for Phase 2 Trial of GB1211 in Combination with Atezolizumab in First Line Non-Small-Cell Lung Cancer](https://ysioscapital.com/2021/11/02/galecto-announces-clinical-collaboration-with-roche-for-phase-2-trial-of-gb1211-in-combination-with-atezolizumab-in-first-line-non-small-cell-lung-cancer/) - Galecto Announces Clinical Collaboration with Roche for Phase 2 Trial of GB1211 in Combination with Atezolizumab in First Line Non-Small-Cell Lung Cancer
- [Aura Biosciences Completes $30 Million Series C Financing](https://ysioscapital.com/2017/12/21/aura-biosciences-completes-30-million-series-c-financing/) - Ocular melanoma, also known as uveal or choroidal melanoma, is a rare and aggressive eye cancer.
- [Aura Biosciences Appoints David Johnson to Its Board of Directors](https://ysioscapital.com/2021/01/05/aura-biosciences-appoints-david-johnson-to-its-board-of-directors/) - Mr. Johnson is a biopharmaceutical business leader with more than 25 years of experience in drug development.
- [Aura Biosciences Announces Dosing of First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma](https://ysioscapital.com/2020/09/11/aura-biosciences-announces-dosing-of-first-patient-in-phase-2-study-evaluating-suprachoroidal-administration-of-au-011-in-patients-with-choroidal-melanoma/) - Aura Biosciences Announces Dosing of First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma.
- [Aura Biosciences Presents Updated AU-011 Clinical Data at ARVO 2020](https://ysioscapital.com/2020/06/12/aura-biosciences-appoints-george-golumbeski-1-1/) - AU-011 Continues to Demonstrate a Favorable Safety Profile Along with Promising Tumor Control and Vision Preservation.
- [Aura Biosciences Presents Updated Phase 1b/2 Clinical Data for AU-011 at the 43rd Annual Macula Society Meeting](https://ysioscapital.com/2020/02/24/aura-biosciences-appoints-george-golumbeski-1/) - Aura Biosciences Presents Updated Phase 1b/2 Clinical Data for AU-011 at the 43rd Annual Macula Society Meeting.
- [Synendos Therapeutics Appoints Scientific Advisory Board](https://ysioscapital.com/2021/10/26/synendos-therapeutics-appoints-scientific-advisory-board/) - Scientific Advisory Board made up of prominent scientists with significant CNS expertise Pre-clinical development on track for IND submission BASEL, Switzerland – 26 October 2021 – Synendos Therapeutics (Synendos), a biopharmaceutical company focused on restoring the natural functioning of the endocannabinoid system to treat Central Nervous System (CNS) disorders, today announces the appointment of well
- [Aura Biosciences Appoints George Golumbeski, Ph.D., as Chairman of the Board of Directors](https://ysioscapital.com/2020/01/07/aura-biosciences-appoints-george-golumbeski/) - George Golumbeskias Chairman of its Board of Directors, a biopharmaceutical business leader with +25 years of experience in the biotechnology industry.
- [Aura Biosciences Announces Oversubscribed $80 Million Financing](https://ysioscapital.com/2021/03/22/aura-biosciences-announces-oversubscribed-80-million-financing/) - Proceeds to Support Pivotal Program of AU-011 for the First Line Treatment of Choroidal Melanoma and Expansion of Virus-like Drug Conjugate (VDC) Platform.
- [Aura Biosciences Announces Updated Phase 1b/2 Clinical Data for AU-011 Presented at the American Academy of Ophthalmology 2019 Annual Meeting](https://ysioscapital.com/2019/10/15/aura-biosciences-announces-updated-phase-1b2-clinical-data-for-au-011/) - Aura Biosciences Announces Updated Phase 1b/2 Clinical Data for AU-011 Presented at the American Academy of Ophthalmology 2019 Annual Meeting
- [Aura Biosciences Completes $40 Million Series D Financing](https://ysioscapital.com/2019/04/02/aura-biosciences-completes-40-million-series-d-financing/) - Aura Biosciences has announced that it closed a $40 million Series D financing. New investor Medicxi led the round, with current investors also participating.
- [Aura Biosciences Presents Updated Phase 1b/2 Clinical Data for AU-011 at the American Academy of Ophthalmology 2018 Annual Meeting](https://ysioscapital.com/2018/10/30/aura-biosciences-presents-updated-phase-1b2-clinical-data-for-au-011-at-the-american-academy-of-ophthalmology-2018-annual-meeting/) - Aura Biosciences announced that updated clinical data from its Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011,
- [Aura Biosciences Boosts Finance Team with Two Key Appointments, Preparing to Move Into Late-Stage Clinical Development in Ocular Melanoma](https://ysioscapital.com/2018/09/04/aura-biosciences-presents-interim-phase-1b2-data-1/) - Aura Biosciences Boosts Finance Team with Two Key Appointments, Preparing to Move Into Late-Stage Clinical Development in Ocular Melanoma.
- [Aura Biosciences Presents Interim Phase 1b/2 Data at the American Society of Retina Specialists (ASRS) Annual Meeting](https://ysioscapital.com/2018/07/25/aura-biosciences-presents-interim-phase-1b2-data/) - Aura Biosciences Presents Interim Phase 1b/2 Data at the American Society of Retina Specialists (ASRS) Annual Meeting
- [Aura Biosciences Announces Update of Clinical Safety and Efficacy Data on Lead Candidate AU-011 for Choroidal Melanoma](https://ysioscapital.com/2018/06/17/aura-biosciences-announces-update-of-clinical-safety-and-efficacy-data-on-lead-candidate-au-011-for-choroidal-melanoma/) - Aura Biosciences Announces Update of Clinical Safety and Efficacy Data on Lead Candidate AU-011 for Choroidal Melanoma
- [Aura Biosciences Strengthens Leadership Team with Addition of Cadmus Rich, M.D., as Chief Medical Officer](https://ysioscapital.com/2017/12/11/aura-biosciences-strengthens-leadership-team-with-addition-of-cadmus-rich-m-d-as-chief-medical-officer/) - CAMBRIDGE, Mass. – Dec. 11, 2017 - Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, today announced that Cadmus Rich, M.D., has joined the company’s leadership team as Chief Medical Officer. In this role, he will oversee all clinical research and
- [New Clinical Data from Aura Biosciences to be Featured in Presentation at the American Academy of Ophthalmology 2017 Annual Meeting](https://ysioscapital.com/2017/10/25/new-clinical-data-from-aura-biosciences-to-be-featured-in-presentation-at-the-american-academy-of-ophthalmology-2017-annual-meeting/) - New Clinical Data from Aura Biosciences to be Featured in Presentation at the American Academy of Ophthalmology 2017 Annual Meeting.
- [Aura Biosciences Announces Initiation of Phase 1b Clinical Trial and Receipt of FDA Fast Track Designation for AU-011 for the Treatment of Primary Ocular Melanoma](https://ysioscapital.com/2017/03/30/aura-biosciences-announces-initiation-of-phase-1b-clinical-trial-and-receipt-of-fda-fast-track-designation/) - Enrolled and dosed the first patient in Ph1b clinical trial of light-activated AU-011, an investigational, first-in-class targeted therapy in development for the treatment of ocular melanoma.
- [Aura Biosciences Receives FDA Clearance of Investigational New Drug Application for Light-activated AU-011 for the Treatment of Ocular Melanoma](https://ysioscapital.com/2017/02/06/aura-biosciences-receives-fda-clearance-of-investigational-new-drug-application/) - U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application (IND) for the company’s lead program, light-activated AU-011 in ocular melanoma (OM).
- [Aura Biosciences Secures $8 Million in Additional Funding and Augments Board of Directors and Clinical Advisory Board](https://ysioscapital.com/2016/09/29/aura-biosciences-secures-8-million-in-additional-funding-and-augments-board-of-directors-and-clinical-advisory-board/) - Aura Biosciences Secures $8 Million in Additional Funding and Augments Board of Directors and Clinical Advisory Board.
- [FDA Grants Orphan Drug Designation to Aura Biosciences’ Novel Treatment for Uveal Melanoma](https://ysioscapital.com/2015/05/21/ysios-capital-participates-in-aura-biosciences-21m-series-b-financing-1/) - FDA Grants Orphan Drug Designation to Aura Biosciences’ Novel Treatment for Uveal Melanoma.
- [Aura Biosciences Closes $21M Series B Financing](https://ysioscapital.com/2015/03/06/ysios-capital-participates-in-aura-biosciences-21m-series-b-financing/) - Aura Biosciences, a biotech company developing highly tumor-targeted breakthrough therapies for rare cancers, has secured a $21M Series B round of funding.
- [VarmX awarded funding from the EIC Accelerator to support scale up and manufacturing of VMX-C001](https://ysioscapital.com/2021/10/21/varmx-awarded-funding-from-the-eic-accelerator-to-support-scale-up-and-manufacturing-of-vmx-c001/) - VarmX has been awarded up to €17.5 million from the European Innovation Council (EIC) Accelerator to upscale and accelerate cost effective manufacturing of its lead compound, VMX-C001.
- [CorWave Wins 2021 HealthTech Award](https://ysioscapital.com/2021/10/19/corwave-wins-2021-healthtech-award/) - CorWave received the Medtech Award, which recognizes a medical device or diagnostic company that has distinguished itself over the past two years.
- [CorWave Successfully Performed a 90-Day In Vivo Study on Its Revolutionary Cardiac Pump Synchronized With the Native Heart, Results Presented at ASAIO Meeting](https://ysioscapital.com/2021/06/14/corwave-successfully-performed-a-90-day-in-vivo-study-on-its-revolutionary-cardiac-pump-synchronized-with-the-native-heart-results-presented-at-asaio-meeting-2/) - The results of the 90-day in vivo study were reported during an oral presentation entitled "Design Optimization of the CorWave Membrane LVAD."
- [ONA Therapeutics Strengthens Scientific Leadership Team](https://ysioscapital.com/2021/10/21/ona-therapeutics-strengthens-scientific-leadership-team/) - Expansion of the Scientific Advisory Board with appointments of leading experts in preclinical, translational and clinical drug development.
- [Kala Pharmaceuticals Announces FDA Approval of EYSUVIS™ for the Short-Term Treatment of the Signs and Symptoms of Dry Eye Disease](https://ysioscapital.com/2020/10/27/kala-pharmaceuticals-announces-fda-approval-of-eysuvis/) - U.S. Food and Drug Administration (FDA) has approved EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease.
- [Kala Pharmaceuticals Announces Appointment of C. Daniel Myers to Board of Directors](https://ysioscapital.com/2021/10/18/kala-pharmaceuticals-announces-appointment-of-c-daniel-myers-to-board-of-directors/) - Kala Pharmaceuticals announced the appointment of C. Daniel Myers to its Board of Directors.
- [LAVA Therapeutics Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment of Chronic Lymphocytic Leukemia](https://ysioscapital.com/2021/10/15/lava-therapeutics-receives-fda-orphan-drug-designation-for-lava-051-for-the-treatment-of-chronic-lymphocytic-leukemia/) - FDA has granted orphan drug designation (ODD) for the company’s CD1d targeted GammabodyTM, LAVA-051, for the treatment of chronic lymphocytic leukemia.
- [Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology](https://ysioscapital.com/2021/10/13/intellia-therapeutics-and-sparingvision-announce-strategic-collaboration/) - Collaboration combines Intellia’s proprietary genome editing technology platform with SparingVision’s significant ophthalmology expertise
- [Aura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma at the ASRS 2021 Annual Meeting](https://ysioscapital.com/2021/10/11/aura-biosciences-presents-interim-phase-2-safety-data/) - Aura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma.
- [Anaconda Biomed to close venture debt operation of up to €10 million with the EIB to treat acute ischemic stroke (AIS)](https://ysioscapital.com/2021/10/06/anaconda-biomed-to-close-venture-debt-operation-of-up-to-e10-million-with-the-eib-to-treat-acute-ischemic-stroke-ais/) - EIB to provide venture debt funding of up to €10M to support the development of Anaconda’s next generation of catheters to treat acute ischemic strokes (AIS).
- [Inbiomotion’s MAF Test® selects breast cancer patients benefitting from adjuvant clodronate, significantly improving their overall survival](https://ysioscapital.com/2021/09/30/inbiomotions-maf-test-selects-breast-cancer-patients-benefitting-from-adjuvant-clodronate-significantly-improving-their-overall-survival/) - The assessment of MAF status has the potential to become an objective approach to the selection of breast cancer patients for adjuvant clodronate treatment.
- [Aura Biosciences Expands Executive Leadership Team and Board of Directors](https://ysioscapital.com/2021/09/29/aura-biosciences-expands-executive-leadership-team-and-board-of-directors/) - Aura biosciences today announced the appointment of Chris Primiano as Chief Business Officer and the appointment of Antony Mattessich to its Board of Directors.
- [AM-Pharma Appoints Lars Boesgaard as Chief Financial Officer and Establishes U.S. Affiliate AM-Pharma Inc.](https://ysioscapital.com/2021/09/15/am-pharma-appoints-lars-boesgaard-as-chief-financial-officer-and-establishes-u-s-affiliate-am-pharma-inc/) - AM-Pharma B.V today announced the appointment of Lars R. Boesgaard as Chief Financial Officer (CFO), effective immediately.
- [Inbiomotion raises an oversubscribed financing round to launch its diagnostic product in breast cancer](https://ysioscapital.com/2021/01/21/phase-3-prospective-retrospective-study-of-maftest-in-lancet-oncology-demonstrates-the-effect-of-maf-gene-amplification-on-treatment-outcomes-with-adjuvant-zoledronic-acid-in-early-breast-cancer/) - The financing round is led by Alta Life Sciences Spain I FCR, a vehicle managed by Altamar Private Equity SGIIC. Existing investors including Institut Català de Finances (ICF) have also participated in the financing. Inbiomotion is in advanced stage of development of a single gene-based test for predicting response to bisphosphonates in breast cancer adjuvant
- [Phase 3 prospective/retrospective study of MAFTest® in Lancet Oncology demonstrates the effect of MAF gene amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer](https://ysioscapital.com/2017/10/19/phase-3-prospectiveretrospective-study-of-maftest-in-lancet-oncology/) - MAFTest® negative in patients treated with zoledronic acid in the adjuvant setting was associated with improved invasive-disease-free survival & overall survival.
- [”la Caixa” leads an investment round in Inbiomotion with the participation of Ysios Capital](https://ysioscapital.com/2016/03/09/la-caixa-leads-an-investment-round-in-inbiomotion-with-the-participation-of-ysios-capital/) - The company concludes a 2.2 million Euro round led by ”la Caixa” through Caixa Capital Risc. Also participating in the operation were Ysios Capital.
- [IRB Barcelona identifies the gene responsible for metastasis of breast cancer to the bone](https://ysioscapital.com/2015/09/16/inbiomotionidentifies-the-gene-responsible-for-metastasis-of-breast-cancer-to-the-bone/) - A study published today may be key to the early detection of patients at risk of developing metastasis to the bone
- [Inbiomotion appoints Dr. David L. Lacey to its Board of Directors](https://ysioscapital.com/2013/01/29/inbiomotion-appoints-dr-david-l-lacey-to-its-board-of-directors/) - Inbiomotion has strengthened its board of directors with the appointment of Dr. David L. Lacey.
- [Inbiomotion creates a world class Scientific Advisory Board chaired by Prof. Rob E. Coleman](https://ysioscapital.com/2012/11/21/inbiomotion-scientific-advisory-board-chaired-by-prof-rob-e-coleman/) - Scientific Advisory Board with renowned experts in various disciplines, including bone metastatic disease, biomarker development, translational research and medical oncology.
- [Jon Askaa joins Inbiomotion Board of Directors – Management team strengthened](https://ysioscapital.com/2012/11/08/jon-askaa-joins-inbiomotion-board-of-directors-management-team-strengthened/) - Inbiomotion today announced the appointment of Dr. Jon Askaa, as non-executive Director, and Dr. Juan Carlos Tercero as Head of Product Development.
- [Ysios Capital leads a € 2M Series A round of Inbiomotion](https://ysioscapital.com/2012/06/28/ysios-capital-leads-a-e-2m-series-a-round-of-inbiomotion/) - The proceeds of the financing will be used to continue the validation of its proprietary biomarker in a number of clinical studies and advance its development.
- [CorWave Attracts Global Talent, Strengthening Its Management Team in Preparation for Clinical Phase and Industrial Ramp Up](https://ysioscapital.com/2021/09/21/corwave-attracts-global-talent-strengthening-its-management-team-in-preparation-for-clinical-phase-and-industrial-ramp-up/) - CorWave, a French medtech developing a next-generation heart pump, is recruiting top talent from throughout the world to strengthen its team.
- [Galecto Announces First Patient Treated in Phase 2 Trial of Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis](https://ysioscapital.com/2021/09/14/galecto-announces-first-patient-treated-in-phase-2-trial-of-oral-galectin-3-inhibitor-gb1211-in-liver-cirrhosis/) - Galecto now has three ongoing Phase 2 clinical trials with three different drug candidates in three high value indications.
- [Ysios Capital achieves Certification under the Diversity VC Standard](https://ysioscapital.com/2021/09/09/ysios-capital-achieves-certification-under-the-diversity-vc-standard/) - Ysios Capital is the first specialized venture capital firm in life sciences globally and the first Spanish firm to achieve the Diversity VC Standard.
- [AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan](https://ysioscapital.com/2021/09/08/am-pharma-and-kyowa-kirin-sign-exclusive-license-agreement/) - Am-Pharma and Kyowa Kirin have entered into an exclusive license agreement under which Kyowa Kirin gains the rights to develop and commercialize ilofotase alfa.
- [VTX‐801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease](https://ysioscapital.com/2021/08/13/vtx‐801-receives-u-s-fda-fast-track-designation-for-the-treatment-of-wilson-disease/) - Paris, France and New York, NY, August 12, 2021 – Vivet Therapeutics (“Vivet”), a clinical‐stage biotechnology company, and Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VTX‐801, Vivet’s clinical‐stage gene therapy for the treatment of Wilson Disease – a rare, genetic disorder that reduces
- [Ysios Capital Partners and “la Caixa” lead MedLumics €3.5million/$4.7million Series A Financing.](https://ysioscapital.com/2011/12/01/ysios-capital-partners-and-la-caixa-lead-medlumics-e3-5million4-7million-series-a-financing/) - MedLumics Announces 3.5 Million Euro/4.7 Million USD Series A Financing, Led by Ysios Capital Partners and “la Caixa” MADRID - December 1, 2011 – MedLumics, a medical imaging diagnostics company specializing in advanced optical coherence tomography (OCT) technology, has announced the closing of a 3.5 million Euro/4.7 million USD Series A financing. Led jointly by
- [Ysios Capital Partners and “la Caixa” lead MedLumics €3.5million/$4.7million Series A Financing.](https://ysioscapital.com/2011/12/01/ysios-capital-partners-and-la-caixa-lead-medlumics-e3-5million4-7million-series-a-financing-2/) - MedLumics Announces 3.5 Million Euro/4.7 Million USD Series A Financing, Led by Ysios Capital Partners and “la Caixa” MADRID - December 1, 2011 – MedLumics, a medical imaging diagnostics company specializing in advanced optical coherence tomography (OCT) technology, has announced the closing of a 3.5 million Euro/4.7 million USD Series A financing. Led jointly by
- [Ysios Capital Partners leads €29.2million Series D Financing of AM-Pharma](https://ysioscapital.com/2011/09/13/ysios-capital-partners-leads-e29-2million-series-d-financing-of-am-pharma-2/) - Barcelona, Spain, 13 September 2011 – Ysios Capital Partners, the Spanish life sciences venture capital firm, today announces that is has led the €29.2 million Series D financing of AM-Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of Alkaline Phosphatase (AP) as a treatment of severe inflammatory diseases. The oversubscribed series
- [Ysios Capital Partners leads €2million series A financing of STAT Diagnostica](https://ysioscapital.com/2011/06/15/ysios-capital-partners-leads-e2million-series-a-financing-of-stat-diagnostica/) - STAT Diagnostica was founded in 2010 and focuses on the development of Point of Care diagnostic solutions for clinical applications. The transaction is the sixth investment managed by Ysios Capital Partners, the third in Spain and the first in diagnostics. The proceeds of this round will fund the initial development of STAT Diagnostica‘s Point of
- [Ysios Capital Partners leads €5million Series A Financing of Sabirmedical](https://ysioscapital.com/2010/09/21/ysios-capital-partners-leads-e5million-series-a-financing-of-sabirmedical/) - Ysios Capital Partners leads € 5 Million Series A Financing of Sabirmedical - Sabirmedical is focused on the development of medical technologies for the diagnosis and monitoring of vital signs and medical information in patients with different pathologies. - Ysios Capital Partners has led the investment in which “la Caixa” has also participated. This transaction
- [Ysios Capital Partners leads €5million Series A Financing of Sabirmedical](https://ysioscapital.com/2010/09/21/ysios-capital-partners-leads-e5million-series-a-financing-of-sabirmedical-2/) - Ysios Capital Partners leads € 5 Million Series A Financing of Sabirmedical - Sabirmedical is focused on the development of medical technologies for the diagnosis and monitoring of vital signs and medical information in patients with different pathologies. - Ysios Capital Partners has led the investment in which “la Caixa” has also participated. This transaction
- [Ysios Capital Partners participates in Cardoz' €10million Series A financing round.](https://ysioscapital.com/2010/05/10/ysios-capital-partners-participates-in-cardoz-e10million-series-a-financing-round/) - Cardoz Raises SEK 100 M (€ 10 M) in Series A Financing to Develop Drug for Aortic Aneurysm Stockholm 2010-05-10 Cardoz AB, a clinical stage company, today announced that it has closed a series A financing round of SEK 100 million (€ 10 million) with an international syndicate of venture capital investors. Cardoz was incubated
- [Ysios Capital Partners participates in Cardoz' €10million Series A financing round.](https://ysioscapital.com/2010/05/10/ysios-capital-partners-participates-in-cardoz-e10million-series-a-financing-round-2/) - Cardoz Raises SEK 100 M (€ 10 M) in Series A Financing to Develop Drug for Aortic Aneurysm Stockholm 2010-05-10 Cardoz AB, a clinical stage company, today announced that it has closed a series A financing round of SEK 100 million (€ 10 million) with an international syndicate of venture capital investors. Cardoz was incubated
- [Ysios Capital Partners participates in Biovex’s $70million final closing](https://ysioscapital.com/2009/11/10/ysios-capital-partners-participates-in-biovexs-70million-final-closing/) - BIOVEX COMPLETES $70 MILLION FINANCING TO CONCLUDE PIVOTAL STUDY WITH ITS PIONEERING CANCER TREATMENT, ONCOVEX GM‐CSF Woburn, MA, November 10, 2009 ‐‐ BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has concluded a $70 million private financing, raising $30 million in
- [Ysios Capital Partners participates in Biovex’s $70million final closing](https://ysioscapital.com/2009/11/10/ysios-capital-partners-participates-in-biovexs-70million-final-closing-2/) - BIOVEX COMPLETES $70 MILLION FINANCING TO CONCLUDE PIVOTAL STUDY WITH ITS PIONEERING CANCER TREATMENT, ONCOVEX GM‐CSF Woburn, MA, November 10, 2009 ‐‐ BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has concluded a $70 million private financing, raising $30 million in
- [Ysios Capital Partners participates in the $36million . €25million Series B Financing of Endosense](https://ysioscapital.com/2009/09/02/ysios-capital-partners-participates-in-the-36million-e25million-series-b-financing-of-endosense/) - Ysios Capital Partners participates in the USD 36 million / € 25 million Series B Financing of Endosense Barcelona – September 1, 2009 – Endosense, a medical technology company focused on improving efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced that it has received USD 36 million in
- [Ysios Capital Partners participates in the $36million . €25million Series B Financing of Endosense](https://ysioscapital.com/2009/09/02/ysios-capital-partners-participates-in-the-36million-e25million-series-b-financing-of-endosense-2/) - Ysios Capital Partners participates in the USD 36 million / € 25 million Series B Financing of Endosense Barcelona – September 1, 2009 – Endosense, a medical technology company focused on improving efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced that it has received USD 36 million in
- [Paula Olazábal joins Ysios Capital Partners as investment manager](https://ysioscapital.com/2008/07/22/paula-olazabal-joins-ysios-capital-partners-as-investment-manager/) - Paula Olazábal joins Ysios Capital Partners as investment manager.
- [Ysios co-leads €27,2million Series B financing of stem cell company Cellerix](https://ysioscapital.com/2007/09/20/ysios-co-leads-e272million-series-b-financing-of-stem-cell-company-cellerix/) - YSIOS CO‐LEADS € 27,2 M SERIES B FINANCING OF STEM CELL COMPANY CELLERIX Barcelona, September 20, 2007. ‐ Cellerix, a biopharmaceutical company leader in the clinical development and production of innovative medicines based on adult stem cells, has closed an oversubscribed Series B financing round for €27.2M. The round was led by two of the
- [Amgen to acquire Biovex for up to $1 bn](https://ysioscapital.com/2011/01/24/amgen-to-acquire-biovex-for-up-to-1-bn/) - AMGEN TO ACQUIRE BIOVEX, A PRIVATELY HELD BIOTECHNOLOGY COMPANYHEADQUARTERED IN WOBURN, MASS Acquisition Includes a Therapeutic in Phase 3 Clinical Trials for the Treatment of Advanced Melanoma and Head and Neck Cancer THOUSAND OAKS, Calif., and WOBURN, Mass. (Jan. 24, 2011) – Amgen (NASDAQ: AMGN) and BioVex Group, Inc. today announced that the companies have
- [TiGenix Completes Private Placement Raising EUR 6.7 million](https://ysioscapital.com/2012/12/20/tigenix-completes-private-placement-raising-eur-6-7-million/) - Leuven, Belgium – 20 December 2012 – TiGenix NV (Euronext Brussels: TIG) announces today that it has raised EUR 6.7 million through a private placement via the accelerated bookbuilding procedure announced on 19 December 2012 after the market closed. The private placement has allowed TiGenix to place 8,629,385 new shares with a wide range of
- [TiGenix reports positive interim safety results of its Phase IIa study of Cx611](https://ysioscapital.com/2012/12/19/tigenix-reports-positive-interim-safety-results-of-its-phase-iia-study-of-cx611/) - Leuven (BELGIUM), Madrid (SPAIN) – December 19, 2012 – TiGenix (NYSE Euronext: TIG), the European leader in cell therapy, announced today positive interim safety results of its Phase IIa study of Cx611 in rheumatoid arthritis (RA). Cx611 is an intravenously injected suspension of expanded allogeneic adult stem cells derived from human adipose (fat) tissue. The
- [TiGenix to Raise Capital via a Private Placement of New Ordinary Shares](https://ysioscapital.com/2012/12/19/tigenix-to-raise-capital-via-a-private-placement-of-new-ordinary-shares/) - Leuven, Belgium – 19 December 2012 – TiGenix NV (Euronext Brussels: TIG) today announced that it will launch a private placement of up to 8,629,385 new ordinary shares. The Board of Directors will disapply the preferential subscription rights of existing shareholders in connection with the intended capital increase, which will take place within the limits
- [Endosense appoints Nicolas Marsault as new CFO](https://ysioscapital.com/2012/12/06/endosense-appoints-nicolas-marsault-as-new-cfo/) - GENEVA – December 6, 2012 – Endosense, a pioneer and leader in contact-force sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has named Nicolas Marsault as its new chief financial officer. Marsault joins the company as it continues to expand the commercial presence of its TactiCath® contact-force sensing ablation
- [Endosense secures USD 40.3M/CHF 37.4M Series C financing](https://ysioscapital.com/2012/11/27/endosense-secures-usd-40-3mchf-37-4m-series-c-financing/) - GENEVA – November 27, 2012 – Endosense, a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced the close of a USD 40.3 million/CHF 37.4 million series C financing. Led by new investor NGN Capital, the round drew large participation from all existing
- [TiGenix focus on advanced cell therapy programs](https://ysioscapital.com/2012/11/23/tigenix-focus-on-advanced-cell-therapy-programs/) - Leuven (BELGIUM) – November 23, 2012 – TiGenix (Euronext Brussels: TIG), the European leader in cell therapy, announced today the definitive closure of its biomaterials unit, TiGenix Ltd., to allow the company to fully focus on the further commercial roll-out of ChondroCelect®, and its cell therapy product development pipeline. “With our Phase II and Phase III cell therapy
- [TiGenix signs agreement for commercialization of ChondroCelect in the Middle East](https://ysioscapital.com/2012/11/13/tigenix-signs-agreement-for-commercialization-of-chondrocelect-in-the-middle-east/) - Leuven (Belgium) – November 13, 2012 – TiGenix NV (Euronext Brussels: TIG) and pharmaceutical marketing and distribution company Genpharm in Dubai, United Arab Emirates, today announced that they have signed an exclusive agreement for the commercialization of ChondroCelect® in the Middle East region. TiGenix and Genpharm have entered into an exclusive distribution agreement to facilitate the successful commercialization
- [TiGenix Business Update & Financial Highlights for Q3 of 2012](https://ysioscapital.com/2012/11/08/tigenix-business-update-financial-highlights-for-q3-of-2012/) - - ChondroCelect Sales EUR 3.2 Million for First Nine Months - Cx611 RA Program on Track to Report Preliminary Results in Q4 - Cx601 Partnering Discussions On-going - Company Sufficiently Financed to Keep Executing on Plan Leuven (BELGIUM) – November 8, 2012 –TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, gives an update
- [TiGenix announces publication of Cx601 Phase I/IIa study in International Journal of Colorectal Disease](https://ysioscapital.com/2012/10/09/tigenix-announces-publication-of-cx601-phase-iiia-study-in-international-journal-of-colorectal-disease/) - Leuven (BELGIUM) – October 9, 2012 – TiGenix (Euronext Brussels: TIG) announced today the publication in the International Journal of Colorectal Disease of the Phase I/II study of Cx601: Expanded allogeneic adipose-derived stems cells (eASCs) for the treatment of complex perianal fistula in Crohn’s disease: results from a multicenter phase I/II clinical trial. The authors of
- [TiGenix’s new European production facility obtains EMA approval for commercial production of ChondroCelect](https://ysioscapital.com/2012/09/25/tigenixs-new-european-production-facility-obtains-ema-approval-for-commercial-production-of-chondrocelect/) - Leuven (BELGIUM) – September 25, 2012 – TiGenix (Euronext Brussels: TIG) announced today that after the successful cGMP inspection by the Dutch authorities earlier this year, it has now obtained the crucial approval from the European Medicines Agency (EMA) for the production of ChondroCelect, the company’s commercial cell therapy product for cartilage repair in the knee, in its new
- [TiGenix appoints Jean Stéphenne chairman & Russell Greig member of board of directors](https://ysioscapital.com/2012/09/20/tigenix-appoints-jean-stephenne-chairman-russell-greig-member-of-board-of-directors/) - Leuven (BELGIUM) – September 20, 2012 – TiGenix (Euronext Brussels: TIG) announcedtoday that the Company has appointed Jean Stéphenne as independent director and new chairman of the Company’s board of directors, and Russell Greig as independent director, in replacement of Koenraad Debackere and Mounia Chaoui-Roulleau, who resigned from the board. Former chairman Willy Duron will remain an independent
- [MedLumics Names Prof. Wolfgang Drexler President of its Scientific Advisory Board](https://ysioscapital.com/2012/08/24/medlumics-names-prof-wolfgang-drexler-president-of-its-scientific-advisory-board/) - MADRID, August 24, 2012 – MedLumics, a medical imaging diagnostics company specializing in advanced optical coherence tomography (OCT) technology, has announced the appointment of world-renowned OCT expert Prof. Wolfgang Drexler as president of the company’s Scientific Advisory Board. In his new role, he will help drive strategic decision-making related to the development of the company’s
- [TiGenix Business Update & Financial Highlights for the First Half of 2012](https://ysioscapital.com/2012/08/23/tigenix-business-update-financial-highlights-for-the-first-half-of-2012/) - - Commercial roll-out of ChondroCelect Continues to Gain Momentum - All Clinical Stem Cell Programs on TrackSufficient - Cash to Bring the Company to the Next Value Inflection Point Leuven (BELGIUM) - August 23, 2012 -TiGenix NV (NYSE Euronext: TIG), the European leader in cell therapy, gives an update of its business activities and provides
- [TiGenix completes patient enrollment in Phase IIa rheumatoid arthritis study](https://ysioscapital.com/2012/08/08/tigenix-completes-patient-enrollment-in-phase-iia-rheumatoid-arthritis-study/) - Leuven (BELGIUM), Madrid (SPAIN) – August 8, 2012 – TiGenix (NYSE Euronext: TIG), the European leader in cell therapy, announced today the completion of patient enrollment in the Company’s Phase IIa study of Cx611, a suspension of expanded allogeneic adult stem cells, in rheumatoid arthritis. The Phase IIa clinical trial is a 53-subject, multicenter, placebo-controlled study in 3 cohorts
- [TiGenix signs up 4th major hospital in the Netherlands for innovative cartilage repair therapy](https://ysioscapital.com/2012/07/17/tigenix-signs-up-4th-major-hospital-in-the-netherlands-for-innovative-cartilage-repair-therapy/) - National reimbursement for ChondroCelect retroactive per January 1, 2011 Leuven (BELGIUM) – July 17, 2012 – TiGenix (NYSE Euronext: TIG), the European leader in cell therapy, announced today that after obtaining national reimbursement for ChondroCelect in the Netherlands last month, the company has now contracted with four major hospitals to make its innovative cartilage repair therapy available to
- [TiGenix enrolls first patients in pivotal Phase III trial with lead product Cx601 in perianal fistulas](https://ysioscapital.com/2012/07/10/tigenix-enrolls-first-patients-in-pivotal-phase-iii-trial-with-lead-product-cx601-in-perianal-fistulas/) - ADMIRE CD trial to enroll over 200 patients in 46 centers across 8 countries Leuven (BELGIUM) – July 10, 2012 – TiGenix (NYSE Euronext: TIG) announced today theenrolment of the first patients in the ADMIRE-CD trial, its pivotal Phase III clinical trial with Cx601 in perianal fistulas in Crohn´s disease patients at Hospital Clínic, Barcelona, Spain. Cx601 is
- [TiGenix reports positive results of Cx621 Phase I](https://ysioscapital.com/2012/07/02/tigenix-reports-positive-results-of-cx621-phase-i/) - Leuven (BELGIUM) – July 2, 2012 – TiGenix (NYSE Euronext: TIG) announced today that it has successfully completed the company’s Phase I clinical trial to assess the safety of intra-lymphatic administration of its expanded adipose stem cells product (Cx621). Cx621 aims to capitalize on the benefits of TiGenix’s proprietary approach of intra-lymphatic administration to treat autoimmune disorders. The confirmation
- [Ysios Capital leads a € 2M Series A round of Inbiomotion](https://ysioscapital.com/2012/06/28/ysios-capital-leads-a-e-2m-series-a-round-of-inbiomotion-2/) - Barcelona June 28, 2012 –Ysios Capital, a leading Spanish life sciences venture capital firm, today announces that it has led the €2 million Series A financing of Inbiomotion SL, a spin-out company from the Growth Control and Cancer Metastasis group at the Institute for Research in Biomedicine (IRB Barcelona) and ICREA focused on the development
- [Endosense completes enrollment in toccastar ide study of its Tacticath force-sensing ablation catheter](https://ysioscapital.com/2012/06/13/endosense-completes-enrollment-in-toccastar-ide-study-of-its-tacticath-force-sensing-ablation-catheter/) - GENEVA – June 13, 2012 - Endosense, a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced enrollment completion in the TOCCASTAR clinical study. TOCCASTAR is a prospective, randomized, multi-center investigational device exemption (IDE) trial designed to evaluate the safety and effectiveness of the
- [Endosense announces ce mark approval, first clinical use of the New tacticath® quartz force-sensing ablation catheter](https://ysioscapital.com/2012/06/12/endosense-announces-ce-mark-approval-first-clinical-use-of-the-new-tacticath-quartz-force-sensing-ablation-catheter/) - GENEVA – June 12, 2012 – Endosense, a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced that its TactiCath Quartz force-sensing ablation catheter has been CE mark approved. In cooperation with the company’s distributor BIOTRONIK, first cases using the new device have
- [TiGenix obtains national reimbursement in the Netherlands for breakthrough cartilage therapy ChondroCelect®](https://ysioscapital.com/2012/06/08/tigenix-obtains-national-reimbursement-in-the-netherlands-for-breakthrough-cartilage-therapy-chondrocelect/) - Leuven (BELGIUM) – June 8, 2012 – TiGenix (NYSE Euronext: TIG) announced today that its innovative cartilage repair therapy ChondroCelect® has obtained national reimbursement in the Netherlands. The Dutch National Health Authority (NZa) has formally announced that ChondroCelect® is to receive national reimbursement retroactively per January 1, 2012. Previously ChondroCelect® was made available in the Netherlands under a risk-sharing scheme.
- [Cristina Garmendia returns to Ysios Capital as Partner](https://ysioscapital.com/2012/05/29/cristina-garmendia-returns-to-ysios-capital-as-partner/) - Joël Jean-Mairet, Julia Salaverria, Josep Ll. Sanfeliu and Cristina Garmendia founded Ysios Capital Partners in 2007, one year before Dr. Garmendia joined the Spanish Ministery. Barcelona – 29th May, 2012 – Ysios Capital Partners, a venture capital firm specialized in healthcare and biotechnology, today announces that Dr. Cristina Garmendia returns to the management team after
- [TiGenix Reports Business & Financial Results for the First Quarter 2012](https://ysioscapital.com/2012/05/15/tigenix-reports-business-financial-results-for-the-first-quarter-2012/) - ChondroCelect Sales up 123% - All Clinical Programs on Track – EUR 16.7 Million Cash Leuven (BELGIUM) – May 15, 2012 – TiGenix NV (NYSE Euronext: TIG), a leader in the field of cell therapy, today gave a business update and announced the financial results for the first quarter ending March 31, 2012. Business highlights
- [Endosense reports strong momentum for contact-force sensing in catheter ablation at heart rhythm 2012.](https://ysioscapital.com/2012/05/14/endosense-reports-strong-momentum-for-contact-force-sensing-in-catheter-ablation-at-heart-rhythm-2012/) - Expansive Body of Data and Professional Consensus Statement Mark Progress in the Field GENEVA - May 14, 2012 – Endosense, a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has reported another year of significant advancement in the move toward making
- [TiGenix obtains manufacturing license for European production facility](https://ysioscapital.com/2012/04/24/tigenix-obtains-manufacturing-license-for-european-production-facility/) - Leuven (BELGIUM) – April 24, 2012 – TiGenix (NYSE Euronext: TIG) announced today that further to the cGMP inspection by the Dutch authorities it has obtained the manufacturing authorization for human medicinal products for its European manufacturing plant in Sittard-Geleen in the Netherlands. “I’d like to commend our manufacturing team responsible for building and validating
- [TiGenix rheumatoid arthritis Phase IIa study successfully passes last safety hurdle.](https://ysioscapital.com/2012/04/17/tigenix-rheumatoid-arthritis-phase-iia-study-successfully-passes-last-safety-hurdle/) - Leuven (BELGIUM), Madrid (SPAIN) – April 17, 2012 – TiGenix (NYSE Euronext: TIG) announced today that upon review of the safety data of the first three patients of the third cohort of the company’s Phase IIa clinical trial in rheumatoid arthritis (Cx611) it has received the go-ahead from the independent Safety Monitoring Board to recruit
- [TiGenix appoints Dr. Guido Schopen as vice president commercial operations.](https://ysioscapital.com/2012/04/14/tigenix-appoints-dr-guido-schopen-as-vice-president-commercial-operations/) - Leuven (Belgium) – April 10, 2012 – TiGenix NV (NYSE Euronext: TIG), a leader in the field of cell therapy, today announced the appointment of Dr. Guido Schopen as vice president commercial operations. Dr. Schopen brings to TiGenix more than 20 years of bio-pharmaceutical industry experience. In addition to his global commercial responsibilities, Dr. Schopen,
- [TiGenix Reports Full Year 2011 Financial Results.](https://ysioscapital.com/2012/03/15/tigenix-reports-full-year-2011-financial-results/) - Merger completed successfully – ChondroCelect® commercial roll-out progressing – clinical programs on track – substantial non-dilutive funding – EUR 20 million cash at 31 Dec. 2011 Leuven (BELGIUM) – March 15, 2012 –TiGenix NV (NYSE Euronext: TIG) today gave a business update and announced financial results for the full year 2011. Business highlights • Successful
- [AM-Pharma Announces Appointment of Industry Expert Guido Magni as Board Member.](https://ysioscapital.com/2012/03/13/am-pharma-announces-appointment-of-industry-expert-guido-magni-as-board-member/) - Bunnik, The Netherlands, 16 March 2012. AM‐Pharma B.V., a biopharmaceutical company focused on the preclinical and clinical development of recombinant human Alkaline Phosphatase (AP) for treatment of Acute Kidney Injury and inflammatory bowel diseases, has appointed Dr Guido Magni as a member of its Supervisory Board. Dr Magni MD PhD was trained as an MD
- [TiGenix announces changes in management responsibilities.](https://ysioscapital.com/2012/02/16/tigenix-announces-changes-in-management-responsibilities/) - Leuven (BELGIUM) – February 16, 2012 – TiGenix (NYSE Euronext: TIG) announced today changes to executive responsibilities within the Company. Gil Beyen, co-founder and Chief Business Officer of TiGenix will hand over part of his responsibilities to take on a mandate outside TiGenix. Gil remains a member of the Board of Directors and the Company's
- [TiGenix rheumatoid arthritis Phase IIa study opens third and last cohort.](https://ysioscapital.com/2012/02/01/tigenix-rheumatoid-arthritis-phase-iia-study-opens-third-and-last-cohort/) - Leuven (BELGIUM), Madrid (SPAIN) – February 1, 2012 – TiGenix (NYSE Euronext: TIG) announced today that upon review of the safety data of the first three patients of the second cohort of the company’s Phase IIa clinical trial in rheumatoid arthritis (Cx611) it has received the go-ahead from the independent Safety Monitoring Board to recruit
- [Endosense launches TactiCath 75 force-sensing catheter, announces new results of EFFICAS clinical study.](https://ysioscapital.com/2012/01/12/endosense-launches-tacticath-75-force-sensing-catheter-announces-new-results-of-efficas-clinical-study/) - GENEVA – January 12, 2011 – Endosense, a pioneer and leader in force-sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced the European launch of the TactiCath 75 force-sensing ablation catheter as well as results of the EFFICAS clinical study of contact force-sensing in
- [TiGenix Reports Positive Results of ChondroCelect. Compassionate Use Program.](https://ysioscapital.com/2012/01/09/tigenix-reports-positive-results-of-chondrocelect-compassionate-use-program/) - Study confirms benefits of ChondroCelect in daily practice, significantly expands data set, and underpins commercial potential Leuven (BELGIUM) – January 9, 2011 – TiGenix (NYSE Euronext: TIG), a leading biopharmaceutical company that commercializes and develops cell therapies, today announced data from a ChondroCelect® compassionate use program (CUP), involving 43 orthopedic centers in 7 European countries,
- [Laia Crespo joins Ysios Capital Partners as Investment Manager](https://ysioscapital.com/2009/09/28/laia-crespo-joins-ysios-capital-partners-as-investment-manager/) - Laia Crespo joins Ysios Capital Partners as Investment Manager
- [Raúl Martín-Ruiz joins Ysios Capital Partners as Investment Manager](https://ysioscapital.com/2008/09/03/raul-martin-ruiz-joins-ysios-capital-partners-as-investment-manager/) - Raúl Martín-Ruiz joins Ysios Capital Partners as Investment Manager
- [Ysios Capital Partners names Marc Casellas as Chief Financial Officer](https://ysioscapital.com/2008/07/09/ysios-capital-partners-names-marc-casellas-as-chief-financial-officer/) - Ysios Capital Partners, a venture capital firm specialized in biotech investments, has named Marc Casellas Chief Financial Officer.
- [LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies](https://ysioscapital.com/2021/07/13/lava-therapeutics-announces-treatment-of-first-patient-in-phase-1-2a-clinical-trial-of-lava-051-for-multiple-hematological-malignancies/) - LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies.
- [TiGenix secures EUR 10 million in financing from Kreos Capital Company ends year in strong position to fully leverage leading cell therapy platform](https://ysioscapital.com/2013/12/23/tigenix-secures-eur-10-million-in-financing-from-kreos-capital/) - Leuven (BELGIUM) – December 23, 2013 – TiGenix (Euronext Brussels: TIG) announced today that it has signed a structured debt financing agreement of up to EUR 10 million with Kreos Capital (Kreos), Europe's largest and leading provider of growth debt to high-growth companies. The funds will supplement the EUR 12 million in equity financing TiGenix recently secured
- [TiGenix completes EUR 12 million capital increase with strategic investor Grifols](https://ysioscapital.com/2013/11/22/tigenix-completes-eur-12-million-capital-increase-with-strategic-investor-grifols/) - Leuven, Belgium – November 22, 2013, 12.15 p.m. – TiGenix NV (Euronext Brussels: TIG) announced today the successful completion of the EUR 12 million capital increase announced on November 20, 2013. In total, 34.188.034 new ordinary shares were issued to Gri-Cel S.A., a fully-owned subsidiary of global healthcare company Grifols S.A. TiGenix will prepare and, after approval by the
- [TiGenix Raises EUR 12 million via a Private Placement of New Ordinary Shares](https://ysioscapital.com/2013/11/20/tigenix-raises-eur-12-million/) - Leuven, Belgium – November 20, 2013, 8.30 a.m.–TiGenix NV (Euronext Brussels: TIG) today announces that on November 19, 2013, after the market closed, it has raised EUR 12 million through a private placement of 34.188.034 new ordinary shares with Gri- Cel S.A., a fully-owned subsidiary of global healthcare company Grifols S.A., at an issue price
- [AM-Pharma presents positive data from recAP preclinical study at ASN meeting](https://ysioscapital.com/2013/11/08/am-pharma-presents-positive-data-from-recap-preclinical-study-at-asn-meeting/) - Data shows anticipated reduction in inflammation and tissue injury in Acute Kidney Injury models Bunnik, The Netherlands; Atlanta, GA, 8 November 2013. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, today presents preclinical data on its drug candidate recAP in an Acute Kidney Injury (AKI)
- [TiGenix Business Update & Financial Highlights for Q3 of 2013](https://ysioscapital.com/2013/11/05/tigenix-business-financial-update-q3-2013/) - - ChondroCelect: sales up 21% for first nine months and advanced discussions to monetize the Dutch manufacturing facility ongoing - Cx601: European ADMIRE-CD Phase III enrollment on schedule and partnering discussions ongoing for non-European territories - EUR 6.4 million cash on hand on September 30. Cash burn for the third quarter reduced to EUR 1.1 million per month
- [CVRx® Closes $12 Million Additional Financing](https://ysioscapital.com/2013/10/30/sios-capital-participates-in-the-usd-42-million-series-f-financing-round-of-cvrx/) - Minneapolis – October 30, 2013 – CVRx, Inc., a privately held medical device company, has closed on an additional $12 million under its Series F financing. This brings the total raised in the Series F financing to $42 million. CVRx plans to use the funding for the primary purposes of advancing its clinical trials and
- [AM-Pharma returns to clinic with Phase I trial of new recombinant human Alkaline Phosphatase to treat Acute Kidney Injury](https://ysioscapital.com/2013/09/23/am-oharma_phasei_alkalinephosphatase/) - Trial to reaffirm safety seen in previous Phase I & II trials of bovine Alkaline Phosphatase Bunnik, The Netherlands, 23 September 2013. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recombinanthuman Alkaline Phosphatase (AP) for inflammatory indications is pleased to announce that the first subjects have entered a Phase I trial of its
- [St. Jude Medical Acquires Endosense](https://ysioscapital.com/2013/09/13/st-jude-medical-acquires-endosense/) - St. Jude Medical adds ablation catheter with contact-force measurement to its industry-leading atrial fibrillation portfolio and accelerates U.S. timeline for AF ablation indication ST. PAUL, Minn. and GENEVA – August 19, 2013 – St. Jude Medical, Inc. (NYSE: STJ), a global medical device company, today announced the acquisition of Endosense SA, a Switzerland-based company that
- [TiGenix Raises EUR 6.5 million in Private Placement](https://ysioscapital.com/2013/07/18/tigenix-raises-eur-6-5-million-in-private-placement/) - Leuven, Belgium – July 18, 2013, 20:00h – TiGenix NV (Euronext Brussels: TIG) announces today that it has raised EUR 6.5 million through a private placement via the accelerated bookbuilding procedure announced on July 17, 2013 after the market closed. The private placement has allowed TiGenix to place 26 million new shares with mainly international
- [TiGenix to Raise Capital via a Private Placement of New Ordinary Shares](https://ysioscapital.com/2013/07/17/tigenix-to-raise-capital-via-private-placement-of-new-ordinary-shares/) - Leuven, Belgium – July 17, 2013, 18:00h – TiGenix NV (Euronext Brussels: TIG) today announced the launch of a private placement of new ordinary shares for a targeted amount of EUR 5 million. The Company may increase this amount without exceeding the limits of its authorized share capital. The Board of Directors will disapply the
- [STAT-Diagnostica Names Gérard Vaillant as Board Chairman](https://ysioscapital.com/2013/06/19/stat-diagnostica-names-gerard-vaillant-as-board-chairman/) - BARCELONA – June 19, 2013 – Medical diagnostics company STAT-Diagnostica has appointed Gérard Vaillant as chairman of the company’s board of directors. With more than three decades of senior leadership experience in the medical device and diagnostics sector, he brings expert industry perspective and guidance to the company as it prepares for the successive European
- [MedLumics appoints Dr. Wolfgang Reim as Independent Director](https://ysioscapital.com/2013/06/10/medlumics-appoints-dr-wolfgang-reim-as-independent-director/) - Madrid, 10th June 2013. MedLumics, a medical imaging company specializing in advanced optical coherence tomography (OCT) technology, has announced the appointment of the industry expert Wolfgang Reim as Independent Director for its board. “Wolfgang’s experience in the process of creation, development and commercialization of medical technology, his global vision of the market of medical imaging
- [TiGenix Business Update & Financial Highlights for Q1 of 2013](https://ysioscapital.com/2013/05/14/tigenix-business-update-financial-highlights-for-q1-of-2013/) - - ChondroCelect Sales up 55% over Q1 2012 - Cx611 Phase IIa delivers positive results in refractory RA - Cx601 Phase III enrollment on schedule Leuven (BELGIUM) – May 14, 2013 –TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, gives an update of its business activities and provides the financial highlights for the first
- [Endosense underscores significance of contact force parameters with new study data at heart rhythm 2013](https://ysioscapital.com/2013/05/13/endosense-underscores-significance-of-contact-force-parameters-with-new-study-data-at-heart-rhythm-2013/) - GENEVA – May 13, 2013 – Endosense, a pioneer and leader in contact force (CF) technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, further advanced its leadership position in the field with new study data validating the importance of several proprietary contact force parameters, including its
- [Medical Diagnostics Company STAT-Diagnostica Secures 22.1 Million USD/17 Million Euros in Series B Financing](https://ysioscapital.com/2013/05/06/stat-diagnostica17-million-euros-in-series-b-financing/) - BARCELONA - May 6, 2013 - STAT-Diagnostica has announced the closing of a Series B financing round totaling 22.1 million USD/17 million Euros, the proceeds of which will be used to complete development of the company’s Near Patient Testing diagnostic system and clinical validation of its first products. Led by new investor Kurma Life Sciences
- [TiGenix reports positive Phase IIa study results in refractory rheumatoid arthritis with allogeneic stem cell product Cx611](https://ysioscapital.com/2013/04/22/tigenix-reports-positive-phase-iia-study-results-cx611/) - Leuven (BELGIUM) – April 22, 2013 – TiGenix (NYSE Euronext: TIG), the European leader in cell therapy, today announced positive 6-month safety data of its Phase IIa study of Cx611 in rheumatoid arthritis (RA), as well as a first indication of therapeutic activity on standard outcome measures and biologic markers of inflammation for at least three months after
- [Endosense’s efficas i study yields new contact force guidelines in catheter ablation treatmentof af: findings published in circulation: arrhythmia and electrophysiology](https://ysioscapital.com/2013/03/26/endosenses-efficas-i-study-yields-new-contact-force-guidelines/) - GENEVA – March 26, 2013 – Endosense, a pioneer and leader in contact-force sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced that the results of its EFFICAS I prospective multi-center study have led to the development of guidelines for target and minimum contact
- [TiGenix to obtain national reimbursement in Spain for its innovative cartilage therapy ChondroCelect®](https://ysioscapital.com/2013/03/12/tigenix-to-obtain-national-reimbursement-in-spain-for-its-innovative-cartilage-therapy-chondrocelect/) - Leuven (BELGIUM), Madrid (SPAIN) – March 12, 2013 – TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that it was informed by the Spanish Health Authority that its innovative cartilage repair therapy ChondroCelect® will obtain national reimbursement in Spain. “We are delighted with the decision of the Spanish health authorities to reimburse ChondroCelect, and
- [TiGenix Reports Full Year 2012 Financial Results](https://ysioscapital.com/2013/03/12/tigenix-reports-full-year-2012-financial-results/) - - ChondroCelect® sales increase to EUR 4.1 million, up 101% - Cx611 RA program reported positive interim safety results - Cx601 ADMIRE-CD trial ongoing in 8 countries - EUR 11.1 million cash at December 31, 2012 Leuven (BELGIUM) – March 12, 2013 –TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, today gave a business
- [Endosense closes an additional USD 4.3 million/CHF 4 million in series C financing](https://ysioscapital.com/2013/03/05/endosense-closes-an-additional-usd-4-3-millionchf-4-million-in-series-c-financing/) - GENEVA – March 5, 2013 – Endosense, a pioneer and leader in contact-force sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, announced today that it has secured an additional USD 4.3 million/CHF 4 million in series C financing from a new strategic industry partner. This
- [First u.s. case performed with endosense’s tacticath quartz contact-force sensing ablation catheter](https://ysioscapital.com/2013/02/01/first-u-s-case-performed-with-endosenses-tacticath-quartz-contact-force-sensing-ablation-catheter/) - GENEVA – February 1, 2013 – Endosense, a pioneer and leader in contact-force sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, has announced that its new generation TactiCath Quartz contact-force sensing ablation catheter has been used for the first time in the United States by Dr. J. Michael
- [TiGenix successfully renews GMP license for stem cell manufacturing facility in Madrid](https://ysioscapital.com/2013/01/29/tigenix-successfully-renews-gmp-license-for-stem-cell-manufacturing-facility-in-madrid/) - Leuven (BELGIUM), Madrid (SPAIN) – January 29, 2013 – TiGenix (Euronext Brussels:TIG), a leader in the field of cell therapy, announced today that further to the cGMPinspection by the Spanish health authorities it has successfully renewed its manufacturingauthorization for stem cell products at its manufacturing facility in Madrid, Spain. “The GMP facility in Madrid performs
- [TiGenix submits its pivotal US trial design for Cx601 to the FDA for Special Protocol Assessment](https://ysioscapital.com/2014/12/22/tigenix-submits-its-pivotal-us-trial-design-for-cx601-to-the-fda-for-special-protocol-assessment/) - Leuven (BELGIUM) – 22 December, 2014 –TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC’s, in inflammatory and autoimmune diseases, announced today that it has submitted to the Food and Drug Administration (FDA) the required documentation
- [TiGenix starts Phase I trial of Cx611 in severe sepsis](https://ysioscapital.com/2014/12/10/tigenix-starts-phase-i-trial-of-cx611-in-severe-sepsis/) - Leuven (BELGIUM) – 10 December, 2014 –TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced today that the first subject has been entered into its Phase I trial of Cx611 in severe
- [AM-Pharma presents preclinical data on mode-of-action for recAP in Acute Kidney Injury at ASN meeting](https://ysioscapital.com/2014/11/13/am-pharma-presents-preclinical-data-on-mode-of-action-for-recap/) - Data shows recAP to increase glomerular filtration rate and creatine clearance Bunnik, The Netherlands, 13 November 2014. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, today presents further preclinical data on its drug candidate recAP, at the American Society of Nephrology (ASN) meeting Kidney Week
- [TiGenix completes patient recruitment for the European Phase III trial of Cx601 ahead of schedule](https://ysioscapital.com/2014/11/12/tigenix-completes-patient-recruitment-for-the-european-phase-iii-trial-of-cx601-ahead-of-schedule/) - Leuven (BELGIUM) – 12 November, 2014 –TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced today that it has completed the patient recruitment for its Phase III trial of Cx601 in Europe
- [MedLumics Introduces NITID Skin Imaging System at EADV](https://ysioscapital.com/2014/10/23/medlumics-introduces-nitid-skin-imaging-system/) - New imaging system allows for evaluation and monitoring of skin cancer without an invasive tissue biopsy MADRID – Oct. 23, 2014 – MedLumics, a medical imaging company specializing in advanced optical coherence tomography (OCT) technology, debuted its NITIDTM skin imaging system at the 23rd Annual European Academy of Dermatology and Venereology Congress in Amsterdam. NITID
- [CVRx® Announces First Successful Barostim Heart Failure Commercial Implants in Europe](https://ysioscapital.com/2014/10/07/cvrx_first_successful_barostim_heart_failure_implant_europe/) - Minneapolis – October 7, 2014 – CVRx, Inc., a private medical device company, announced today the first 10 heart failure patients treated with the Barostim neo System™ under CE Mark approval. The newly approved therapy was made available to a few select Barostim Heart Failure Centers of Excellence beginning October 1st. Asklepios Hospital Altona in
- [CVRx® Receives CE Mark Approval of the Barostim neo System™ for the Treatment of Heart Failure](https://ysioscapital.com/2014/09/30/cvrx-receives-ce-mark-approval-of-the-barostim-neo/) - Minneapolis – September 29, 2014 – CVRx, Inc., a private medical device company, announced today it received CE Mark approval from the National Standards Authority of Ireland (NSAI) of the Barostim neo System™ for the treatment of heart failure. The therapy is approved for use in heart failure patients having an ejection fraction ≤ 35%
- [CVRx® Secures $15 Million Growth Capital Facility from Silicon Valley Bank](https://ysioscapital.com/2014/09/22/cvrx-secures-15-million-growth-capital-facility-from-silicon-valley-bank/) - Minneapolis – September 22, 2014 – CVRx, Inc., a private medical device company, announced today it secured a $15 million growth capital debt facility from Silicon Valley Bank. “Obtaining this funding significantly extends our cash availability to advance CVRx’s hypertension and heart failure businesses. This growth capital will help ensure that CVRx can continue to
- [European Medicines Agency accepts TiGenix Paediatric Investigation Plan for Cx601](https://ysioscapital.com/2014/09/08/european-medicines-agency-accepts-tigenix-paediatric-investigation-plan-for-cx601/) - Leuven (BELGIUM) – 8 September, 2014 –TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC’s, in inflammatory and autoimmune diseases, announced today that the Paediatric Committee of the European Medicines Agency (EMA) has issued a positive
- [TiGenix appoints Chief Medical Officer and Vice President Medical Affairs and New Product Commercialisation](https://ysioscapital.com/2014/09/01/tigenix-appoints-chief-medical-officer-and-vice-president-medical-affairs-and-new-product-commercialisation/) - Leuven (BELGIUM) – 1 September, 2014 –TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC’s, in inflammatory and autoimmune diseases, announced today that it has appointed Dr Marie Paule Richard as the Company’s Chief Medical Officer,
- [TiGenix Business and Financial Update for the First Half of 2014](https://ysioscapital.com/2014/08/28/tigenix-business-and-financial-update-for-the-first-half-of-2014/) - Leuven, Belgium – 26 August, 2014 – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic, expanded adipose-derived stem cells, or eASC’s, in inflammatory and autoimmune diseases, issued an update on business and financial progress in the first half of this year
- [European Medicines Agency renews Marketing Authorisation for ChondroCelect](https://ysioscapital.com/2014/07/01/european-medicines-agency-renews-marketing-authorisation-for-chondrocelect/) - Leuven (BELGIUM) – 1 July, 2014 –TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that the Committee for Medicinal Products for Human Use (CHMP) has renewed for an additional five years its marketing authorisation for ChondroCelect in all of the 31 countries of the European Union (EU) and European Economic
- [TiGenix announces the clinical development of Cx611 in early rheumatoid arthritis and severe sepsis](https://ysioscapital.com/2014/06/30/tigenix-announces-the-clinical-development-of-cx611-in-early-rheumatoid-arthritis-and-severe-sepsis/) - Leuven, Belgium – 30 June, 2014 – TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that it will develop its intravenous-administered allogeneic stem cell product, Cx611, for patients suffering from early rheumatoid arthritis and for patients suffering from severe sepsis, a potentially life-threatening complication of infection. “Having considered the demonstrated
- [Kala Pharmaceuticals Initiates Phase 3 Clinical Trial for Treatment of Post-Surgical Ocular Inflammation and Phase 2 Clinical Trial in Dry Eye Disease](https://ysioscapital.com/2014/06/19/kala-pharmaceuticals-initiates-phase-3-clinical-trial-for-treatment-of-post-surgical-ocular-inflammation-and-phase-2-clinical-trial-in-dry-eye-disease/) - Advances Two U.S. Clinical Trials for Lead Ophthalmic Products Utilizing Proprietary Mucus Penetrating Particle Platform WALTHAM, Mass.,June 19, 2014--Kala Pharmaceuticals, Inc., a leading developer of innovative ophthalmic products based on the company’s proprietary Mucus Penetrating Particle (MPP) platform, today announced the initiation of two clinical trials with its nanotechnology-based loteprednol etabonate MPP (LE-MPP) program, KPI-121. Kala
- [CVRx® Achieves Two Significant Milestones for its Heart Failure and Hypertension Businesses](https://ysioscapital.com/2014/06/10/cvrx-achieves-two-significant-milestones-for-its-heart-failure-and-hypertension-businesses/) - Minneapolis – June 9, 2014 – CVRx, Inc., a private medical device company, announced today it achieved two significant milestones in its heart failure and hypertension businesses. “We are very excited to announce that CVRx has completed enrollment of our Barostim HOPE4HF heart failure study and that the French Ministry of Health has selected Barostim Therapy™ for
- [TiGenix completes the sale of its Dutch manufacturing facility to PharmaCell](https://ysioscapital.com/2014/06/02/tigenix-completes-the-sale-of-its-dutch-manufacturing-facility-to-pharmacell/) - TiGenix to receive a total consideration of Euro 5.75 million PharmaCell will continue to manufacture ChondroCelect, which Sobi will market and distribute TiGenix to focus on bringing its development pipeline to patients Leuven, Belgium – 2 June, 2014 – TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, announced today that it has
- [TiGenix Business and Financial Update for the first quarter of 2014](https://ysioscapital.com/2014/05/13/tigenix-business-and-financial-update-for-the-first-quarter-of-2014/) - ChondroCelect® agreements enable short and long term value creation Leuven, Belgium - 13 May, 2014 – TiGenix NV (Euronext Brussels: TIG), the European leader in cell therapy, issued today a business and financial update for the first three months of 2014. Business highlights Agreement to license the marketing and distribution rights of ChondroCelect to Sobi,
- [St. Jude Medical Announces TOCCASTAR Clinical Trial Meets Primary Safety and Efficacy Endpoints at Heart Rhythm 2014](https://ysioscapital.com/2014/05/09/st-jude-medical-announces-toccastar-clinical-trial-meets-primary-safety-and-efficacy-endpoints/) - ST. PAUL, Minn.--(BUSINESS WIRE)-- St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced results of the TOCCASTAR clinical trial at Heart Rhythm 2014, the Heart Rhythm Society’s 35th Annual Scientific Sessions in San Francisco. Results from the first prospective, randomized study of contact-force ablation technology for the treatment of paroxysmal atrial fibrillation (AF) met primary endpoints
- [Kala Pharmaceuticals Announces $22.5 Million Series B Financing](https://ysioscapital.com/2014/04/23/kala-pharmaceuticals-announces-22-5-million-series-b-financing/) - Ysios Capital Joins as Lead Investor; Proceeds to Advance Four U.S. Clinical Trials for Lead Ophthalmic Product Candidates Waltham, Mass., April 23, 2014 – Kala Pharmaceuticals, Inc., a leading developer of innovative ophthalmic products based on the company’s proprietary Mucus Penetrating Particle (MPP) platform technology, today announced it has completed a $22.5 million Series B
- [TiGenix licenses exclusive marketing and distribution rights for ChondroCelect to Sobi](https://ysioscapital.com/2014/04/03/tigenix-licenses-exclusive-marketing-and-distribution-rights-for-chondrocelect-to-sobi/) - Sobi to assume responsibility for the commercialisation of ChondroCelect in existing and new markets in Europe and beyond Sobi’s considerable expertise and resources will enhance the availability of ChondroCelect to many more patients in many more countries TiGenix to focus its resources on developing its pipeline of allogeneic treatments using expanded adipose-derived stem cells (eASC’s)
- [AM-Pharma announces positive Phase I data on recAP, for Acute Kidney Injury](https://ysioscapital.com/2014/03/26/am-pharma-announces-positive-phase-i-data-on-recap-for-acute-kidney-injury/) - Trial shows recAP to be safe and well tolerated at maximum dose, and ready for Phase II development Bunnik, The Netherlands, 26 March 2014. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces the results of its Phase I trial with both single and multiple
- [MedLumics Announces “BiopsyPen Project” with €3.6M EU in Funding](https://ysioscapital.com/2014/03/25/medlumics-announces-biopsypen-project/) - Initiative Aimed at New Clinical Applications for Optical Coherence Tomography March 25, 2014 07:00 AM Eastern Daylight Time MADRID--(BUSINESS WIRE)– MedLumics, a medical imaging company specializing in advanced optical coherence tomography (OCT) technology, today announced the kick off of a three-year initiative to translate the latest OCT research into new clinical applications. Called the “BiopsyPen
- [TiGenix Reports Full Year 2013 Financial Results](https://ysioscapital.com/2014/03/11/tigenix-reports-full-year-2013-financial-results/) - ChondroCelect® sales increase to EUR 4.3 million, up 25% Cx601 US regulatory and development path confirmed EUR 18.5 million secured in private placements, of which EUR 12 million with strategic investor Grifols EUR 15.9 million cash at December 31, 2013 Leuven (BELGIUM) – March 11, 2014 –TiGenix NV (Euronext Brussels: TIG), the European leader in cell
- [TiGenix reaches major cell therapy milestone with 1000th implant of ChondroCelect](https://ysioscapital.com/2014/02/04/tigenix-reaches-major-cell-therapy-milestone-with-1000th-implant-of-chondrocelect/) - Leuven (BELGIUM) – February 4, 2014 – TiGenix (NYSE Euronext: TIG), a leader in thefield of cell therapy, announced today that it reached a major milestone with the performance of the 1000th ChondroCelect implantation for cartilage repair in the knee. ChondroCelect is the first cell therapy that was granted approval by the European Medicines Agency (EMA) as an
- [American Journal of Kidney Disease publishes review article of Alkaline Phosphatase](https://ysioscapital.com/2014/01/28/american-journal-of-kidney-disease-publishes-review-article-of-alkaline-phosphatase/) - Leading journal presents case for AM-Pharma product to treat sepsis-associated acute kidney injury Bunnik, The Netherlands, 28 January 2014. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces that the American Journal of Kidney Disease has published an In Translation feature entitled: Alkaline phosphatase: a
- [TiGenix to sell Dutch manufacturing facility to PharmaCell](https://ysioscapital.com/2014/01/24/tigenix-to-sell-dutch-manufacturing-facility-to-pharmacell/) - Leuven (BELGIUM) – January 24, 2014 – TiGenix (NYSE Euronext: TIG), a leader in the field of cell therapy, announced today that it has signed an agreement for the sale of its stateof- the-art Dutch production facility to PharmaCell B.V for a total consideration of EUR 5.75 million.PharmaCell, a leading European-based contract manufacturing organization active in the area of
- [MedLumics Expands Management Team in Preparation for 2014 Launch of First Generation Diagnostic Imaging System for Dermatology](https://ysioscapital.com/2014/01/22/medlumics-expands-management-team-in-preparation-for-2014-launch-of-first-generation-diagnostic-imaging-system-for-dermatology/) - New Vice President and COO Miguel Eslava Hails from GE Healthcare January 22, 2014 07:00 AM Eastern Standard Time MADRID--(BUSINESS WIRE)--MedLumics, a medical imaging company specializing in advanced optical coherence tomography (OCT) technology, has announced the appointment of Miguel Eslava to the new position of vice president and chief operating officer. With more than a
- [TiGenix files Registration Statement for proposed initial public offering in the United States](https://ysioscapital.com/2015/12/23/tigenix_us_publicoffering/) - Leuven (BELGIUM) – December 22, 2015, 22:30h CET – TiGenix NV (Euronext Brussels: TIG; the “Company”), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today that it has filed a Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission
- [TiGenix completes enrolment of its Phase I/II study in acute myocardial infarction](https://ysioscapital.com/2015/11/19/tigenix-completes-enrolment-of-its-phase-iii-study-in-acute-myocardial-infarction/) - Leuven (BELGIUM) – 19th November 2015 – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today that it has completed enrolment of its Phase II study in acute myocardial Infarction (CAREMI study). CAREMI is a two phase
- [CVRx® Announces Expedited Access Pathway Designation by FDA for Barostim Therapy® for the Treatment of Heart Failure in Order to Accelerate Access for US Patients](https://ysioscapital.com/2015/11/19/cvrx-announces-expedited-access-pathway-designation-by-fda-for-barostim-therapy/) - Minneapolis – November 19, 2015 – CVRx, Inc., a private medical device company, announced that it received Expedited Access Pathway (EAP) Designation by FDA for Barostim Therapy® for the treatment of heart failure. The EAP designation is based on Barostim Therapy being intended to treat a life-threatening or irreversibly debilitating disease where there is no
- [AM-Pharma publishes further preclinical data on recAP to treat Acute Kidney Injury](https://ysioscapital.com/2015/09/30/am-pharma-publishes-further-preclinical-data-on-recap-to-treat-acute-kidney-injury/) - Two papers present mode of action and pharmacokinetic model for recAP Bunnik, The Netherlands, 30 September 2015. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase), today announces the publication of two papers on recAP for the potential treatment of Acute Kidney Injury (AKI). The first, published in the
- [AM-Pharma and Pfizer Inc. shortlisted for “Best Partnership Alliance” in 2015 Scrip Awards](https://ysioscapital.com/2015/09/29/am-pharma-and-pfizer-inc-shortlisted-for-best-partnership-alliance-in-2015-scrip-awards/) - Bunnik, The Netherlands, 29 September 2015. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase), and Pfizer Inc. have been nominated for the prestigious category of “Best Partnership Alliance” for the 11th Annual Scrip Awards, organised by Scrip Intelligence, the leading source of news and strategic analysis for the
- [TiGenix Business and Financial Update for the First Half of 2015](https://ysioscapital.com/2015/09/15/tigenix-business-and-financial-update-for-the-first-half-of-2015/) - Leuven (BELGIUM) - 15 September 2015 - TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, today announced its Business and Financial Update for the first half of 2015 and recent significant events. Cx601 reached major value inflection
- [Xeltis Closes €45 Million in Oversubscribed Series C Financing to Advance Aortic and Pulmonary Valve Programs](https://ysioscapital.com/2017/11/15/xeltis-closes-e45-million-in-oversubscribed-series-c-financing-to-advance-aortic-and-pulmonary-valve-programs/) - Financing will support continuation of clinical activities and acceleration of product and market development for novel aortic and pulmonary valve programs.
- [Xeltis’ closes €10.5 million Series D financing](https://ysioscapital.com/2019/09/05/xeltis-closes-e10-5-million-series-d-financing/) - Xeltis €10.5 M Series D financing round to support its vascular and valve trial programs this week provided by existing institutional and private investors.
- [Xeltis initiates first-ever pivotal trial of a synthetic restorative pulmonary heart valve](https://ysioscapital.com/2021/07/08/xeltis-initiates-first-ever-pivotal-trial-of-a-synthetic-restorative-pulmonary-heart-valve/) - Following implantation, Xeltis’ synthetic restorative pulmonary heart valves evolve into fully functioning, natural heart valves through colonization by the patient’s tissue.
- [Adcendo Appoints Michael Pehl as Chief Executive Officer](https://ysioscapital.com/2021/07/07/adcendo-appoints-michael-pehl-as-chief-executive-officer/) - Adcendo Appoints Michael Pehl as CEO, an Experienced Industry Leader with successful Oncology, Immunotherapy & ADC Development Track Record.
- [NITID (optical coherence tomography and digital dermatoscope handheld device) – CE Mark approval received](https://ysioscapital.com/2015/09/10/nitid-ce-mark-approval-received/) - DermaLumics announces CE Mark certification of NITID DermaLumics and MedLumics are now ISO 9001:2008 & 13485:2012 certified DermaLumics is ready to launch its first product Madrid, September 10, 2015. DermaLumics, a recently founded spin-off of optical tomography systems developer MedLumics, announces that NITID, its first skin diagnostic solution, received CE Mark approval in Europe. NITID
- [TiGenix announces Cx601 meets primary endpoint in pivotal Phase III trial](https://ysioscapital.com/2015/08/24/tigenix-expands-pipeline-and-enters-the-cardiology-field-with-clinical-stage-company-acquisition-1/) - A single injection of Cx601 was statistically superior to placebo in achieving combined remission at week 24 of complex perianal fistulas in Crohn's disease patients with inadequate response to previous therapies, including anti-TNFs More than 50% of patients treated with Cx601 achieved combined remission at week 24 A higher number of Cx601-treated patients had their
- [TiGenix expands pipeline and enters the cardiology field with clinical-stage company acquisition](https://ysioscapital.com/2015/07/30/tigenix-expands-pipeline-and-enters-the-cardiology-field-with-clinical-stage-company-acquisition/) - TiGenix acquires Coretherapix, a cell therapy company with an ongoing Phase II clinical trial of allogeneic cardiac stem cells in acute myocardial infarction (AMI) Leuven (BELGIUM) – July 30, 2015 – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic adipose-derived stem
- [AM‐Pharma receives FDA and EMA orphan drug designation to treat hypophosphatasia](https://ysioscapital.com/2015/06/09/am‐pharma-receives-fda-and-ema-orphan-drug-designation-to-treat-hypophosphatasia/) - The orphan designations secure recAP position in rare disease area Bunnik, The Netherlands, 9 June 2015. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase), today announces that the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have both granted orphan designation status to recAP for the treatment of
- [CVRx® Barostim Therapy® for Heart Failure Clinical Trial Results Presented in the Late-Breaking Clinical Session of the ESC-Heart Failure 2015 Annual Conference](https://ysioscapital.com/2015/05/27/cvrx_esc-heart-failure-2015/) - Seville– May 27, 2015 – CVRx, Inc., a private medical device company, announced that positive results from the ‘Barostim Therapy for Heart Failure’ randomized, controlled clinical trial were presented at the ESC-Heart Failure 2015 Annual Conference in a Late-Breaking Trial Session. Results were presented by Professor Jochen Müller-Ehmsen from Asklepios Hospital Altona in Hamburg, Germany.
- [CVRx® Barostim Therapy® for Heart Failure Clinical Trial Results Presented in the Late-Breaking Clinical Trial Session of the Heart Rhythm Society 2015 Annual Conference](https://ysioscapital.com/2015/05/26/cvrx_heart-rhythm-society-2015/) - Minneapolis – May 26, 2015 – CVRx, Inc., a private medical device company, announced that positive results from the ‘Barostim Therapy for Heart Failure’ randomized, controlled clinical trial were presented at the 2015 annual Scientific Sessions of the Heart Rhythm Society (HRS) in a Late-Breaking Clinical Trial Session. Results were presented by Dr. Michael Zile
- [Kala Pharmaceuticals Appoints Mark Iwicki as Executive Chairman](https://ysioscapital.com/2015/05/14/positive-results-from-phase-3-trial-of-kpi-121-in-cataract-surgery/) - WALTHAM, Mass., May 14, 2015 -- Kala Pharmaceuticals, Inc. (Kala), a developer of innovative ophthalmic products based on its proprietary mucus penetrating particle (MPP) technology, today announced the appointment of Mark Iwicki as Executive Chairman and a member of its board of directors. Mr. Iwicki will help guide corporate strategy and commercial preparations for Kala’s
- [Pfizer Acquires Minority Interest in AM-Pharma; Secures Option to Acquire Company](https://ysioscapital.com/2015/05/13/pfizer-acquires-minority-interest-in-am-pharma-secures-option-to-acquire-company/) - Option may be exercised based on Phase II trial results for recombinant human Alkaline Phosphatase Bunnik, The Netherlands, and New York, NY – 11 May 2015 – AM‐Pharma B.V., a privately held Dutch biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP ) for inflammatory diseases, and Pfizer Inc. (NYSE: PFE) announced
- [Kala Pharmaceuticals Announces Positive Results from Phase 2 Trial of KPI-121 in Dry Eye Disease](https://ysioscapital.com/2015/04/02/positive-results-from-phase-2-trial-of-kpi-121-in-dry-eye-disease/) - - KPI-121 meets primary sign endpoint, demonstrating statistical superiority over vehicle in reducing conjunctival hyperemia - WALTHAM, Mass., April 1, 2015 -- Kala Pharmaceuticals, Inc. (Kala), a developer of innovative ophthalmic products based on its proprietary mucus-penetrating particle (MPP) technology, today announced positive top-line results from a Phase 2 clinical trial of KPI-121, its nanoparticle
- [Kala Pharmaceuticals Announces Positive Results from Phase 3 Trial of KPI-121 in Cataract Surgery](https://ysioscapital.com/2015/04/01/kala-pharmaceuticals-announces-positive-results-from-phase-3-trial-of-kpi-121-in-cataract-surgery/) - KPI-121 meets all primary endpoints, achieving statistical superiority over vehicle for elimination of inflammation and pain following cataract surgery when dosed either twice or four times daily WALTHAM, Mass., April 1, 2015 -- Kala Pharmaceuticals, Inc. (Kala), a developer of innovative ophthalmic products based on its proprietary mucus penetrating particle (MPP) technology, today announced positive
- [CVRx® Barostim Therapy™ for Heart Failure Clinical Trial Results Presented in a Featured Clinical Research Session of the American College of Cardiology Annual Conference](https://ysioscapital.com/2015/03/17/cvrx_first_successful_barostim_heart_failure_implant_europe-1/) - Minneapolis – March 17, 2015 – CVRx, Inc., a private medical device company, announced that positive results from the Barostim Therapy for Heartn Failure randomized, controlled clinical trial were presented at American College of Cardiology (ACC) in a Featured Clinical Research Session. Results were presented by Dr. William Abraham from The Ohio State University, who
- [AM-Pharma Appoints Mark Altmeyer as Chairman of its Supervisory Board](https://ysioscapital.com/2021/07/06/am-pharma-appoints-mark-altmeyer/) - Mr. Altmeyer will provide important guidance as the Company expands its global clinical development program and identifies possible future pipeline initiatives for treating serious diseases.
- [Prexton Therapeutics raises €8.7 million ($10 million) in a Series A round](https://ysioscapital.com/2015/02/24/prexton-therapeutics-raises-e8-7-million-10-million-in-a-series-a-round/) - Swiss based startup attracts venture funding from leading European VC firms to address Parkinson’s disease and other CNS conditions Geneva, Switzerland, February 24 2015 - Prexton Therapeutics, a biopharmaceutical company developing novel therapeutic compounds for the treatment of CNS conditions including Parkinson’s disease, today announced the closing of a Series A financing of €8.7 million ($10 million)
- [CVRx® Barostim Therapy™ for Heart Failure Clinical Trial Results Selected to be Presented in a Featured Clinical Research Session of the American College of Cardiology Annual Conference](https://ysioscapital.com/2015/02/02/cvrx-barostim-therapy-for-heart-failure-clinical-trial-results-selected-to-be-presented-in-a-featured-clinical-research-session-of-the-american-college-of-cardiology-annual-conference/) - Minneapolis – February 2, 2015 – CVRx, Inc., a private medical device company, announced that the results from the Barostim Therapy for Heart Failure randomized, controlled clinical trial have been accepted by the American College of Cardiology (ACC) for presentation in a Featured Clinical Research Session. Results will be presented by Dr. William Abraham from
- [European Patent Office issues key patent to TiGenix for expanded adipose-derived stem cell compositions](https://ysioscapital.com/2015/01/22/european-patent-office-issues-key-patent-to-tigenix-for-expanded-adipose-derived-stem-cell-compositions/) - Leuven (BELGIUM) – 22 January, 2015 –TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platform of allogeneic expanded adipose-derived stem cells in inflammatory and autoimmune diseases, announced today that the European Patent Office (EPO) has issued European Patent EP2292736 relating to an adipose-derived stem
- [AM-Pharma starts Adaptive Phase II trial of recAP in Acute Kidney Injury](https://ysioscapital.com/2015/01/20/am-pharma-starts-adaptive-phase-ii-trial-of-recap/) - Adaptive trial, largest ever intervention study in AKI Bunnik, The Netherlands, 20 January 2015. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory diseases, has recruited the first 3 patients into its Phase II trial of recAP in sepsis-associated Acute Kidney Injury (AKI). The clinical trial is
- [Ysios Capital’s portfolio company CVRx Inc. prices IPO on NASDAQ](https://ysioscapital.com/2021/07/05/cvrx_ipo/) - CVRx Inc announced the pricing of its initial public offering of 7,000,000 shares of its common stock at a public offering price of $18.00 per share.
- [CVRx® Secures $113 Million in New Financing](https://ysioscapital.com/2016/08/10/cvrx-secures-113-million-in-new-financing/) - Equity Offering to Support Heart Failure Trial was Oversubscribed Minneapolis – August 09, 2016 – CVRx, Inc., a private medical device company, has secured equity financing totaling $93 million and a new $20 million debt facility. CVRx plans to use the proceeds for the primary purposes of completing the Baroreflex Activation Therapy for Heart Failure
- [Ysios Capital Partners leads €29.2million Series D Financing of AM-Pharma](https://ysioscapital.com/2011/09/13/ysios-capital-partners-leads-e29-2million-series-d-financing-of-am-pharma/) - Ysios Capital Partners, the Spanish life sciences venture capital firm, today announces that is has led the €29.2 million Series D financing of AM-Pharma.
- [AM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Pivotal REVIVAL Trial](https://ysioscapital.com/2021/07/01/am-pharma-enrolls-first-patient-in-japan/) - AmPharma announced the enrollment of the first patient in Japan as part of its ongoing global pivotal Phase III trial, called REVIVAL.
- [Ysios Capital Partners announces the imminent first closing of the largest Spanish venture capital fund in the biotech sector](https://ysioscapital.com/2008/03/10/ysios-capital-partners-announces-the-imminent-first-closing-of-the-largest-spanish-venture-capital-fund-in-the-biotech-sector/) - Ysios has received the approval of the Spanish Securities and Exchange Commission (CNMV) as a venture capital management company specialized in biotechnology.
- [Ysios Capital Partners Starts Registration as an Independent Biotech Venture Capital Firm in Spain](https://ysioscapital.com/2007/09/13/ysios-capital-partners-will-be-raising-e65million-for-their-first-fund-ysios-biofund-i-the-largest-biotechnology-venture-capital-fund-ever-launched-in-spain/) - Ysios Capital Partners will be raising €65 million for their first fund, Ysios BioFund I, the largest biotechnology venture capital fund ever launched in Spain.
- [Aura Biosciences Assembles New Bladder Cancer Focused Scientific Advisory Board](https://ysioscapital.com/2021/06/18/aura-biosciences-assembles-new-bladder-cancer-focused-scientific-advisory-board/) - SAB will work closely with Aura’s senior management to advance the Company’s novel VDC technology for the treatment of non-muscle-invasive bladder cancer.
- [QIAGEN enters into agreement to acquire STAT-Dx, plans to launch a next-generation, fully integrated multiplex platform for syndromic disease testing](https://ysioscapital.com/2018/01/31/qiagen-enters-into-agreement-to-acquire-stat-dx/) - New system launch planned for second half of 2018 with two CE-IVD molecular diagnostics, U.S. launch planned for 2019 and broad pipeline in development Barcelona, January 31, 2018 – STAT-Dx announces today that QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has entered into an agreement to acquire STAT-Dx, a privately-held company developing the next
- [Ysios Capital closes its third fund at €216 million ($260 million)](https://ysioscapital.com/2021/05/26/ysios-capital-closes-its-third-fund-at-e216-million/) - Strategy to provide early and development-stage investment to entrepreneurial businesses, developing therapeutics for indications with high unmet medical need.
- [AM-Pharma Appoints Martijn Negen as VP Commercial Strategy](https://ysioscapital.com/2021/06/16/am-pharma-appoints-martijn-negen-as-vp-commercial-strategy/) - Am-Pharma appoints Martijn Negen as VP for Commercial Strategy, he has over 20 years of experience in pharmaceutical, biotech and diagnostic companies.
- [VarmX appoints Dr. Jan Öhrström as CEO, and Dr. Alex Gold to Supervisory Board](https://ysioscapital.com/2021/06/15/varmx-appoints-dr-jan-ohrstrom-as-ceo-and-dr-alex-gold-to-supervisory-board/) - VarmX announces the appointment of Dr. Jan Öhrström, as Chief Executive Officer, succeeding Alexander Vos, and Dr. Alex Gold to the Company’s Supervisory Board.
- [CorWave Successfully Performed a 90-Day In Vivo Study on Its Revolutionary Cardiac Pump Synchronized With the Native Heart, Results Presented at ASAIO Meeting](https://ysioscapital.com/2021/06/14/corwave-successfully-performed-a-90-day-in-vivo-study-on-its-revolutionary-cardiac-pump-synchronized-with-the-native-heart-results-presented-at-asaio-meeting/) - CorWave has successfully completed the first 90-day preclinical study to evaluate its left ventricular assist device (LVAD).
- [AELIX Therapeutics appoints Dr Melanie Rolli as CEO](https://ysioscapital.com/2021/05/18/aelix-therapeutics-appoints-dr-melanie-rolli/) - Dr Rolli will support the company’s vision of positioning HTI vaccines for future functional cure strategies andwill lead Aelix through the next growth stage
- [SparingVision to Present at the American Society of Gene and Cell Therapy (ASGCT) 24th Annual Meeting](https://ysioscapital.com/2021/05/11/sparingvision-to-present-at-the-american-society-of-gene-and-cell-therapy-asgct/) - SparingVision has presented three posters highlighting the Company’s recent research into ocular diseases and its lead gene therapy treatment, SPVN06.
- [Minoryx publishes mechanism of action of leriglitazone in X-ALD in Science Translational Medicine journal](https://ysioscapital.com/2021/06/03/minoryx-publishes-mechanism-of-action-of-leriglitazone/) - Minoryx mechanism of action of leriglitazone in X-ALD. Published results show efficacy in both adrenomyeloneuropathy (AMN) and cerebral ALD (cALD).
- [Aura Biosciences Appoints Sapna Srivastava, Ph.D., to its Board of Directors](https://ysioscapital.com/2021/06/08/aura-biosciences-appoints-sapna-srivastava/) - Aura Biosciences Appoints Sapna Srivastava, Ph.D., to its Board of Directors
- [OxThera reports results from Phase 3 ePHex study with Oxabact in primary hyperoxaluria patients with maintained kidney function](https://ysioscapital.com/2021/06/11/oxthera-reports-results-from-phase-3-ephex/) - The study results have been accepted for oral presentation at the upcoming European Society of Pediatric Nephrology meeting in Amsterdam.
- [TiGenix Enrolls First Patient in Phase Ib/IIa Clinical Trial of Cx611 in Severe Sepsis](https://ysioscapital.com/2017/01/31/tigenix-enrolls-first-patient-in-phase-ibiia-clinical-trial-of-cx611-in-severe-sepsis/) - Leuven (BELGIUM) – 31st January, 2017, 07:00h CET – TiGenix NV (Euronext Brussels and Nasdaq: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, today announced that the first patient has been enrolled and treated in its Phase Ib/IIa clinical trial for Cx611
- [CorWave Secures a €500,000 Grant From the Paris Region for Its Industrial Facilities](https://ysioscapital.com/2020/11/19/corwave-secures-a-e500000-grant-from-the-paris-region-for-its-industrial-facilities/) - Clichy, France, November 18th, 2020 - CorWave has won the call for projects “Industry Stimulus Plan” ("Relance Industrie") operated by the Paris Region (“Ile-de-France”). CorWave will benefit from a €500,000 grant, which will be instrumental for the development of its Left Ventricular Assist Device (LVAD). Valérie Pécresse, President of the Paris Region, commented: "At the
- [Ysios Capital Partners announces the first closing of the largest Spanish biotech fund at €67million](https://ysioscapital.com/2008/09/15/ysios-capital-partners-announces-the-first-closing-of-the-largest-spanish-biotech-fund-at-e67million/) - Ysios Capital Partners announces the first closing of the largest Spanish biotech fund at €67million and will invest in 10 to 12 biotechnology companies.
- [Ysios co-leads €27,2million Series B financing of stem cell company Cellerix](https://ysioscapital.com/2007/09/20/ysios-co-leads-e272million-series-b-financing-of-stem-cell-company-cellerix-2/) - Ysios co-leads €27,2million oversubscribed Series B financing of stem cell company Cellerix alognside LSP and Ventech.
- [AM-Pharma closes €12.2m financing round](https://ysioscapital.com/2014/09/16/am-pharma-closes-e12-2m-financing-round/) - Ysios Capital joins Am Pharma's 12.2 million euro financing.
- [SparingVision Presents Three Posters at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting](https://ysioscapital.com/2021/05/06/sparingvision-presents-three-posters-at-the-association-for-research-in-vision-and-ophthalmology-arvo-2021-annual-meeting/) - SparingVision has presented three posters highlighting the Company’s recent research into ocular diseases and its lead gene therapy treatment, SPVN06.
- [Vivet Therapeutics Announces Multiple Projects Update, Including New VTX-803 Preclinical data To Be Presented At 2021 American Society Of Gene And Cell Therapy Annual Meeting](https://ysioscapital.com/2021/05/10/vivet-therapeutics-announces-multiple-projects-update/) - Compelling additional preclinical data further support therapeutic potential of gene therapy product to treat PFIC3.
- [CVRx® Raises $50 Million in New Equity Financing](https://ysioscapital.com/2020/07/07/cvrx-raises-50-million-in-new-equity-financing-2/) - Offering Will Support US Commercialization of BAROSTIM NEO™ MINNEAPOLIS, July 7, 2020 /PRNewswire/ -- CVRx, Inc., a private medical device company with a novel technology that treats patients suffering from chronic heart failure ("HF") and resistant hypertension, announced today that it raised $50 million to close its latest round of equity financing. Proceeds from the financing will be used to
- [International Consortium Awarded Eurostars Grant for the Development of First-in-class Treatment of Metastatic Cancer](https://ysioscapital.com/2020/12/16/international-consortium-awarded-eurostars-grant-for-the-development-of-first-in-class-treatment-of-metastatic-cancer/) - ONA Therapeutics,specialized in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells, will take the lead in the LIPOLOGIC program
- [Ona Therapeutics raises €30M in Series A financing](https://ysioscapital.com/2020/06/16/ona-therapeutics-raises-e30m-in-series-a-financing-2/) - Financing to complete the pre-clinical development in a variety of tumor types and to move its lead candidate into first clinical studies in patients with metastatic cancer.
- [Splice Bio announces research funding by Cystic Fibrosis Foundation to develop novel AAV vectors](https://ysioscapital.com/2020/12/10/splice-bio-announces-research-funding-by-cystic-fibrosis-foundation-to-develop-novel-aav-vectors/) - Splice Bio announces research agreement with the Cystic Fibrosis Foundation to develop novel adeno-associated viruses (AAVs).
- [VarmX raises €32 million in Series B financing to develop innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants](https://ysioscapital.com/2020/07/08/varmx-raises-32m-eur-series-b-financing-led-by-ysios/) - Financing co-led by Ysios Capital & INKEF Capital, joined by Lundbeckfonden Ventures, LSP, & existing investors. Proceeds to achieve clinical proof of concept.
- [LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs](https://ysioscapital.com/2020/09/18/lava-therapeutics-announces-83-million-series-c-financing/) - Funding to support advancement of powerful bispecific Gamma-Delta T cell engager programs for the treatment of a broad range of cancers.
- [Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline](https://ysioscapital.com/2020/09/28/galecto-raises-64-million-to-accelerate-development-of-clinical-pipeline/) - Funds will support preparations for potential EU conditional approval of GB0139 in IPF and multiple new Phase 2 clinical trials.
- [SparingVision Raises €44.5 Million and Appoints Stéphane Boissel as Chief Executive Officer](https://ysioscapital.com/2020/10/21/sparingvision-raises-e44-5-million/) - Funds will be used to advance the development of SparingVision’s breakthrough treatment SPVN06 for the mutation-agnostic treatment of retinitis pigmentosa.
- [Galecto Announces Pricing of Initial Public Offering](https://ysioscapital.com/2020/11/12/galecto-announces-pricing-of-initial-public-offering/) - The shares are expected to begin trading on the Nasdaq Global Market on October 29, 2020 under the ticker symbol “GLTO
- [Ysios Capital presents its third fund of € 200M](https://ysioscapital.com/2020/06/10/ysiosbiofundiiifirstclosing/) - Ysios Capital is the largest venture capital firm in Spain specialized in biotechnology, with € 346M under management, through three funds
- [Ysios Capital begins fundraising for Ysios Biofund II](https://ysioscapital.com/2014/03/19/ysios-capital-begins-fundraising-for-ysios-biofund-ii/) - The fund seeks 100M€ to invest in disruptive products, platforms or technologies in the pharmaceutical and Medtech and diagnostics segments in Europe and the US
- [Ysios Capital strengthens its team with the appointment of Guillem Laporta as Principal and two new Venture Partners](https://ysioscapital.com/2018/09/24/ysios-capital-strengthens-its-team-with-the-appointment-of-guillem-laporta/) - Ysios Capital strengthens its team with the appointment of Guillem Laporta as Principal and two new Venture Partners; Lance Berman and Claudia D'Augusta.
- [AELIX Therapeutics presents positive results from randomized placebo-controlled phase I/IIa therapeutic HIV vaccine clinical trial](https://ysioscapital.com/2021/03/10/aelix-therapeutics-presents-positive-results-from-randomized-placebo-controlled-phase-i-iia-therapeutic-hiv-vaccine-clinical-trial/) - Results support development of combination strategies based on HTI vaccine to control HIV – without the need for ongoing antiretroviral medication
- [Ysios Capital raises €126,4 m ($140 m) for its second fund, Ysios Biofund II Innvierte](https://ysioscapital.com/2016/10/18/ysios-capital-begins-fundraising-for-ysios-biofund-ii-1/) - Ysios Capital has closed its second fund, Ysios BioFund II Innvierte, at €126,4 M exceeding its initial target fund size of €100 M.
- [Aelix Therapeutics completes Series A funding of €11.5M ($12.7M) for therapeutic HIV vaccine](https://ysioscapital.com/2016/01/11/elix-therapeutics-completes-series-a-funding-of-e11-5mled-by-ysios-capital/) - Funds will support proof of concept studies for AELIX Therapeutics lead candidate HTI immunogen as a therapeutic vaccine against HIV infection.
- [AELIX Therapeutics enrolls first patient in company’s initial therapeutic HIV vaccine clinical trial](https://ysioscapital.com/2017/09/06/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial/) - AELIX Therapeutics enrolls first patient in company’s initial therapeutic HIV vaccine clinical trial to evaluate safety and immunogenicity of the HTI vaccine.
- [AELIX Therapeutics appoints Dr. Thomas Hecht as Chairman of the Board of Directors](https://ysioscapital.com/2017/10/18/aelix-therapeutics-enrolls-first-patient-in-companys-initial-therapeutic-hiv-vaccine-clinical-trial-1/) - Dr. Hecht joins the company as the first patient has been enrolled in the company’s phase I clinical trial for the assessment of its proprietary HTI vaccine.
- [AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure](https://ysioscapital.com/2018/10/18/aelix-therapeutics-and-gilead-sciences-enter-into-a-clinical-research-collaboration-agreement-to-evaluate-a-therapeutic-vaccine-and-tlr7-agonist-regimen-for-hiv-cure/) - AELIX Therapeutics will investigate the safety, immunogenicity, & efficacy of AELIX Therapeutics’ HTI vaccine & Gilead´s Toll-Like in HIV-infected individuals.
- [MedLumics closes upsized EUR 18M (21.7M USD) financing round and appoints new Chairman](https://ysioscapital.com/2021/02/10/medlumics-closes-upsized-eur-18m-21-7m-usd-financing-round-and-appoints-new-chairman/) - MedLumics’ financing round closes at 18M€ to advance optically-guided real-time ablation catheter technology for the treatment of Atrial Fibrillation
- [New Data Supports High Reperfusion Rate for Anaconda Biomed’s Mechanical Thrombectomy System](https://ysioscapital.com/2021/02/17/new-data-supports-high-reperfusion-rate-for-anaconda-biomeds-mechanical-thrombectomy-system/) - Researchers evaluated the suction force and aspiration flow generated by the ANA Catheter device and compared them with other neurovascular catheters.
- [ONA Therapeutics appoints Mark Throsby to its Board of Directors](https://ysioscapital.com/2021/03/05/ona-therapeutics-appoints-mark-throsby-to-its-board-of-directors/) - ONA Therapeutics has appointed Dr. Mark Throsby as independent board member of its Board of Directors.
- [CorWave presents an unprecedented chronic In Vivo Study at the 41st Annual Meeting of the International Society of Heart and Lung Transplantation](https://ysioscapital.com/2021/04/27/corwave-presents-an-unprecedented-chronic-in-vivo-study/) - Corwave presented the first-ever study demonstrating sensorless synchronization of a pericardial pump with the native heart for over 30 days.
- [LAVA Therapeutics Announces Pricing of Initial Public Offering](https://ysioscapital.com/2021/03/25/lava-therapeutics-announces-pricing-of-initial-public-offering/) - LAVA therapeutics biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy announces NASDAQ IPO.
- [Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board](https://ysioscapital.com/2021/01/29/renowned-pioneers-in-ophthalmology-join-sparingvisions-scientific-advisory-board/) - SparingVision strengthens its Scientific Advisory Board (“SAB”) with the appointment of internationally renowned ophthalmology pioneers Dr. Paul A. Sieving.
- [Minoryx Phase 2/3 ‘ADVANCE’ study results to be presented at the 2021 American Neurological Association (AAN) Annual Meeting](https://ysioscapital.com/2021/04/12/minoryx-phase-2-3-advance-study-results-to-be-presented-at-the-2021-american-neurological-association-aan-annual-meeting/) - Minoryx Phase 2/3 ADVANCE overall results support the positive effects of leriglitazone on reducing the progression of cerebral lesions and myelopathy symptoms.
- [Mirum Pharmaceuticals and Vivet Therapeutics enter into exclusive worldwide option and license agreement for Vivet’s gene therapy programs targeting PFIC](https://ysioscapital.com/2021/04/13/mirum-pharmaceuticals-and-vivet-therapeutics-enter-into-exclusive-worldwide-option-and-license-agreement-for-vivets-gene-therapy-programs-targeting-progressive-familial-intrahepatic-cholestas/) - Vivet to lead pre-clinical development of its two gene therapy programs for PFIC3 and PFIC2.
- [Aura Biosciences Announces Publication of Data in Cancer Immunology Research Supporting the Immune Mediated Mechanism of Action of the Virus-Like Drug Conjugate (VDC) Technology Platform](https://ysioscapital.com/2021/04/15/aura-biosciences-announces-publication-of-data-in-cancer-immunology-research-supporting-the-immune-mediated-mechanism-of-action-of-the-virus-like-drug-conjugate-vdc-technology-platform/) - Results Support VDCs induction of Pro Immunogenic Cell Death and the Generation of Long Lasting Adaptive Anti-Tumor Immunity
- [SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics](https://ysioscapital.com/2021/04/20/sparingvision-expands-novel-ocular-disease-pipeline-with-acquisition-of-gamut-therapeutics/) - Broadens SparingVision’s innovative genomic medicine pipeline to address both mid & late stages of rod-cone dystrophies with the potential to combine both products.
- [Cytoki Pharma raises $45 million Series A financing](https://ysioscapital.com/2021/05/05/ysios-capital-joins-cytoki-pharma-usd45million-series-a-financing/) - Cytoki Pharma is advancing a long-acting Interleukin-22 (IL-22) variant to clinical testing with initial focus on Inflammatory Bowel Disease.
- [Aura Biosciences Presents New Preclinical AU-011 Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting](https://ysioscapital.com/2021/05/03/aura-biosciences-presents-new-preclinical-au-011-data-at-arvo/) - AU-011 Demonstrates Targeted Cytotoxicity In Vitro and In Vivo in Both Breast and Lung Tumors, Demonstrating the Potential to Treat Human Choroidal Metastases.
- [VarmX appoints Dr. Gerard Short as Chief Medical Officer](https://ysioscapital.com/2021/01/27/varmx-appoints-dr-gerard-short-as-chief-medical-officer/) - Leiden, The Netherlands, 27 January 2021 – VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the appointment of Dr. Gerard Short, MBBS, as Chief Medical Officer (CMO). As CMO, Dr. Short will be responsible for overseeing the clinical development of VarmX’s pipeline, including progression of
- [CorWave Joins the French Tech 120 Index, a Community That Brings Together the Top French Tech Scale-up Companies](https://ysioscapital.com/2021/02/09/corwave-joins-the-french-tech-120-index-a-community-that-brings-together-the-top-french-tech-scale-up-companies/) - The company develops breakthrough cardiac pumps with the aim of improving the lives of advanced heart failure patients Clichy, France, February 8th, 2021 – Mr. Bruno Le Maire, Economy and Finance Minister and Mr. Cédric O, Secretary of State for Digital Transition and Electronic Communications, announced the selection of CorWave to join the French Tech
- [Sanifit Granted Orphan Drug Designation by the FDA for SNF472 for the Treatment of Peripheral Arterial Disease in Patients with End-stage Kidney Disease](https://ysioscapital.com/2021/02/10/sanifit-granted-orphan-drug-designation-by-the-fda-for-snf472-for-the-treatment-of-peripheral-arterial-disease-in-patients-with-end-stage-kidney-disease/) - Palma, Spain and San Diego, USA, February 10, 2021 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead compound SNF472 for the treatment of peripheral arterial disease (PAD) in patients with end-stage
- [Kala pharmaceuticals announces new drug application for inveltystm (kpi-121 1%) has been accepted for review by the u.s. Food and drug administration](https://ysioscapital.com/2018/01/05/kala-pharmaceuticals-announces-new-drug-application-for-inveltystm-kpi-121-1-has-been-accepted-for-review-by-the-u-s-food-and-drug-administration/) - INVELTYS expected to be the first twice-daily ocular steroid indicated for the treatment of inflammation and pain following ocular surgery, if approved PDUFA target action date of August 24, 2018 WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 5, 2018-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating
- [CVRx® Names Tom Moore Vice President of U.S. Market Development](https://ysioscapital.com/2016/10/07/cvrx-names-tom-moore-vice-president-of-u-s-market-development/) - Minneapolis – October 6, 2016 - CVRx, Inc., a private medical device company, today announced the appointment of Tom Moore to the newly created, officer position of Vice President, U.S. Market Development. In this role, Mr. Moore will lead all field efforts related to the successful completion of the Baroreflex Activation Therapy for Heart Failure
- [TiGenix announces launch of proposed initial public offering in the United States](https://ysioscapital.com/2016/12/05/tigenix-announces-launch-of-proposed-initial-public-offering-in-the-united-states/) - Leuven (BELGIUM) – December 5, 2016, 22:01h CET – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today that it intends to offer and sell, subject to market and other conditions, 2.75 million American Depositary Shares (“ADSs”)
- [Minoryx Therapeutics receives European Orphan Drug Designation for its lead candidate MIN-102](https://ysioscapital.com/2016/12/15/minoryx-therapeutics-receives-european-orphan-drug-designation-for-its-lead-candidate-min-102/) - Minoryx Therapeutics receives European Orphan Drug Designation for its lead candidate MIN-102 MIN-102 targets X-linked Adrenoleukodystrophy (X-ALD), a life threatening orphan CNS disease with high unmet medical need Orphan Drug Designation by the European agency brings a number of benefits to Minoryx including ten years market exclusivity Mataró, Barcelona, Spain, December 14, 2016 – Minoryx
- [TiGenix raises $35.65 million gross proceeds with NASDAQ IPO](https://ysioscapital.com/2016/12/15/tigenix-raises-35-65-million-gross-proceeds-with-nasdaq-ipo/) - Leuven (BELGIUM) – December 15, 2016, 3:00h CET – TiGenix NV (Euronext Brussels: TIG; "TiGenix"), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today the pricing of its initial public offering in the United States (the "Offering") totalling $35.65 million gross proceeds
- [TiGenix announces closing of NASDAQ IPO](https://ysioscapital.com/2016/12/20/tigenix-raises-35-65-million-gross-proceeds-with-nasdaq-ipo-1/) - Leuven (BELGIUM) – December 20, 2016, 16:00h CET – TiGenix NV (Euronext Brussels & NASDAQ: TIG; "TiGenix"), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today the closing of its initial public offering in the United States (the "Offering") totalling $35.65 million
- [Takeda makes €10 million equity investment in TiGenix](https://ysioscapital.com/2016/12/20/takeda-makes-e10-million-equity-investment-in-tigenix/) - Leuven (BELGIUM) – December 20, 2016, [22:01]h CET – TiGenix NV (Euronext Brussels and NASDAQ: TIG; "TiGenix"), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today that it has exercised the option granted by Takeda under the licensing agreement to make a
- [Kala Pharmaceuticals to Present Update on Phase 3 Programs at the 35th Annual J.P. Morgan Healthcare Conference](https://ysioscapital.com/2017/01/06/tigenix-raises-35-65-million-gross-proceeds-with-nasdaq-ipo-1-1/) - WALTHAM, Mass., January 6, 2017 -- Kala Pharmaceuticals, Inc. (Kala), a developer of innovative ophthalmic medicines based on its proprietary mucus-penetrating particle (MPP) technology, announced today that Mark Iwicki, Chairman and Chief Executive Officer of Kala, is scheduled to present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation will
- [Aelix Therapeutics appoints industry expert Philippe Monteyne as independent board member](https://ysioscapital.com/2017/01/17/aelix-therapeutics-appoints-industry-expert-philippe-monteyne/) - Dr Monteyne will help the company further advance HTI immunogen, a therapeutic HIV vaccine Barcelona, Spain, January 16, 2017 - Aelix Therapeutics, a drug development company specialized in the discovery and development of immunotherapies against HIV infection, has appointed Dr Philippe Monteyne as an independent member of its board of directors. Philippe Monteyne MD, PhD
- [Minoryx Therapeutics further strengthens its scientific advisory board](https://ysioscapital.com/2017/01/18/minoryx-therapeutics-receives-european-orphan-drug-designation-for-its-lead-candidate-min-102-1/) - Four US and EU clinical experts in X-ALD join the board as company prepares to launch phase II/III trial in H1 2017 Mataró, Barcelona, Spain, January 18, 2017 – Minoryx Therapeutics, a drug development company specialized in the discovery of new drugs for orphan diseases, today announces that, Dr. Patrick Aubourg, Dr. Marc Engelen, Dr. Florian
- [Sanifit Announces Enrollment of First Patient in CaLIPSO – a Phase IIb Study for the Treatment of Cardiovascular Calcification in End-Stage-Renal-Disease Patients on Haemodialsis](https://ysioscapital.com/2017/01/23/sanifit-announces-enrollment-of-first-patient-in-calipso/) - San Diego, USA and Palma, Spain, January 23, 2017 - San Diego, USA and Palma, Spain, January 23, 2016 - Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced that the first patient has been enrolled in the Phase IIb “CaLIPSO Study” clinical trial of lead candidate, SNF472, for the
- [Prexton Therapeutics Series B financing round raises EUR 29 million (USD 31 million) to advance its novel Parkinson’s therapeutic](https://ysioscapital.com/2017/02/08/prexton-therapeutics-series-b-financing-round-raises-eur-29-million/) - Forbion & Seroba co-led funding, forming international consortium of Merck Ventures, Ysios and Sunstone Funding to finance two Phase II trials in Parkinson’s disease Geneva, Switzerland and Amsterdam, The Netherlands, 7 February 2017 - Prexton Therapeutics (Prexton), a biopharmaceutical company developing novel therapeutic compounds for the treatment of Central Nervous System (CNS) conditions, today announces
- [Dr Claude Nicaise joins Minoryx Therapeutics as independent board member](https://ysioscapital.com/2017/02/08/dr-claude-nicaise-joins-minoryx-therapeutics-as-independent-board-member/) - Expert brings more than 30 years of clinical and regulatory experience Mataró, Barcelona Spain, February 8, 2017 – Minoryx Therapeutics, a drug development company specialized in the discovery of new drugs for orphan diseases, today announces that Dr Claude Nicaise has joined its board of directors as an independent member. Dr Nicaise has over 30
- [Takeda and TiGenix Report New Data Highlighting Maintenance of Long-Term Remission of Complex Perianal Fistulas in Crohn’s Disease Patients with Cx601](https://ysioscapital.com/2017/02/17/tigenix-enrolls-first-patient-in-phase-ibiia-clinical-trial-of-cx611-in-severe-sepsis-1/) - 52-week results of the Phase 3 ADMIRE-CD trial presented at the 12th Congress of the European Crohn’s and Colitis Organisation (ECCO) Osaka, Japan, February 17, 2017, and Leuven, Belgium, February 17, 2017, 9:01 am CET – Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and Nasdaq: TIG) (“TiGenix”) today announced new
- [Minoryx Therapeutics receives Orphan Drug Designation from the US FDA for its lead candidate MIN-102](https://ysioscapital.com/2017/02/22/minoryx-therapeutics-receives-european-orphan-drug-designation-for-its-lead-candidate-min-102-1-1/) - MIN-102 targets X-linked Adrenoleukodystrophy (X-ALD), a life threatening orphan CNS disease with high unmet medical need Orphan drug status for MIN-102 has now been granted by both the FDA and the EMA Mataró, Barcelona, Spain, February 22, 2017 – Minoryx Therapeutics, a drug development company specialized in the discovery and development of new drugs for
- [TiGenix Provides Update on Cx601 Marketing Authorization Application procedure in Europe](https://ysioscapital.com/2017/03/06/tigenix-provides-update-on-cx601-marketing-authorization-application-procedure-in-europe/) - Leuven (BELGIUM) – 6th March, 2017, 7:00 am CET – TiGenix NV (Euronext Brussels and Nasdaq: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platform of allogeneic stem cells, announces that it has received the Day 180 List of Outstanding Issues (LoOI) from the Committee for Medicinal Products
- [TiGenix Receives Positive Feedback from the FDA on Cx601 Global Phase III Trial Protocol](https://ysioscapital.com/2017/03/07/tigenix-announces-positive-topline-week-104-data-for-cx601-admire-cd-trial/) - Leuven (BELGIUM) – 7th March, 2017, 7:00 am CET – TiGenix NV (Euronext Brussels and Nasdaq: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platform of allogeneic stem cells, announced today that it has received positive feedback from the U.S. Food and Drug Administration (FDA) on an improved
- [TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial](https://ysioscapital.com/2017/03/09/tigenix-announces-positive-topline-week-104-data-for-cx601-admire-cd-trial-1/) - Leuven (BELGIUM) – 9th March, 2017, 7:00 am CET – TiGenix NV (Euronext Brussels and Nasdaq: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic stem cells, today announced week 104 data from the Cx601 ADMIRE-CD study, a pivotal Phase III trial for complex perianal fistulas
- [TiGenix Announces Top-Line Phase I/II Results of AlloCSC-01 in Acute Myocardial Infarction](https://ysioscapital.com/2017/03/13/tigenix-enrolls-first-patient-in-phase-ibiia-clinical-trial-of-cx611-in-severe-sepsis-1-1/) - Leuven (BELGIUM) – March 13, 2017, 07:00h CET – TiGenix NV (Euronext Brussels and Nasdaq: TIG), an advanced biopharmaceutical company focused on developing novel therapeutics from its two proprietary platforms of donor-derived expanded adipose derived stem cells (eASC) and donor-derived expanded cardiac stem cells (AlloCSCs), today announced top-line one-year results from the CAREMI clinical trial,
- [Minoryx Therapeutics successfully completes phase 1 clinical trial for lead candidate MIN-102](https://ysioscapital.com/2017/03/22/minoryx-therapeutics-successfully-completes-phase-1-clinical-trial-for-lead-candidate-min-102/) - MIN-102 was well-tolerated at much higher doses than those required for efficacy MIN-102 exhibited linear pharmacokinetics and no food effects were observed Blood brain barrier penetration and biomarkers confirm PPAR gamma receptor engagement in the central nervous system Phase 2/3 trial in AMN patients expected to begin in 2017 Mataró, Barcelona Spain, March 21, 2017
- [Aelix Therapeutics appoints Dr. Ian McGowan as Chief Medical Officer](https://ysioscapital.com/2017/04/05/aelix-therapeutics-appoints-dr-ian-mcgowan-as-chief-medical-officer/) - HIV expert will support company in advancing therapeutic HIV vaccine to clinical proof-of-concept Barcelona, Spain, April 5, 2017 - Aelix Therapeutics, a drug development company specialized in the discovery and development of immunotherapies against HIV infection, today announces the appointment of Dr. Ian McGowan as Chief Medical Officer (CMO), effective March 1, 2017. Aelix Therapeutics’
- [TiGenix reports 2016 full year results](https://ysioscapital.com/2017/04/06/tigenix-enrolls-first-patient-in-phase-ibiia-clinical-trial-of-cx611-in-severe-sepsis-1-1-1/) - Leuven (BELGIUM) – April 6, 2017, 07:00h CEST – TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company developing and commercializing novel therapeutics which exploit the anti-inflammatory properties of allogeneic, or donor-derived, stem cells, today reported its business and financial highlights for 2016 and post year-end events. Key 2016 and post year-end highlights:
- [STAT-Dx Unveils New In-Vitro Diagnostic System DiagCORE®](https://ysioscapital.com/2017/04/21/stat-dx-unveils-new-in-vitro-diagnostic-system-diagcore/) - Fully-Integrated, Molecular Diagnostics System Unveiled at ECCMID First Assay for Acute Respiratory Syndromic Testing BARCELONA – 21 April, 2017 – STAT-Dx, a company specialising in the development of advanced molecular diagnostic systems, is unveiling DiagCORE®, its fully-integrated platform for multiplex real-time PCR diagnosis, at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID),
- [Kala Pharmaceuticals Announces Positive Results from Confirmatory Phase 3 Trial of KPI-121 1% Following Cataract Surgery](https://ysioscapital.com/2017/05/01/kala-pharmaceuticals-announces-positive-results-from-confirmatory-phase-3-trial-of-kpi-121/) - KPI-121 1% ophthalmic suspension demonstrated effective resolution of ocular inflammation and pain following cataract surgery when dosed twice-a-day for two weeks - Kala’s two ongoing Phase 3 trials in dry eye disease expected to complete in late 2017 WALTHAM, Mass., May 1, 2017 -- Kala Pharmaceuticals, Inc. (Kala), a developer of innovative ophthalmic medicines based
- [AM-Pharma completes patient recruitment of recombinant human Alkaline Phosphatase (recAP) Phase II trial in Acute Kidney Injury](https://ysioscapital.com/2017/05/22/am-pharma-completes-patient-recruitment-of-recombinant-human-alkaline-phosphatase/) - Recruitment of 301 patients in STOP-AKI adaptive Phase II trial marks largest ever therapeutic study in AKI Bunnik, The Netherlands, 22 May 2017. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (reCAP) for inflammatory diseases, announced completion of recruitment in the adaptive Phase II trial to treat sepsis patients
- [EUR 20 million EIB loan facility under the InnovFin programme to support medical diagnostics innovation in Spain](https://ysioscapital.com/2017/06/01/ur-20-million-eib-loan-facility-under-the-innovfin-programme-to-support-statdx/) - The EIB is providing STAT-Dx (STAT-Diagnostica & Innovation, S.L.), a Spanish company developing advanced molecular diagnostic systems to help combat meningitis and other infectious diseases, with a EUR 20 million loan facility. The European Investment Bank (EIB), the EU bank, is supporting the improvement of infectious diseases diagnostics through a EUR 20 million loan agreement
- [TiGenix announces final equity payment for cardiac platform acquisition](https://ysioscapital.com/2017/06/12/tigenix-announces-positive-topline-week-104-data-for-cx601-admire-cd-trial-1-1/) - Leuven (BELGIUM) – June 12, 2017, 07:00h CEST – TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti- inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, today announces a €5 million milestone payment in new TiGenix shares to Genetrix in
- [TiGenix Launches Global Phase III Trial for Cx601](https://ysioscapital.com/2017/06/13/tigenix-launches-global-phase-iii-trial-for-cx601/) - Leuven (BELGIUM) – June 13, 2017, 07:00h CEST – TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti- inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, today announces that it has hosted its first European investigator meeting, which formally launches
- [TiGenix Partners with U.S. and European Patient Advocacy Groups Focused on Crohn’s Disease and Ulcerative Colitis](https://ysioscapital.com/2017/06/15/tigenix-launches-global-phase-iii-trial-for-cx601-1/) - Leuven (BELGIUM) – June 15, 2017, 07:00h CEST – TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti- inflammatory properties of allogeneic, or donor-derived, stem cells to develop novel therapies for serious medical conditions, today announces partnerships with the largest patient advocacy groups focused on Crohn’s disease and
- [Takeda and TiGenix announce that Swissmedic has accepted for review the file on Cx601 for the treatment of complex perianal fistulas in Crohn’s disease patients](https://ysioscapital.com/2017/06/19/takeda-and-tigenix-announce-that-swissmedic-has-accepted-for-review-the-file-on-cx601-for-the-treatment-of-complex-perianal-fistulas-in-crohns-disease-patients/) - Pfäffikon, SZ, June 19, 2017, and Leuven, Belgium, June 19, 2017 – Takeda Pharma AG (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels and Nasdaq: TIG) (“TiGenix”) today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has accepted for review the file on investigational compound Cx601 to treat complex perianal fistulas in patients with
- [Prexton announces initiation of phase II clinical testing in Parkinson’s disease](https://ysioscapital.com/2017/07/10/prexton-announces-initiation-of-phase-ii-clinical-testing-in-parkinsons-disease/) - Study will evaluate first-in class treatment in six European countries Geneva, Switzerland and Amsterdam, The Netherlands, July 10, 2017 - Prexton Therapeutics (Prexton), a biopharmaceutical company developing novel therapeutic compounds for the treatment of Central Nervous System (CNS) conditions, today announces the launch of phase II clinical testing of its investigational drug candidate, Foliglurax, in
- [TiGenix obtains commercial production license for expanded manufacturing facility](https://ysioscapital.com/2017/09/05/tigenix-obtains-commercial-production-license-for-expanded-manufacturing-facility/) - Provides capacity for potential European commercial roll out of investigational stem cell therapy, Cx601 Expanded facility also secures manufacturing for other pipeline products Leuven (BELGIUM) – September 05, 2017, 7:00h CEST – TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop
- [Vivet’s First Gene Therapy Product Receives European and US Orphan Drug Designation VTX 801 for Wilson’s Disease](https://ysioscapital.com/2017/09/25/vivets-first-gene-therapy-product-receives-european-and-us-orphan-drug-designation-vtx-801-for-wilsons-disease/) - PARIS, France September 25th, 2017, Vivet Therapeutics, announced today that both the Food and Drug Administration (FDA) and the European Commission (EC) have granted Orphan Drug Designation (ODD) for Vivet’s lead gene therapy product, VTX-801, for the treatment of Wilson’s Disease (WD), a chronically debilitating and life-threatening condition if not treated. « This designation validates Vivet’s
- [FierceBiotech names Vivet Therapeutics as one of its 2017 “Fierce 15” Biotech Companies](https://ysioscapital.com/2017/09/27/fiercebiotech-names-vivet-therapeutics-as-one-of-its-2017-fierce-15-biotech-companies/) - PARIS, France September 28th, 2017, Vivet Therapeutics is proud to announce that it has been named by FierceBiotech as one of 2017's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. The announcement was made during the FierceBiotech Drug Development Forum, which took place Tuesday September 26th
- [Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for INVELTYSTM (KPI-121 1%)](https://ysioscapital.com/2017/10/25/kkala-pharmaceuticals-submits-new-drug-application-to-u-s-fda/) - Kala seeks approval for its topical twice-a-day product candidate for the treatment of inflammation and pain following ocular surgery WALTHAM, Mass., October 25, 2017 – Kala Pharmaceuticals, Inc. (NASDAQ:KALA) today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for INVELTYSTM (KPI-121 1%), a topical
- [Kala Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Business Update](https://ysioscapital.com/2017/11/07/kala-pharmaceuticals-reports-third-quarter-2017-financial-results-and-provides-business-update/) - Completed Initial Public Offering Raising $103.5 million in gross proceeds Submitted New Drug Application to U.S. Food and Drug Administration for INVELTYSTM (KPI-121 1%) WALTHAM, Mass., November 07, 2017 – Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today reported
- [CorWave Receives 2017 Deloitte 'Technology Fast 50 Biotech of the Future' Award of the Parisian Region](https://ysioscapital.com/2017/11/09/orwave-receives-2017-deloitte-technology-fast-50-biotech-of-the-future-award/) - Clichy, 9 November 2017 – CorWave, a medical technology company developing innovative implantable cardiac assist devices, announced today that it received the 'Deloitte In Extenso Technology Fast 50 Biotech of the Future' award for the Parisian Region which rewards the outstanding contribution of technology companies to economic growth. CorWave received the Parisian Region 'Biotech of
- [MedLumics Appoints Medtech Industry Veterans James Greene as Chief Executive Officer and Giovanni Leo as Member of the Board of Directors](https://ysioscapital.com/2017/11/28/medlumics-appoints-medtech-industry-veterans-james-greene-as-chief-executive-officer-and-giovanni-leo-as-member-of-the-board-of-directors/) - MADRID – Nov. 28, 2017 – MedLumics, a medical device company developing an optically guided cardiac ablation platform for the treatment of Atrial fibrillation (AF), announced today it has appointed James Greene as Chief Executive Officer and named Giovanni Leo to the board of directors. The addition of two medical device industry veterans positions the
- [Sanifit appoints Alexander M. Gold, M.D., F.A.C.C. as Chief Medical Officer and President of its US subsidiary](https://ysioscapital.com/2017/12/14/sanifit-announces-enrollment-of-first-patient-in-calipso-1/) - Former SVP and Head of Clinical Development at Portola Pharmaceuticals appointed as Chief Medical Officer Palma, Spain and San Diego, USA, 14 December 2017 - Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announces the appointment of Alexander M. Gold, M.D., F.A.C.C. as Chief Medical Officer and President of
- [Sanifit Announces Last Patient Last Visit completed in Clinical Trial of SNF472 in Patients with Calciphylaxis](https://ysioscapital.com/2017/12/21/sanifit-announces-last-patient-last-visit-completed-in-clinical-trial-of-snf472-in-patients-with-calciphylaxis/) - Last Patient Last Visit (LPLV) completed in Phase II Study for the Treatment of Calcific Uraemic Arteriolopathy in End Stage Renal Disease Patients Palma, Spain and San Diego, USA, December 21, 2017 - Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, announced today that the Last Patient's Last Visit (LPLV)
- [Minoryx Therapeutics announces the dosing of first patient in ADVANCE, a phase 2/3 clinical study of MIN-102 in patients with adrenomyeloneuropathy (AMN)](https://ysioscapital.com/2018/01/04/minoryx-therapeutics-successfully-completes-phase-1-clinical-trial-for-lead-candidate-min-102-1/) - ADVANCE trial expected to initiate patient recruitment shortly in several other EU countries, followed by the US Mataró, Barcelona, Spain, January 4, 2018 - Minoryx Therapeutics, a company specialized in the development of new drugs for orphan diseases, today announces the initiation of treatment of the first two patients in the ADVANCE trial, a pivotal
- [Takeda announces its intention to acquire TiGenix](https://ysioscapital.com/2018/01/05/takeda-announces-its-intention-to-acquire-tigenix/) - NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO, OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION. Communication in accordance with section 8, §1 of the Belgian Royal Decree of 27 April 2007 on public takeover bids Leuven (BELGIUM) – January
- [Sanifit announces the appointment of Cris Calsada as Chief Financial Officer](https://ysioscapital.com/2018/01/08/sanifit-announces-the-appointment-of-cris-calsada-as-chief-financial-officer/) - Palma, Spain, and San Diego, USA, January 8, 2018 - Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced the appointment of Cris Calsada as Chief Financial Officer. Ms. Calsada joins Sanifit with over 20 years of corporate finance and executive experience in the life sciences and technology industries.
- [BioClin Therapeutics Appoints Graeme Currie, Ph.D., as Chief Operating Officer and Esteban (Steve) Abella, M.D., as Chief Medical Officer](https://ysioscapital.com/2018/01/10/bioclin-therapeutics-appoints-graeme-currie/) - (San Ramon, California, January 9, 2018) BioClin Therapeutics, Inc.(BioClin), a privately-held clinical stage biotechnology company developing a first-in class anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibody to treat solid tumors, specifically metastatic bladder cancer, announced today the appointments of Graeme Currie, Ph.D., as Chief Operating Officer and Esteban (Steve) Abella, M.D., as Chief Medical
- [Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain Therapeutics](https://ysioscapital.com/2018/02/20/inoryx-therapeutics-spins-off-see-tx-platform-into-new-company-gain-therapeutics/) - The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril Mataró, Barcelona, Spain and Lugano, Switzerland, February 20, 2018 - Minoryx Therapeutics and Gain Therapeutics announce today the spin off of the Minoryx Site-directed Enzyme Enhancement Therapy (SEE-Tx) platform into Gain Therapeutics, a new company
- [Kala Pharmaceuticals Appoints Gregory Perry to Board of Directors and as Audit Committee Chair](https://ysioscapital.com/2018/03/05/kala-pharmaceuticals-announces-new-drug-application-for-inveltystm-kpi-121-1-has-been-accepted-for-review-by-the-u-s-food-and-drug-administration-1/) - WALTHAM, Mass., March 5, 2018 – Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced the appointment of Gregory Perry to the Company’s Board of Directors and Chair of its Audit Committee. “We are pleased to welcome Greg to
- [Sanifit Announces Results of the Phase II Clinical Trial of SNF472 in Patients with Calciphylaxis](https://ysioscapital.com/2018/03/06/sanifit-announces-results-of-the-phase-ii-clinical/) - Palma, Spain and San Diego, USA March 06, 2018 - Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, announced today the completion of its Phase II clinical trial of SNF472, its lead candidate for the treatment of the orphan disease calciphylaxis (calcific uraemic arteriolopathy, CUA), with both primary and secondary
- [AM-Pharma announces Phase II study results of recAP in sepsis-associated Acute Kidney Injury](https://ysioscapital.com/2018/03/09/am-pharma-completes-patient-recruitment-of-recombinant-human-alkaline-phosphatase-1/) - Study shows use of recAP results in greater than 40% relative reduction in mortality Bunnik, The Netherlands, March 9th 2018. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases, today announced positive results from its adaptive Phase II study in 301 sepsis patients with Acute Kidney
- [CorWave is set to receive about €3 million in financing through France’s Worldwide Innovation Challenge for its NovaPulse program, a mini-invasive solution for cardiac support](https://ysioscapital.com/2018/04/03/corwave-is-set-to-receive-about-e3-million-in-financing/) - Clichy, April 3rd, 2018 – CorWave, a French medical technology company that develops innovative implanted cardiac support devices for patients suffering from heart failure, announced today that it has been awarded almost €3 million in financing for its R&D program NovaPulse in the Silver Economy category. This is part of phase 2 of France’s Concours
- [BioClin Therapeutics, Inc.,Completes $50 Million Series B Financing with Addition of New Investors](https://ysioscapital.com/2018/05/10/bioclin-therapeutics-inc-completes50-millionseries-b/) - (San Leandro, California, May 9, 2018) BioClin Therapeutics, Inc., a clinical stage drug development company developing a first-in-class anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibody for metastatic bladder cancer, announced today expansion of its Series B financing to $50 million to broaden its clinical development activities. New investors, Sectoral Asset Management and INKEF Capital,
- [Vivet Therapeutics Appoints Eduardo Bravo as New Chairman of the Board](https://ysioscapital.com/2018/06/12/vivet-therapeutics-appoints-eduardo-bravo-as-new-chairman-of-the-board/) - PARIS, France June 12th, 2018, Vivet Therapeutics, a biotechnology company developing novel gene therapies for rare, inherited metabolic diseases today announced the appointment of Eduardo Bravo as Chairman of its Board of Directors. Eduardo Bravo takes over from Dr. Florent Gros who served as Chairman since the creation of Vivet Therapeutics. With more than twenty-five
- [BioClin Therapeutics Appoints Scott Myers as Chairman to its Board of Directors](https://ysioscapital.com/2018/06/27/bioclin-therapeutics-inc-completes50-millionseries-b-1/) - (San Leandro, California, June 26, 2018) BioClin Therapeutics, Inc., a privately-held clinical stage drug development company developing a first-in-class anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibody in areas of high unmet medical need, announced today the appointment of Scott D. Myers as chairman of Board of Directors. Stephen Lau, Chief Executive Officer of BioClin,
- [CorWave’s next-generation LVAD, Neptune, receives funding](https://ysioscapital.com/2018/07/10/corwaves-next-generation-lvad-neptune-receives-funding/) - The CALYPSO program will receive 14 million euros to develop CorWave Neptune, a new type of cardiac support to improve the management of patients with severe heart failure, as part of the Program d’Investissements d’Avenir (PIA) operated by Bpifrance. The CALYPSO Research and Development (R&D) program, with a total budget of 25 million euros over
- [Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period](https://ysioscapital.com/2018/07/31/takeda-completes-its-acquisition-of-tigenix-following-expiration-of-the-squeeze-out-period/) - TiGenix becomes a wholly owned subsidiary of Takeda Ordinary Shares have been delisted from Euronext Brussels The ADSs have been delisted from Nasdaq and TiGenix plans to terminate the ADS Facility and suspend its U.S. reporting obligations July 31, 2018 Osaka, Japan and Leuven, Belgium - Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV
- [Sanifit announces completion of enrollment in CaLIPSO – its Phase 2b Study for the Treatment of Cardiovascular Calcification in End-Stage-Renal-Disease Patients on Haemodialsis](https://ysioscapital.com/2018/08/06/sanifit-announces-completion-of-enrollment-in-calipso/) - Palma, Spain and San Diego, USA, August 6th, 2018 - Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced the completion of enrollment of its Phase 2b CaLIPSO clinical trial investigating Sanifit’s lead candidate SNF472, for the treatment of cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) patients on haemodialysis (HD).
- [Minoryx Therapeutics announces dosing of first US patient in phase 2/3 clinical study of MIN-102 (ADVANCE)](https://ysioscapital.com/2018/09/05/inoryx-therapeutics-spins-off-see-tx-platform-into-new-company-gain-therapeutics-1/) - ADVANCE trial recruitment is progressing rapidly in Europe with over 50 percent X-ALD patients enrolled Mataró, Barcelona, Spain, September 5, 2018- Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces the dosing of its first US patient as part of its ongoing phase 2/3 clinical trial of MIN-102
- [BioClin Therapeutics Announces New Leadership to Advance Late-Stage Bladder Cancer Development Program](https://ysioscapital.com/2018/09/18/bioclin-therapeutics-inc-completes50-millionseries-b-1-1/) - SAN LEANDRO, Calif., September 18, 2018—BioClin Therapeutics, Inc., a privately-held clinical stage drug development company, today announced the appointment of Scott Myers as Chief Executive Officer, and Julie Eastland as Chief Financial Officer and Chief Business Officer. Mr. Myers will also continue in his role as company Chairman. “We are excited to announce the appointment
- [Kala Pharmaceuticals announces financing from Athyrium Capital Management totaling $110 Million](https://ysioscapital.com/2018/10/02/kala-pharmaceuticals-announces-financing-from-athyrium-capital/) - Financing provides support for NDA filing of KPI-121 0.25%, INVELTYS launch, and topline results for the STRIDE-3 trial of KPI-121 0.25% - Initial $75 million tranche funded immediately and additional $35 million of funding available upon either INVELTYS revenue milestone or FDA approval of KPI-121 0.25% for dry eye disease WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 2, 2018-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused
- [Kala Pharmaceuticals announces pricing of public offering of 7,500,000 shares of common stock](https://ysioscapital.com/2018/10/03/kala-pharmaceuticals-announces-pricing-of-public-offering/) - WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 3, 2018-- Kala Pharmaceuticals, Inc. (“Kala”) (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, announced today the pricing of an underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $8.25 per share, before offering discounts. The offering will
- [Kala Pharmaceuticals submits new drug application to U.S. Food and Drug Administration for KPI-121 0.25% for dry eye disease](https://ysioscapital.com/2018/10/16/kala-pharmaceuticals-submits-new-drug-application-to-u-s-fda/) - WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 16, 2018-- Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for KPI-121 0.25%, a topical product candidate which, if approved, could be the first FDA-approved product for the temporary relief of signs and symptoms of dry eye disease. There are
- [Data from first in-human clinical trial of SNF472 in haemodialysis patients published in British Journal of Clinical Pharmacology](https://ysioscapital.com/2018/10/23/sanifit-announces-completion-of-enrollment-in-calipso-1/) - Palma, Spain and San Diego, USA, 23 October, 2018 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announces that data from a phase I study assessing the safety and tolerability of its lead drug candidate SNF472 in haemodialysis patients has been published in the British Journal of Clinical Pharmacology.
- [JAMA publishes Phase II recAP data for sepsis-associated Acute Kidney Injury](https://ysioscapital.com/2018/10/24/jama-publishes-phase-ii-recap-data-for-sepsis-associated-acute-kidney-injury-1/) - JAMA paper to be presented at ESICM conference in Paris New data on mode of action to be presented at ASN conference in San Diego Bunnik, The Netherlands, October 24th 2018. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recombinant human Alkaline Phosphatase (recAP) for inflammatory diseases, today publishes data in the prestigious
- [Galecto Biotech Raises €79 Million in Series C Financing Co-Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late-Stage Clinical Development](https://ysioscapital.com/2018/10/26/galecto-biotech-raises-e79-million-in-series-c-financing-co-led-by-ysios-capital-and-orbimed/) - Proceeds to fund Phase 2/3 trial of inhaled TD139 in idiopathic pulmonary fibrosis (IPF) and advancement of oral and ocular pipeline candidates into clinical studies Copenhagen, Denmark, 26 October 2018 – Galecto Biotech AB, the leading developer of galectin modulators for the treatment of severe diseases, including fibrosis and cancer, today announced the successful closing
- [BioClin Therapeutics Announces Name Change to Rainier Therapeutics](https://ysioscapital.com/2018/11/28/bioclin-therapeutics-announces-name-change-to-rainier-therapeutics/) - SAN LEANDRO, Calif., November 27 2018— BioClin Therapeutics, Inc., a privately-held clinical stage drug development company focused on helping patients in the high unmet need of bladder cancer, today announced the company is changing its name to Rainier Therapeutics, Inc. The new name, which will be implemented immediately, comes as the company prepares for late-stage,
- [Minoryx Therapeutics extends its activities in Belgium](https://ysioscapital.com/2019/01/15/minoryx-therapeutics-extends-its-activities-in-belgium/) - Minoryx Therapeutics opens Belgian subsidiary that will lead important development activities Mataró, Barcelona, Spain and Charleroi, Belgium, January 15, 2019 - Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that it has created a fully owned subsidiary in Belgium. The new office, located in Brussels South Biopark
- [Minoryx Therapeutics receives approval from Spanish Regulatory Agency to initiate phase 2 study in Friedreich’s Ataxia](https://ysioscapital.com/2019/02/27/minoryx-therapeutics-receives-approval-from-spanish-regulatory-agency-to-initiate-phase-2-study-in-friedreichs-ataxia/) - FRAMES trial expected to initiate patient recruitment in upcoming weeks in Spain, Belgium and other European countries Two Key Opinion Leaders join Minoryx’s scientific advisory board Mataró, Barcelona, Spain and Charleroi, Belgium, February 27, 2019- Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that it has received approval
- [Pfizer secures exclusive option to acquire gene therapy company vivet therapeutics](https://ysioscapital.com/2019/03/20/pfizer-secures-exclusive-option-to-acquire-gene-therapy-company-vivet-therapeutics/) - Pfizer and Vivet to collaborate on development of potential breakthrough therapy for Wilson disease Pfizer acquires 15% ownership stake in Vivet Paris, France and New York, US, March 20, 2019 – Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical
- [Rainier Therapeutics Announces Results from First Interim Analysis of the FIERCE-22 Trial of Vofatamab in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cell Carcinoma (Bladder Cancer)](https://ysioscapital.com/2019/06/03/ysios-leads-a-30m-usd-financing-round-in-bioclin-therapeutics-1/) - Targeted antibody elicits responses in both FGFR3 wild-type and mutant/fusion patients- Favorable tolerability and safety profile and prolonged treatment duration- Results presented at America Society of Oncology (ASCO) Annual Meeting SAN LEANDRO, Calif., June 3, 2019—Rainier Therapeutics, Inc., a privately held clinical stage drug development company, today announced the first interim analysis results from its
- [Minoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia](https://ysioscapital.com/2019/06/04/minoryx-therapeutics-receives-approval-from-spanish-regulatory-agency-to-initiate-phase-2-study-in-friedreichs-ataxia-1/) - Mataró, Barcelona, Spain and Charleroi, Belgium, June 4, 2019- Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that the first patient has been dosed with its lead candidate, leriglitazone (MIN-102), in the phase 2 FRAMES clinical trial in Friedreich’s Ataxia. This first patient was dosed at the
- [Rainier Therapeutics Announces Presentation of Patient Biopsy Data Demonstrating Vofatamab’s Ability to Increase Immune Cell Activation](https://ysioscapital.com/2019/06/04/ysios-leads-a-30m-usd-financing-round-in-bioclin-therapeutics-1-1/) - Vofatamab activates immune changes in immunologically cold tumors and in combination increases patient response rates - Data from FIERCE-22 Trial in Patients with Metastatic Bladder Cancer Presented at AACR Bladder Cancer Conference SAN LEANDRO, Calif., May 20, 2019—Rainier Therapeutics, Inc., a privately-held clinical stage drug development company, today announced the presentation of data from its
- [AM-Pharma Raises €116m [$133m] to Conduct Pivotal Phase III Trial of recAP in Acute Kidney Injury](https://ysioscapital.com/2019/07/16/am-pharma-raises-e116m-133m-to-conduct-pivotal-phase-iii-trial-of-recap/) - Financing co-led by new investors LSP and Andera Partners, with participation of existing investors Forbion, Ysios Capital, Kurma Partners, ID Invest Partners, BB Pureos Bioventures and Gilde Healthcare Proceeds to be used for the 1,400-patient international pivotal Phase III trial of recombinant human Alkaline Phosphatase (recAP) in patients with sepsis-associated acute kidney injury (SA-AKI) AKI
- [CorWave Presented First Successful In Vivo 60-Day Study on Its Innovative LVAD Cardiac Support Device](https://ysioscapital.com/2019/09/11/corwave-presented-first-successful-in-vivo-60-day-study-on-its-innovative-lvad-cardiac-support-device/) - Data was reported at the 46 th Annual Conference of the European Society for Artificial Organs (ESAO) CLICHY, France, September 11th, 2019 – CorWave announced that it successfully completed its first 60-day preclinical study to evaluate its Left Ventricular Assist Device (LVAD). The results were presented at the 46th Annual Conference of the European Society
- [AM-Pharma Expands its Senior Team in Preparation for a Pivotal Phase III Trial of recAP in Acute Kidney Injury](https://ysioscapital.com/2019/10/01/am-pharma-expands-its-senior-team-in-preparation-for-a-pivotal-phase-iii-trial-of-recap/) - Dr. Juliane Bernholz has joined as Chief Operating Officer Ms. Kristie Bass has joined as VP Clinical Operations Bunnik, The Netherlands, 1 October 2019 – AM-Pharma B.V. (‘AM-Pharma, the Company’), a clinical stage biopharmaceutical company, leading in the development of a treatment for acute kidney injury (AKI) with its innovative recombinant human Alkaline Phosphatase therapeutic (recAP)
- [Minoryx Therapeutics completes enrollment in FRAMES phase 2 trial with leriglitazone in Friedreich’s Ataxia](https://ysioscapital.com/2019/10/09/minoryx-therapeutics-completes-enrollment-in-frames-phase-2-trial-with-leriglitazone-in-friedreichs-ataxia/) - Recruitment of 39 patients in multicenter European phase 2 trial completed ahead of schedule Mataró, Barcelona, Spain and Charleroi, Belgium, October 8, 2019 – Minoryx Therapeutics, a company specializing in the development of innovative treatments for orphan central nervous system (CNS) diseases, today announces that it has completed recruitment in the FRAMES phase 2 clinical
- [Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia](https://ysioscapital.com/2019/10/17/minoryx-therapeutics-receives-fda-orphan-drug-designation-for-leriglitazone-in-friedreichs-ataxia/) - Leriglitazone (MIN-102) is a novel, brain penetrant, orally bioavailable and selective PPARγ agonist Second Orphan Drug Designation granted by the FDA for leriglitazone in addition to X-linked adrenoleukodystrophy (X-ALD) Potential for seven years of marketing exclusivity in the USA upon approval in the orphan designation indication Mataró, Barcelona, Spain and Charleroi, Belgium, October 17, 2019
- [Sanifit announces that the Phase 2b CaLIPSO trial of SNF472 met its primary endpoint in slowing the progression of cardiovascular calcification in patients on hemodialysis](https://ysioscapital.com/2019/10/30/sanifit-announces-e72-2m-80-9m-financing-in-spains-largest-private-biotech-fundraise-1/) - Top line data to be presented at 2019 Scientific Sessions of American Heart Association Webcast to be held on Monday 18 November at 11.00 ET Palma, Spain and San Diego, USA, 30 October 2019 – Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced that the international Phase 2b
- [Anaconda biomed announces first-in-human study of Next-generation thrombectomy system](https://ysioscapital.com/2019/11/05/anaconda-biomed-s-l-secures-e20-million-round-of-funding/) - Trial Data to Support Regulatory Submission to U.S. Food and Drug Administration BARCELONA – November 5, 2019 – Anaconda Biomed, a medical technology company developing a next-generation thrombectomy system for the treatment of ischemic stroke, has announced the completion of initial patient cases in a first-in-human study at Hospital Vall d’Hebron in Barcelona. This 125-patient,
- [Galecto Appoints Industry Leader Bertil Lindmark, MD, PhD, as Chief Medical Officer](https://ysioscapital.com/2020/02/06/alecto-appoints-industry-leader-bertil-lindmark/) - Dr. Lindmark brings broad R&D expertise, particularly in respiratory and inflammation Appointment reinforces Galecto’s ambition to be a global player following PharmAkea merger Copenhagen, Denmark, February 3, 2020 – Galecto, Inc., a leading developer of novel treatments for fibrosis and cancer, today announces the appointment of the highly experienced industry leader Bertil Lindmark as Chief Medical Officer
- [Galecto and PharmAkea merge to create strong clinical-stage company developing first-in-class therapeutics in fibrosis and cancer](https://ysioscapital.com/2020/01/07/galecto-and-pharmakea-merge/) - Clinical programs in IPF, NASH and cancer Joint entity to be named Galecto, Inc. San Diego, CA/Copenhagen, Denmark, January 7, 2020 – Galecto, the leading developer of galectin modulators for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and cancer, and PharmAkea, Inc., a privately held San Diego-based pharmaceutical company developing novel small molecules
- [Anaconda biomed secures €20 million round of funding](https://ysioscapital.com/2019/12/04/anaconda-biomed-s-l-secures-e20-million-round-of-funding-1/) - Proceeds to Be Used for Clinical Studies, Regulatory Submissions, Further Product Development and Manufacturing Scale-up BARCELONA – December 4, 2019 – Anaconda Biomed S.L., a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, has closed €20 million in new funding. The funding will be used for clinical studies of the
- [Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALD](https://ysioscapital.com/2020/01/09/minoryx-therapeutics-receives-us-fda-fast-track/) - Leriglitazone (MIN-102), a novel, brain penetrant, orally bioavailable and selective PPARγ agonist, is currently in late-stage development for treatment of severe orphan CNS disorders, including X-ALD and Friedreich’s Ataxia. It previously received Orphan Drug Designation from EMA and FDA for both conditions Pivotal ADVANCE trial in adult X-ALD patients with adrenomyeloneuropathy (AMN) on track, with
- [CorWave Appoints Jim Schuermann as an Independent Director](https://ysioscapital.com/2020/02/11/corwave-presented-first-successful-in-vivo-60-day-study-on-its-innovative-lvad-cardiac-support-device-1/) - Medtech industry veteran of two IPOs on the Nasdaq Stock Market (HeartWare, Avedro) CLICHY, France, Feb. 11th, 2020 – CorWave, a medtech company focused on the development of an innovative Left Ventricular Assist Device (LVAD) to treat patients suffering from severe heart failure, announced today the election of Jim Schuermann to its board of directors.
- [AM-Pharma Increases Funding to €163m for Phase-III Trial of recAP in SA-AKI](https://ysioscapital.com/2020/03/31/aam-pharma-increases-funding-to-e163m-for-phase-iii-trial-of-recap-in-sa-aki/) - €23m [US$25.5m] equity provided mainly by US-based Cowen Healthcare Investments €24m [US$26.5m] finance facility provided by the European Investment Bank (EIB) Increased funding allows for finalization of all Marketing Authorization Application preparation activities Utrecht, The Netherlands, 31 March 2020 – AM-Pharma B.V. (‘AM-Pharma, the Company’), a clinical stage biopharmaceutical company leading in the development of
- [First patient dosed in pivotal phase 3 trial of SNF472 in calciphylaxis](https://ysioscapital.com/2020/02/13/first-patient-dosed-in-pivotal-phase-3-trial-of-snf472-in-calciphylaxis/) - First patient dosed in phase 3 trial of SNF472 for the treatment of calcific uremic arteriolopathy (CUA) or calciphylaxis Palma, Spain and San Diego, USA, 13 February 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announced that the first patient has successfully been dosed in its pivotal phase
- [SNF472 Mechanism of Action data published in British Journal of Pharmacology](https://ysioscapital.com/2020/06/25/snf472-mechanism-of-action-data-published-in-british-journal-of-pharmacology/) - SNF472 selectively inhibits pathological calcification by binding to hydroxyapatite crystals Palma, Spain and San Diego, USA, 25 June 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announced that data examining the mechanism of action of SNF472, Sanifit’s lead compound in development, has been published in the British Journal
- [Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease](https://ysioscapital.com/2020/07/20/sanifit-to-start-new-clinical-development-program-of-snf472-in-end-stage-kidney-disease-patients-with-peripheral-artery-disease/) - FDA has agreed to key aspects of the clinical program, including the primary endpoint for the single pivotal phase 3 study There are approximately 175,000 and 150,000 ESKD patients with PAD in the USA and Europe respectively with no approved treatments Palma, Spain and San Diego, USA, 20 July 2020 – Sanifit, a clinical-stage biopharmaceutical company
- [Sanifit to Present New Data on SNF472 for Vascular Calcification at the American Society of Nephrology Kidney Week 2020](https://ysioscapital.com/2020/10/12/sanifit-to-present-new-data-on-snf472/) - Palma, Spain and San Diego, USA, October 12, 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for vascular calcification disorders, announced that it will present new data on its lead asset SNF472 at the American Society of Nephrology (ASN) Kidney Week 2020 Annual Meeting on October 22, 2020. Sanifit will make four
- [European Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases](https://ysioscapital.com/2020/10/30/minoryx-therapeutics-and-sperogenix-therapeutics-enter-into-an-exclusive-license-agreement-1/) - EIB support to develop breakthrough treatments to address orphan neurodegenerative diseases with high unmet medical needs Focus on Minoryx’s lead asset, leriglitazone, a novel, disease-modifying PPAR-γ agonist Venture debt operation supported by the Investment Plan for Europe Mataró, Barcelona, Spain and Gosselies, Belgium, October 30, 2020, Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused
- [AM-Pharma Announces Enrollment of the First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury](https://ysioscapital.com/2020/11/12/am-pharma-announces-enrollment-of-the-first-patient-in-revival-phase-iii-pivotal-trial-in-patients-with-sepsis-associated-acute-kidney-injury/) - Trial to confirm potential of AM-Pharma’s recombinant alkaline phosphatase to reduce mortality, as demonstrated in the Phase II STOP-AKI study Target enrolment of up to 1,600 SA-AKI patients at ICUs in Europe, United Kingdom and North America Utrecht, The Netherlands, 12 November 2020 – AM-Pharma B.V., an emerging leader focused on the treatment of kidney
- [Minoryx’s preclinical data for leriglitazone in Friedreich’s Ataxia published in Neurobiology of Disease Journal](https://ysioscapital.com/2020/11/16/minoryx-therapeutics-and-sperogenix-therapeutics-enter-into-an-exclusive-license-agreement-1-1/) - Preclinical data highlights potential therapeutic action and protection against neurodegeneration Mataró, Barcelona, Spain and Gosselies, Belgium, November 16, 2020 - Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating treatment options in orphan central nervous system (CNS) disorders with high unmet need, today announces the publication in ‘Neurobiology of
- [CorWave Raises €35 Million in Series C Funding for Its Breakthrough Heart Pump; EIC Fund Joins as New Investor](https://ysioscapital.com/2021/01/06/corwave-raises-e35-million-in-series-c/) - Clichy, France, January 6th, 2021 – CorWave raises 35 million euros to fund the next stages of its development, with the ambition to become a world-class medtech company serving heart failure patients. The capital increase is subscribed by returning investors joined by the EIC Fund, the European Commission's venture capital mega-fund, which makes its first
- [Xeltis trials show promising function of living heart valves restored in children](https://ysioscapital.com/2020/02/14/eltis-trials-show-promising-function-of-living-heart-valves-restored-in-children/) - CEO Announced continuation of the clinical trial program for the Pulmonary Valve in EU, Asia and USA more data Clinical trial results of Xeltis pulmonary valve (PV) show promising functionality of the living valves developed in patients as a result of its restorative implants. The recent trial data have been presented today at the International
- [Galecto Appoints New Chair and Strengthens Board of Directors](https://ysioscapital.com/2020/05/19/galecto-appoints-jonathan-freve-1/) - Appoints Amit Munshi as Chair, deeply experienced industry executive, CEO of Arena Pharmaceuticals Succeeds Magnus Persson, who oversaw period of rapid growth and success for Galecto Appoints David Shapiro MD, former CMO of Intercept Pharmaceuticals, to Board of Directors BOSTON and COPENHAGEN, Denmark, May 19, 2020 (GLOBE NEWSWIRE) -- Galecto, Inc., a privately-held biotechnology company
- [Vivet’s Second Gene Therapy Product, VTX-803 for PFIC3, Receives US and European Orphan Drug Designation](https://ysioscapital.com/2020/06/01/vivets-second-gene-therapy-product-vtx-803-for-pfic3-receives-us-and-european-orphan-drug-designation/) - PARIS, France June 1st, 2020, Vivet Therapeutics announced today that both the Food and Drug Administration (FDA) and the European Commission (EC) have granted Orphan Drug Designation (ODD) for Vivet’s second gene therapy product, VTX-803, for the treatment of Progressive Familial Intrahepatic Cholestasis type 3 (PFIC3). PFIC3 is a rare life-threatening and chronically debilitating condition
- [Sanifit Enhances Leadership Team with New Executive Appointments](https://ysioscapital.com/2020/06/01/sanifit-enhances-leadership-team-with-new-executive-appointments/) - Newly appointed VP of Business Development and SVP of Clinical Development each bring to Sanifit over 20 years of industry experience Palma, Spain and San Diego, USA, 01 June 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, is delighted to announce two new appointments to its Executive leadership team,
- [CorWave Reports Two Critical Technical Milestones Required to Proceed to the Clinical Phase at the American Society for Artificial Internal Organs Annual Meeting](https://ysioscapital.com/2020/06/10/corwavecriticalmilestones/) - The presentation was selected as Top Bioengineering Abstract and confirms CorWave's commitment to scientific excellence, which enabled demonstration of its Left Ventricular Assist Device’s (LVAD) capability to provide durable, long-term circulatory support with high-fidelity physiologic flowCLICHY, France, Feb. 11th, 2020 – CorWave, a medtech company focused on the development of an innovative Left Ventricular Assist
- [SparingVision Strengthens Management Team](https://ysioscapital.com/2020/10/29/sparingvision-raises-e44-5-million-1/) - Dr. Florence Lorget to lead development sciences as Chief Development Sciences Officer Dr. Rajiv Gangurde to lead manufacturing operations as Chief Technology Officer Both positions are US-based Paris, October 29 2020 – SparingVision (the “Company”), a genomic medicine company focused on ocular diseases, today announces the strengthening of its senior management team with the appointment
- [Kala Pharmaceuticals Announces Closing of $68 Million Series C Financing](https://ysioscapital.com/2016/04/14/kkala-pharmaceuticals-announces-closing-of-68-million-series-c-financing/) - Secures financing needed to complete registration trials for KPI-121 WALTHAM, Mass., April 13, 2016 -- Kala Pharmaceuticals, Inc. (Kala), a developer of innovative ophthalmic products based on its proprietary mucus penetrating particle (MPP) technology, announced that it has closed a highly oversubscribed $68 million Series C preferred stock financing, led by Longitude Capital. Additional new
- [CorWave Raises $17.1 Million in Series B Financing](https://ysioscapital.com/2016/11/04/corwave-raises-17-1-million-in-series-b-financing/) - Funding brings resources to conduct first-in-man study designed to transform LVAD therapy PARIS, November 4th, 2016 – CorWave, a medical technology company that develops innovative mechanical circulatory support devices, has announced that it has completed a $17.1 million (€15.5M) Series B financing. Existing shareholders including Sofinnova Partners, Bpifrance and Seventure were joined by two new
- [OxThera raises EUR 32 million to complete development of Oxabact® for treatment of Primary hyperoxaluria](https://ysioscapital.com/2016/11/30/oxthera-raises-eur-32-million/) - Stockholm – 29 November 2016 - OxThera AB, a Stockholm-based privately-held biopharmaceutical company, announces today that it has agreed on a EURO 32 million investment to complete the Oxabact® development program for treatment of Primary hyperoxaluria. The investment round is co-led by Life Sciences Partners, Netherlands, Ysios Capital, Spain, Sunstone Capital, Denmark, and Flerie Invest,
- [Matthew Gantz Appointed CEO of Oxthera](https://ysioscapital.com/2017/07/05/oxthera-raises-eur-32-million-1/) - Stockholm – 5 July 2017 - OxThera AB, a Stockholm-based privately-held biopharmaceutical company today announced the appointment of Matthew Gantz as their new CEO. He succeeds Elisabeth Lindner as CEO, who will continue as COO of Oxthera overseeing the Oxabact program. OxThera is developing a novel treatment, Oxabact, for Primary hyperoxaluria (PH), a fatal disease
- [Dr Bastian Dehmel Appointed CMO of OxThera](https://ysioscapital.com/2017/10/12/dr-bastian-dehmel-appointed-cmo-of-oxthera/) - Stockholm – 12 October 2017 - OxThera AB, a Stockholm-based privately-held biopharmaceutical company today announced the appointment of Dr Bastian Dehmel as their new Chief Medical Officer. OxThera is developing a novel treatment, Oxabact, for Primary hyperoxaluria (PH), a severe and often fatal disease in children, and where there are currently no available therapies. The
- [OxThera announces the randomization of the first patient into its phase III EPHEX study with Oxabact](https://ysioscapital.com/2018/03/15/oxthera-announces-the-randomization-of-the-first-patient-into-its-phase-iii-ephex-study-with-oxabact/) - Stockholm – 15 March 2018 - OxThera AB, a Stockholm-based privately-held biopharmaceutical company with a product in late stage clinical development focusing on Primary hyperoxaluria (PH), announces the randomization of the first patient into its phase III study, EPHEX, with Oxabact. Study OC5-DB-02 (EPHEX) is a randomized, placebo-controlled, 52-week study with the goal to investigate
- [Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson’s disease](https://ysioscapital.com/2018/03/16/lundbeck-to-acquire-prexton-therapeutics/) - Lundbeck will make an upfront payment of EUR 100 million and the deal terms also include up to EUR 805 million in development, regulatory and sales milestones Foliglurax is a first-in-class treatment which entered clinical phase II testing in Parkinson’s disease in July 2017 There remains a large unmet need for effective treatments for Parkinson’s
- [Kala Pharmaceuticals Announces Pricing of Initial Public Offering](https://ysioscapital.com/2017/07/21/kala-pharmaceuticals-compania-participada-por-ysios-capital-anuncia-su-salida-a-bolsa-en-el-nasdaq/) - WALTHAM, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc. (Kala), a biopharmaceutical company focused on the development and commercialization of two Phase 3 product candidates, KPI-121 1.0% for the treatment of inflammation and pain following ocular surgery and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease using its proprietary mucus-penetrating particle
- [Babyscripts Raises $5.7 Million to Build the Market's Most Robust, Clinically-Validated Virtual Care Women's Health Platform](https://ysioscapital.com/2017/06/30/babyscripts-raises-5-7-million-led-by-ysios-capital/) - New funding round will support expanded services for expecting mothers Washington, DC, June 29, 2017 (GLOBE NEWSWIRE) -- Babyscripts, the leading virtual care women's health platform, announced today that it has raised $5.7 million in new funding. Ysios Capital is the lead investor. Other strategic investors include Chemo Group, CG Health Ventures, Aurora Health Care Ventures,
- [Anaconda Biomed Secures 15 Million Euro in Series A Financing Led by Ysios Capital, Innogest Capital and Omega Funds.](https://ysioscapital.com/2017/05/23/anaconda-biomed-secures-15-million-euro-in-series-a-financing-led-by-ysios-capital-innogest-capital-and-omega-funds/) - Barcelona, Spain May 22, 2017 - Anaconda Biomed, a pre-clinical stage medical device company focused on the development of the next generation of neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke (AIS), today announces it has closed a Series A financing of 15 million Euro. The leading investors include new investors Ysios Capital (Barcelona,
- [Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases](https://ysioscapital.com/2017/05/04/vivet-therapeutics-raises-e37-5-million-in-series-a-financing/) - Paris, France, 4th May 2017 – Vivet Therapeutics (‘Vivet’), an emerging biotechnology company developing novel gene therapies for rare, inherited metabolic diseases, announced it has raised €37.5 million in a Series A financing round. The round involved a syndicate of leading international life sciences investors led by Novartis Venture Fund and Columbus Venture Partners, and
- [BioClin Therapeutics, Inc., Raises $30 Million in Series B Financing Led by Sofinnova Ventures and Ysios Capital](https://ysioscapital.com/2017/03/23/ysios-leads-a-30m-usd-financing-round-in-bioclin-therapeutics/) - (San Ramon, California, March 22, 2017) BioClin Therapeutics, Inc., a privately-held clinical stage drug development company developing a first-in-class anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibody in areas of high unmet medical need, announced today the closing of a $30 million Series B financing. The financing was led by new investors Sofinnova Ventures and
- [MedLumics Secures 34.4 Million Euros in Series B Funding](https://ysioscapital.com/2017/03/20/medlumics-secures-34-4-million-euros-in-series-b-funding/) - Investment Allows Company to Advance Product and Clinical Development of Atrial Fibrillation Technology MADRID – March 20, 2017 – MedLumics, a cardiac device company specializing in optically guided minimally invasive instruments, announced today that it has raised 34.4 million Euros in financing that will be used to help advance the product and clinical development of
- [CorWave Awarded €2.5M From the European Commission Through the EIC Accelerator Program](https://ysioscapital.com/2020/07/21/corwave-awarded-e2-5m-from-the-european-commission-through-the-eic-accelerator-program/) - Clichy, France, July 21st, 2020 – CorWave is one of the 44 companies selected among 1,800+ applicants by the European public program EIC Accelerator. CorWave will receive a €2.5 million grant from the European Innovation Council (EIC) to develop its innovative Left Ventricular Assist Device (LVAD). CorWave’s pulsatile LVAD, based on the breakthrough wave membrane
- [Sanifit Appoints Adam Levy as Chief Financial Officer](https://ysioscapital.com/2020/08/20/sanifit-to-start-new-clinical-development-program-of-snf472-in-end-stage-kidney-disease-patients-with-peripheral-artery-disease-1/) - FDA has agreed to key aspects of the clinical program, including the primary endpoint for the single pivotal phase 3 study There are approximately 175,000 and 150,000 ESKD patients with PAD in the USA and Europe respectively with no approved treatments Palma, Spain and San Diego, USA, 20 August 2020 – Sanifit, a clinical-stage biopharmaceutical company
- [Galecto, Inc. Receives U.S. and EU Orphan Drug Designations for GB0139 in Idiopathic Pulmonary Fibrosis](https://ysioscapital.com/2020/08/27/galecto-appoints-jonathan-freve-1-1/) - The EMA cited GB0139’s clinically relevant biomarker data in IPF patients Significant reduction of YKL-40 biomarker in fibrosis, inflammation, tissue remodeling diseases Boston, MA/Copenhagen, Denmark, August 27, 2020 – Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it has received Orphan Drug Designation (ODD) from both
- [Medlumics raises €14M in a Series E financing co-led by Asabys Partners, VI Partners and CDTI Innvierte, together with existing investors Andera Partners, Caixa Capital Risc and Innogest](https://ysioscapital.com/2020/09/09/medlumics-new-round/) - Medlumics develops a unique real-time, photonically guided radiofrequency (RF) irrigated ablation catheter to improve the treatment of Atrial Fibrillation The proceeds from the Series E financing will be used to complete the preclinical development and obtain first in human data Madrid, Spain, October 6th 2020: Medlumics, which develops Ablaview®, a unique RF irrigated ablation catheter
- [Galecto’s Oral Galectin-3 Inhibitor GB1211 Well Tolerated in Phase 1 Clinical Data Presented Recently at Several Scientific Conferences](https://ysioscapital.com/2020/09/15/galectos-oral-galectin-3-inhibitor-gb1211-well-tolerated/) - GB1211, a potent oral small molecule galectin-3 inhibitor was well tolerated in Phase 1 studies Phase 2a study planned to establish the anti-fibrotic effects of GB1211 in grade 2 to 4 Non-Alcoholic SteatoHepatitis (NASH) Data presented at the American Chemical Society Meeting, Drug Discovery Chemistry and EFMC-ISMC Boston, MA/Copenhagen, Denmark, August 27, 2020 – Galecto, Inc.,
- [Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau](https://ysioscapital.com/2020/09/24/minoryx-therapeutics-and-sperogenix-therapeutics-enter-into-an-exclusive-license-agreement/) - Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-threatening neurological condition Minoryx will receive an upfront and milestone payments of up to $78 million, as well as double digit royalties on annual net sales Hong Kong, Beijing, Shanghai (China) and Mataró, Barcelona (Spain), September
- [Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for Wilson Disease](https://ysioscapital.com/2020/11/18/vivet-therapeutics-and-pfizer-inc-announce-fda-authorization/) - PARIS, France and NEW YORK, N.Y.—November 18, 2020— Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has cleared Vivet’s Investigational New Drug (IND) application for
- [Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich´s ataxia](https://ysioscapital.com/2020/12/15/minoryx-therapeutics-and-sperogenix-therapeutics-enter-into-an-exclusive-license-agreement-1-1-1/) - Study demonstrates leriglitazone improves relevant disease biomarkers and ataxia resulting in clinical benefit in this orphan disease Mataró, Barcelona, Spain, December 15, 2020 - Minoryx Therapeutics, a Phase 3 clinical stage biotech company focused on the development of differentiating treatment options in orphan central nervous system (CNS) disorders, today announces topline results from the Phase
- [Hospital Vall d’Hebron Investigators Publish Early Data on Anaconda Biomed’s Mechanical Thrombectomy System for Ischemic Stroke](https://ysioscapital.com/2021/01/19/hospital-vall-dhebron-investigators-publish-early-data-on-anaconda-biomeds-mechanical-thrombectomy-system-for-ischemic-stroke/) - Single-Center Results Published in Journal of Neuroradiology BARCELONA, Spain–(BUSINESS WIRE)–Initial single-center clinical study data supporting Anaconda Biomed’s Advanced Neurovascular Access™ (ANA) Catheter System for the treatment of ischemic stroke have been published in the Journal of Neuroradiology by investigators at Hospital Vall d’Hebron in Barcelona. The hospital is participating in the multi-center SOLONDA (“SOL”itaire in
- [SparingVision Raises €44.5 Million and Appoints Stéphane Boissel as Chief Executive Officer](https://ysioscapital.com/2020/12/29/sparingvision-raises-e44/)
- [SparingVision Raises](https://ysioscapital.com/2020/12/28/sparingvision-raises/)
- [STAT-Dx announces CE-IVD mark completion for DiagCORE® System and Respiratory Panel](https://ysioscapital.com/2018/01/08/stat-dx-announces-ce-ivd-mark-completion-for-diagcore-system-and-respiratory-panel/) - BARCELONA – 08 January, 2018 – STAT-Dx, a company specialising in the development of advanced molecular diagnostic systems, announces that it has completed CE-IVD marking for DiagCORE®, its fully-integrated Syndromic Testing System, and its first assay, the DiagCORE® Respiratory Panel 1, following the successful completion of evaluation studies. Clinical data from the evaluation studies will
- [Galecto Appoints Jonathan Freve as Chief Financial Officer](https://ysioscapital.com/2020/04/27/galecto-appoints-jonathan-freve/) - Copenhagen, Denmark, April 27, 2020 – Galecto, Inc., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of Jonathan Freve, CPA, as its Chief Financial Officer (CFO). Jon brings more than 20 years of financial experience in progressively senior roles in the biotechnology sector, where he has
- [AM-Pharma Adds Regulatory, Business Development and Legal Expertise to Leadership Team](https://ysioscapital.com/2020/06/29/am-pharma-adds-regulatory-business-development-and-legal-expertise-to-leadership-team/) - Utrecht, The Netherlands, June 29, 2020 – AM-Pharma B.V., an emerging leader focused on the treatment of acute kidney injury, today announced the appointment of Wolfgang Meder, Ph.D., as Vice President, Regulatory Affairs and Quality Management, and Laetitia Szaller as General Counsel & Vice President, Business Development. Dr. Meder, who brings nearly 20 years of expertise
- [TiGenix announces acceptance of Cx601 abstract for presentation at ECCO 2016 Congress](https://ysioscapital.com/2016/01/11/tigenix-announces-acceptance-of-cx601-abstract-for-presentation-at-ecco-2016-congress/) - Leuven (BELGIUM) – January 11, 2016, 7:00h CET – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today that the abstract related to the positive results of the ADMIRE-CD pivotal Phase III trial of Cx601 for complex
- [MedLumics Appoints Cardiovascular Device Expert Tim Lenihan to Board of Directors](https://ysioscapital.com/2016/01/11/edlumics-appoints-cardiovascular-device-expert-tim-lenihan-to-board-of-directors/) - MADRID – Jan 7, 2016 – MedLumics, a cardiology device company specializing in the application of advanced optical coherence tomography (OCT) technology, has announced the appointment of cardiovascular device veteran Tim Lenihan to its board of directors. With vast experience in field of electrophysiology, Lenihan will help guide the continued advancement of the company’s catheter
- [Minoryx Therapeutics appoints Dr. Khalid Islam as chairman of the board of directors](https://ysioscapital.com/2016/01/27/minoryx-therapeutics-completes-series-a-funding-of-e19-4-1/) - Mataró, Barcelona, Spain, January 27, 2016 – Minoryx Therapeutics, a drug development company specialized in the discovery of new drugs for orphan diseases, today announces the appointment of Dr. Khalid Islam as chairman of the board of directors. Dr. Islam has 27 years experience in the pharmaceutical and biotechnology industries. Dr. Islam previously served as
- [TiGenix obtains commercial production license for Cx601](https://ysioscapital.com/2016/02/23/tigenix-submits-maa-to-ema-for-cx601-1/) - Leuven (BELGIUM) – February 23, 2016, 07:00h CET – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today that it has successfully obtained the license for commercial production of Cx601, TiGenix’s product for the treatment of complex
- [TiGenix submits MAA to EMA for Cx601 for the treatment of complex perianal fistulas in Crohn’s disease patients](https://ysioscapital.com/2016/03/03/tigenix-submits-maa-to-ema-for-cx601/) - Leuven (BELGIUM) – March 2, 2016, 19:00h CET – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today the submission of a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Cx601 for the
- [TiGenix announces positive 52-week Phase III results of Cx601 in complex perianal fistulas in Crohn’s disease patients](https://ysioscapital.com/2016/03/07/tgenix-announces-positive-52-week-phase-iii-results-of-cx601-in-complex-perianal-fistulas-in-crohns-disease-patients/) - A single injection of Cx601 was statistically superior to placebo in achieving combined remission at week 52 in the treatment of complex perianal fistulas in Crohn's disease patients with inadequate response to previous therapies, including anti-TNFs 54.2% of patients treated with Cx601 achieved combined remission at week 52 compared to 37.1% in the placebo arm
- [Parkinson’s disease: Prexton Therapeutics starts phase 1 clinical trial](https://ysioscapital.com/2016/03/08/prexton-therapeutics-raises-e8-7-million-10-million-in-a-series-a-round-1/) - First clinical trial with an mGluR4 positive allosteric modulator, a first-in-class compound for treating Parkinson’s disease, will assess safety and tolerability Geneva, Switzerland, March 7, 2016 - Prexton Therapeutics, a biopharmaceutical company developing novel therapeutics for the treatment of CNS conditions, today announces the launch of a phase 1 clinical trial. Prexton Therapeutics is the first company
- [TiGenix Presents 24 Week Results of its Cx601 Phase III Trial at ECCO 2016](https://ysioscapital.com/2016/03/17/tgenix-announces-positive-52-week-phase-iii-results-of-cx601-in-complex-perianal-fistulas-in-crohns-disease-patients-1/) - Leuven (BELGIUM) – March 17, 2016, 19:00h CET – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today the presentation of the 24 week results from the Phase III ADMIRE-CD pivotal trial of Cx601 for complex perianal fistulas in Crohn’s disease
- [STAT-Diagnostica Announces 25 Million Euros in Series C Financing Led by Gilde Healthcare](https://ysioscapital.com/2016/04/11/tat-diagnostica-announces-25-million-euros-in-series-c/) - Funding will be used to accelerate go-to-market strategy BARCELONA – April 11, 2016 – Medical diagnostics company STAT-Diagnostica has closed a Series C financing round totaling 25 million Euros/28.5 million USD. The proceeds will be used to prepare for the 2017 European launch of its DiagCORE Near Patient Testing system. Led by new investor Gilde
- [TiGenix reports 2015 full year results](https://ysioscapital.com/2016/04/11/tgenix-announces-positive-52-week-phase-iii-results-of-cx601-in-complex-perianal-fistulas-in-crohns-disease-patients-1-1/) - Leuven (BELGIUM) – April 12, 2016, 07:00h CET – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, reported today its business and financial highlights for 2015 and post year-end events. Key 2015 and post year-end highlights Cx601 reached
- [AM-Pharma publishes safety and pharmacokinetic data from Phase I recAP trial](https://ysioscapital.com/2016/05/10/am-pharma-publishes-safety-and-pharmacokinetic-data-from-phase-i-recap-trial/) - Pharmacokinetic model determines optimal dose regimen for current Phase IIb recAP dose finding clinical study treating sepsis-associated acute kidney injury Bunnik, The Netherlands, 10 May 2016. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase), has published data from its Phase I trial of recAP, for the potential treatment
- [AM-Pharma receives FDA fast track designation for recAP in Acute Kidney Injury, and reports completion of first stage in Phase II trial](https://ysioscapital.com/2016/04/26/am-pharma-publishes-further-preclinical-data-on-recap-to-treat-acute-kidney-injury-1-1/) - Trial on track and FDA regulatory status may allow accelerated patient access to new drug Bunnik, The Netherlands, 26 April 2016. AM‐Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory diseases, announces that it has received fast track designation from the U.S. Food and Drug Administration (FDA)
- [AM-Pharma STOP-AKI Phase II trial nominated for “Most Innovative Clinical Trial Design” in 2016 CARE Awards](https://ysioscapital.com/2016/04/19/am-pharma-publishes-further-preclinical-data-on-recap-to-treat-acute-kidney-injury-1/) - Bunnik, The Netherlands, 19 April 2016. AM-Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) has been shortlisted for the “Most Innovative Clinical Trial Design” in the inaugural Clinical & Research Excellence Awards in Boston, organised by Informa Business Intelligence (IBI). The nomination is based on AM-Pharma's two-part adaptive
- [TiGenix Cx601 positive Phase III results to be presented at Digestive Disease Week in the USA](https://ysioscapital.com/2016/05/18/tigenix-cx601-positive-phase-iii-results/) - Leuven (BELGIUM) – May 18, 2016, 7:00am CET – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, is proud to present the week 24 positive results from its Phase III ADMIRE-CD pivotal study of Cx601 at the 2016
- [CVRx® Announces that the First Two Patients were Treated in the Phase III Pivotal Trial Evaluating BAROSTIM THERAPY® for the Treatment of Heart Failure](https://ysioscapital.com/2016/06/07/cvrx-announces-that-the-first-two-patients-were-treated-in-the-phase-iii-pivotal-trial-evaluating-barostim-therapy-for-the-treatment-of-heart-failure/) - Minneapolis - June 6, 2016 - CVRx, a global medical device company, today announced that the first two patients have been treated with the BAROSTIM NEO® System in the Baroreflex Activation Therapy for Heart Failure Pivotal Clinical Trial (BeAT-HF). The procedures were done at the University of California San Francisco and Abrazo Arizona Heart Hospital
- [Minoryx Therapeutics appoints Dr. Uwe Meya as Chief Medical Officer](https://ysioscapital.com/2016/06/14/minoryx-therapeutics-completes-series-a-funding-of-e19-4-1-1/) - As a specialist in neurological disorders, Dr. Meya will advance the clinical development of Minoryx’s lead candidate MIN-102 for XALD Mataró, Barcelona, Spain, June 14, 2016 – Minoryx Therapeutics, a drug development company specialized in the discovery of new drugs for orphan diseases, today announces the appointment of Dr. Uwe Meya as Chief Medical Officer (CMO). Dr. Meya is
- [TiGenix CEO Eduardo Bravo assumes leadership of European Biopharmaceutical Enterprises (EBE)](https://ysioscapital.com/2016/06/16/tigenix-ceo-eduardo-bravo-assumes-leadership-of-european-biopharmaceutical-enterprises-ebe/) - Leuven (BELGUIM) - June 16, 2016, 7:00h CET - TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics based on proprietary platforms of allogeneic expanded stem cells, today announced that its CEO, Eduardo Bravo, has been named President of the EBE Board of Directors. At the conclusion of
- [TiGenix announces six-month Phase I/II results of AlloCSC-01 in Acute Myocardial Infarction](https://ysioscapital.com/2016/06/17/tigenix-announces-six-month-phase-iii-results-of-allocsc-01-in-acute-myocardial-infarction/) - Leuven (BELGIUM) – June, 17, 2016, 20:30h CET – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on the development and commercialization of novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, today announced preliminary six-month results from the CAREMI clinical trial, an exploratory Phase I/II study of AlloCSC-01, TiGenix’s expanded
- [TiGenix reconfirms its strategic focus on its allogeneic stem cell platforms](https://ysioscapital.com/2016/07/05/tigenix-reconfirms-its-strategic-focus-on-its-allogeneic-stem-cell-platforms/) - Leuven (BELGUIM) – July 5, 2016, 8:00h CEST – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on the development and commercialization of novel therapeutics based on its proprietary platforms of allogeneic expanded stem cells, today announced the initiation of the withdrawal of the Marketing Authorization for ChondroCelect® due to commercial reasons. This
- [Takeda and TiGenix Enter into Licensing Agreement for Ex-U.S. rights to Cx601 for the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease](https://ysioscapital.com/2016/07/05/takeda-and-tigenix-enter-into-licensing-agreement-for-ex-u-s-rights-to-cx601-for-the-treatment-of-complex-perianal-fistulas-in-patients-with-crohns-disease/) - Osaka, Japan, July 5, 2016, and Leuven, Belgium, July 5, 2016, 8:00am CEST - Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") and TiGenix NV (Euronext Brussels: TIG) ("TiGenix") today announced that the companies have entered into an exclusive ex-U.S. license, development and commercialization agreement for Cx601, a suspension of allogeneic adipose-derived stem cells (eASC) injected intra-lesionally for the treatment of
- [Takeda and TiGenix Announce Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn’s Disease](https://ysioscapital.com/2016/08/04/takeda-and-tigenix-announce-publication-in-the-lancet-of-24-week-results-of-the-phase-3-admire-cd-trial-investigating-cx601-in-the-treatment-of-complex-perianal-fistulas-in-patients-with-crohn/) - Osaka, Japan, August 2, 2016, and Leuven, Belgium, August 2, 2016, 08:00h CEST – Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (Euronext Brussels: TIG) (“TiGenix”) today announced that the 24-week results of the Phase 3 ADMIRE-CD trial investigating Cx601 have been published in The Lancet.1 Cx601 is a suspension of allogeneic adipose-derived
- [Parkinson’s disease: Prexton Therapeutics completes phase 1 clinical trial](https://ysioscapital.com/2016/09/20/parkinsons-disease-prexton-therapeutics-completes-phase-1-clinical-trial/) - Study shows mGluR4 positive allosteric modulator is safe and well tolerated at doses well above those that produce robust effects in Parkinson’s disease animal models Geneva, Switzerland, September 19, 2016 - Prexton Therapeutics, a biopharmaceutical company developing novel therapeutics for the treatment of CNS conditions, today announces the successful completion of the phase 1
- [TiGenix Business and Financial Update for the First Half 2016](https://ysioscapital.com/2016/09/20/tigenix-business-and-financial-update-for-the-first-half-2016/) - Leuven (BELGIUM) – September 20, 2016, 07:00h CET – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, today reported its business and financial highlights for the first half of 2016. Below are the key business and financial highlights
- [TiGenix Appoints Dr. June Almenoff to its Board of Directors](https://ysioscapital.com/2016/09/23/tigenix-appoints-dr-june-almenoff-to-its-board-of-directors/) - Leuven (BELGIUM) – September 22, 2016, 07:00h CET – TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, today announced that it has appointed June Almenoff, M.D., Ph.D., as a member of its Board of Directors in replacement of
- [STAT-Diagnostica Attracts Siemens Venture Capital as a New Investor](https://ysioscapital.com/2016/10/05/stat-diagnostica-attracts-siemens-venture-capital-as-a-new-investor/) - Funding will be used to support go-to-market activities in Europe BARCELONA – October 5, 2016 – Medical diagnostics company STAT-Diagnostica has closed an extension of its Series C financing with Siemens Venture Capital. The additional proceeds will be used to support the 2017 European launch of its DiagCORE Near Patient Testing system. Led by Gilde
- [Ona Therapeutics raises €30M in Series A financing](https://ysioscapital.com/2020/12/24/ona-therapeutics-raises-e30m-in-series-a-financing/)
- [CVRx® Raises $50 Million in New Equity Financing](https://ysioscapital.com/2020/12/24/cvrx-raises-50-million-in-new-equity-financing/)
## Pages
- [home](https://ysioscapital.com/) - Ysios Capital is a leading life sciences investor financing highly innovative companies worldwide fostering a positive impact on patients and society.
- [](https://ysioscapital.com/aussie-pokies-reviews-on-trustpilot-unveiling-reputation-customer-experience-and-ratings/) - Aussie Pokies Reviews on Trustpilot - Unveiling Reputation, Customer Experience, and Ratings Wondering where to find reliable gaming insights? Trustpilot hosts a treasure trove of aussie pokies reviews, highlighting genuine user experiences. Customers praise the platform for its interactive gameplay and swift customer service. Readers often applaud the transparency of reviews, as they reflect on
- [Whistleblowing Channel Policy and Information Management Procedure](https://ysioscapital.com/whistleblowing-channel-policy-and-information-management-procedure/) - Ysios Capital Partners, S.G.E.I.C., S.A.U. 1. PURPOSE The purpose of this policy is to set out the general principles of the internal reporting system ("Whistleblowing Channel") of YSIOS CAPITAL PARTNERS, SGEIC, S.A.U. (hereinafter, "Ysios"), as well as other matters set out in Spanish Act 2/2023, of February 20, regulating the protection of persons who report
- [Join Us](https://ysioscapital.com/join-us/) - Join our Ysios Capital Fellowship Programme. We are a team of scientific and investment experts, united by a shared philosophy.
- [Funds](https://ysioscapital.com/our-funds/) - Ysios Capital provides venture capital to cutting-edge private biotech companies through specialized funds.
- [Impact/ESG](https://ysioscapital.com/impact-esg/) - A Ysios Capital integrate ESG principles and best practices, we're committed to investing in diverse and environmentally conscious companies
- [About us](https://ysioscapital.com/about-us/) - Ysios Capital is a leading European venture capital firm. Our international team is driven by science, aiming to transform capital into medical breakthroughs.
- [News & Events](https://ysioscapital.com/news-events/) - Latest news about Ysios Capital investments and portfolio companies. Subscribe to our newsletter.
- [Measure your Y-score](https://ysioscapital.com/measure-your-y-score/)
- [Y-Impact](https://ysioscapital.com/y-impact/) - The Y-mpact model explained Ysios has developed an in-house proprietary methodology to measure the impact of our investment activity. We call it Y-mpact, which is measured by the Y-score. The Y-mpact model requests inputs relating to three pillars: Innovation, Social and Governance (ISG), with the goal of providing an overall impact rating, the Y-Score for
- [Contact us](https://ysioscapital.com/contact-us/)
- [Contact us - original](https://ysioscapital.com/contact-us-original/) - Get in touch with Ysios Capital offices in Barcelona and San Sebastian.
- [Política del Sistema Interno de Información y Procedimiento de Gestión de Informaciones](https://ysioscapital.com/internal-information-system-policy-spanish/) - OBJETO ÁMBITO MATERIAL DE APLICACIÓN ÁMBITO PERSONAL DE APLICACIÓN PRINCIPIOS RECTORES Y GARANTÍAS DEL SISTEMA INTERNO DE INFORMACIÓN SISTEMA INTERNO DE INFORMACIÓN – “WHISTLEBLOWER CHANNEL” RESPONSABLE DEL SII PROCEDIMIENTO DE GESTIÓN DE INFORMACIONES CANALES EXTERNOS DE INFORMACIÓN LIBRO REGISTRO DE INFORMACIONES PROTECCIÓN DE DATOS PERSONALES RÉGIMEN DISCIPLINARIO HISTÓRICO DE VERSIONES 1. OBJETO La presente política
- [Investment Strategy](https://ysioscapital.com/investment-strategy/) - We invest in biotech ventures developing novel drugs, across a diversity of modalities and therapeutic areas.
- [Cookie Policy](https://ysioscapital.com/cookie-policy/) - Policy for cookies A cookie is a file that is downloaded to the user’s PC/Smartphone/Tablet to access certain web pages in order to store and recover information on browsing performed from this device. Consent By using this website you hereby consent and agree to let us store these cookies on your computer or device for
- [Legal Notice](https://ysioscapital.com/legal-notice/) - www.ysioscapital.com is an Internet domain owned by Ysios Capital Partners SGEIC, S.A. (“YSIOS”), with present legal address at Avenida de la Libertad 25, 4 A-B, Donostia-San Sebastian (Spain), and the Tax ID Number of which is A-85386373. It is registered at the Company Register of Gipuzkoa, Page SS-4021, Folio 150, Volume 2823. 1. Website Conditions
- [Privacy Policy](https://ysioscapital.com/privacy-policy/) - Your personal data will be processed for the purposes of the management of the contractual and/or commercial relationship
- [Our Portfolio](https://ysioscapital.com/our-portfolio/) - Ysios Capital diverse portfolio features disruptive biotech ventures with exceptional teams and innovative science.
- [The Team](https://ysioscapital.com/the-team/) - Meet our international team of scientific investment experts, key to our success. We offer first-hand experience in building successful biotech ventures.
## Team
- [Malgorzata Rogalska](https://ysioscapital.com/team/malgorzata-rogalska/) - Malgorzata is responsible for identifying and assessing investment opportunities at Ysios Capital from both scientific and business perspectives.
- [Carlos Garcia-Echeverria](https://ysioscapital.com/team/carlos-garcia-echeverria/) - Senior biopharma executive and advisor with extensive experience in drug discovery and early clinical development.
- [Joan Perelló](https://ysioscapital.com/team/joanperello/) - Joan heads the firm’s company creation and early-stage vertical and is involved in the overall management, strategy and operations of Ysios Capital.
- [Arturo Urrios](https://ysioscapital.com/team/arturo-urrios/) - Biography Arturo leads early-stage investments and company creation at Ysios Capital, driving the firm's early-stage initiative. Previously, he worked at M Ventures and most recently at Wellington Parties, where he was involved in multiple financings including Riffyn (acquired by Siemens), Plexium, eGenesis, Themis Biosciences (acquired by MSD) and Seamless Therapeutics, among others. In 2022, Arturo played a
- [Pamela Klein](https://ysioscapital.com/team/pamela-klein/) - Dr. Pamela M. Klein is Founder and Principal of PMK BioResearch, offering advisory and strategic consulting for biotechnology industry.
- [Thomas Harth](https://ysioscapital.com/team/thomasharth/) - Thomas is responsible for identifying and evaluating investment opportunities at Ysios Capital. Prior to joining Ysios, Thomas was Senior Associate at Gimv.
- [Guillem Laporta](https://ysioscapital.com/team/guillem-laporta/) - Guillem is responsible for making and managing investments at Ysios Capital and responsible for reporting to investors
- [Jordi Xiol](https://ysioscapital.com/team/jordixiol/) - Jordi has more than 10 years experience in biomedical research. Contributes to the identification and evaluation of investment opportunities at Ysios Capital.
- [Wen Wen Cheng](https://ysioscapital.com/team/wenwen_cheng/) - Wen Wen is responsible for the legal matters relating to the management company, funds, and portfolio companies.
- [Almudena Méndez](https://ysioscapital.com/team/almudena-mendez/) - Almudena is an Associate on Advisory team at the Telescope Biotech Fund
- [Sriram Balusu](https://ysioscapital.com/team/sriram-balusu/) - Sriram is an Associate on the Advisory team at the Telescope Biotech Fund
- [Laura Argelich](https://ysioscapital.com/team/laura-argelich/) - Laura Argelich contributes to the identification and evaluation of investment opportunities at Ysios Capital, from both scientific and business viewpoints.
- [Karen Wagner](https://ysioscapital.com/team/karen-wagner/) - Karen focuses on therapeutic investments at Ysios Capital, and coordinates the identification and evaluation of investment opportunities.
- [Joël Jean-Mairet](https://ysioscapital.com/team/joel-jean-mairet/) - Joël jean-Mairet, managing partner, oversees all operations at Ysios Capital, including management, strategy and day-to-day operations.
- [Lance Berman](https://ysioscapital.com/team/lance-berman/) - Biography Lance has more than 20 years of operational experience in big pharma and the small biotech start-up space. Prior to joining Ysios, Lance was Chief Medical Officer and Senior Vice President at Relypsa. There he was responsible for building and leading the Company’s clinical development, medical affair and drug safety functions, as well as
- [Julia Salaverría](https://ysioscapital.com/team/julia-salaverria/) - Julia. managing Partner, s responsible for investor relations and corporate development and management at Ysios Capital.
- [Iñigo López-Huerta](https://ysioscapital.com/team/inigo-lopez-huerta/) - Íñigo is responsible for the overall Financial and Compliance matters of Ysios.
- [Carlos Paya](https://ysioscapital.com/team/carlos-paya/) - Dr. Paya has a distinguished track record of leadership in academic medicine and in large-cap pharma and mid-cap biotech and start-up companies.
- [Cristina Garmendia](https://ysioscapital.com/team/cristina-garmendia/) - Cristina Garmendia, General Partner, supports institutional relations at Ysios Capital, both in Spain and abroad, as well as investor relations and fundraising.
- [Catalina Cuchy](https://ysioscapital.com/team/catalina-cuchy/) - Catalina supports the Ysios Capitals’ Managing Partners and investors. She handles office operations and logistics in San Sebastián and administration support.
- [Míriam Cortés](https://ysioscapital.com/team/miriam-cortes/) - Miriam supports Ysios Capitals’ Managing Partners and investors, and handles media relations. She oversees office operations, including IT.
- [David L. Lacey](https://ysioscapital.com/team/david-l-lacey/) - Dr David Lacey has a distinguished & highly accomplished academic & biopharmaceutical industry career, discovering and creating life-changing therapies for patients.
- [María Vega de Seoane](https://ysioscapital.com/team/maria-vega-de-seoane/) - María is responsible for financial control across the management company and its funds.
- [Antoni Ribas](https://ysioscapital.com/team/antoni-ribas/) - Antoni Ribas, M.D., Ph.D. is Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA).
## Tags
- [Team Carousel](https://ysioscapital.com/tag/team_carousel/)
Version History
Version 19/22/2026, 4:02:39 AMvalid
385947 bytes
Categories
newsdocumentationtechnologybusinesshealthfinancefoodgamingsocial
Visit Website
Explore the original website and see their AI training policy in action.
Visit ysioscapital.comContent Types
postspagesproductsapidocumentationreviews
Recent Access
No recent access
API Access
Canonical URL:
https://llmscentral.com/ysioscapital.com/llms.txt
API Endpoint:
/api/llms?domain=ysioscapital.com